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Cancer metastasis is particularly deadly, leading to 90% of cancer deaths. During 
metastasis, tumor cells break off from a primary tumor and travel to distant sites. Metastasis to 
the brain results in a poor patient prognosis. However, several common cancers, such as breast 
cancer and melanoma, metastasize to the brain. In order to metastasize to the brain, tumor cells 
have been shown to cross the highly selective blood-brain barrier (BBB), which separates the 
brain parenchyma from the circulatory system. The BBB is highly impermeable, even for many 
chemotherapeutics, however, tumor cells are able to cross it by a poorly understood 
mechanism. The BBB consists of endothelial cells connected by tight junctions, and is 
supported by cells of the neurovascular unit, such as astrocytes. Furthermore, the composition 
of the extracellular matrix beyond the BBB is unique and contains hyaluronic acid (HA). In 
disease, HA organization or biophysical properties may become altered. The goal of this study 
was to investigate how specific physico-chemical interactions of tumor cells and the BBB 
microenvironment may impact tumor cell behavior at the BBB, as well as explore cold 
atmospheric plasma (CAP) as potential cancer treatment. This understanding could lead to 
better future therapeutics and a better prognosis for patients.  
 
We hypothesized that biophysical and biochemical cues from the BBB 
microenvironment, as well as the tumor cell phenotype, can influence tumor cells’ migration 
and morphology. In this dissertation, we investigated the interaction of tumor cells with 
astrocyte-secreted biochemical cues and the biophysical cues from a HA/gelatin extracellular 
matrix on tumor cell morphology, migration, and incorporation into an endothelium. Our 
results showed that tumor cell migration and morphology are significantly altered by astrocyte-
secreted factors and the HA/gelatin extracellular matrix; however, the extracellular matrix is 
less significant during incorporation. We also showed that brain- and bone-seeking tumor cells 
display varied morphologies on matrices with niche-relevant mechanical properties. Finally, 
we demonstrated that CAP selectivity for reducing migration of tumor vs. normal cells is highly 
sensitive to cell culture media formulation. Together, these results provide new insights into 
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Cancer metastasis is the process by which tumor cells break away from a 
primary tumor, travel through the circulatory system, and colonize a distant site, 
forming a secondary tumor [1]–[3]. Metastasis can occur at various sites, such as 
brain and bone [4]. Metastasis of tumor cells from a primary tumor to the brain is a 
particularly deadly aspect of cancer progression, with very short survival post-
diagnosis [5], [6]. However, several common cancers, such as breast cancer and 
melanoma, preferentially metastasize to the brain [5]. In order to metastasize to the 
brain, tumor cells have to cross the blood-brain barrier (BBB), which lines brain 
capillaries and separates the brain parenchyma from the circulatory system [7], [8]. 
The BBB consists of brain endothelial cells connected by tight junctions, consisting 
of tight junction proteins such as Occludins, Zonula Occludens (ZO), and Claudins, 
and tight slightly less tight adherens junctions, consisting of adherens junction 
proteins such as VE-cadherin [7]. The BBB is supported by other cells of the 
neurovascular unit, such as astrocytes, pericytes, and neurons [7]. This creates a 
highly selective barrier between the brain and the circulatory system that is 
impermeable to most molecules, including many chemotherapeutic drugs [5], [6], [9]. 
However, despite the highly selective and protective properties of the BBB, 
metastatic tumor cells are able to cross the BBB by a not fully understood mechanism 
[5].  
In addition to being a uniquely impermeable barrier, the BBB 





extracellular matrix that lies beyond it [10] with an elastic modulus of 0.1 - 1 kPa [10] 
and is primarily made up of hyaluronic acid (HA) [11]. Additionally, brain capillaries 
are very narrow, ranging in average diameter from 7 µm to 10 µm [11]. These factors 
distinguish the BBB from many other organs in the body and create an important 
niche for cancer research.  
The overall goal of this dissertation is to evaluate physico-chemical cues 
of the BBB microenvironment and metastatic breast tumor cells in order to 
begin to understand what leads tumor cells to cross the BBB and metastasize to 
the brain as well as investigate a novel therapeutic approach. We evaluate three 
tumor cell-BBB interactions: 1) Biochemical factors from the BBB 
microenvironment, 2) biophysical factors at the BBB, and 3) phenotypic properties of 
metastatic breast tumor cells that preferentially metastasize to brain and bone. 
Specifically, this dissertation addresses the effects of biochemical cues (e.g., from 
astrocytes), physical cues (e.g., HA), and organotropism of tumor cells on the 
 
Figure 1.1: Dissertation outline. Biophysical and biomechanical cues from the brain 
microenvironment on the behavior of metastatic breast tumor cells were investigated. CAP-
treated media was examined as a potential cancer therapeutic and the effect of confounding 





migration, morphology, and incorporation of metastatic breast tumor cells. 
Additionally, this dissertation addresses a potential therapeutic approach, Cold 
Atmospheric Plasma (CAP), which has the potential to selectively damage tumor 
cells while leaving normal cells intact (Figure 1.1).  
In this dissertation, we examined the biochemical effect of astrocytes on 
metastatic breast tumor cells with the use of conditioned media (ACM) (Chapter 3). 
Prior literature showed that astrocytes play a key role both in BBB integrity as well as 
in BBB interaction with tumor cells [12]–[15], making them an important BBB 
component during tumor cell invasion. However, it was unknown whether astrocyte-
secreted factors could alter tumor cell migration via the cell’s extracellular matrix, 
and whether the effects of astrocyte secreted factors were dependent on the degree of 
metastatic potential of the tumor cells or specific extracellular matrix components. 
This dissertation directly addresses these topics. Here, we examined the effect of 
direct ACM treatment, or pre-treatment of the extracellular matrix with ACM, on the 
migration and morphology of MDA-MB-231 metastatic tumor cells (Chapter 3). We 
also examined the differences in the effect of ACM on tumor cells with different 
metastatic potentials and on tumor cells cultured on different extracellular matrix 
proteins (Chapter 3). We found that both direct ACM treatments of tumor cells and -
pre-treatment of tumor cells’ extracellular matrix increases tumor cell velocity; 
however, tumor cell area only increases with direct ACM treatment of the cells 
(Chapter 3). Interestingly, pre-treatment of the extracellular matrix with ACM 
resulted in even larger increases in cell velocity compared to direct treatment of cells 





extracellular matrix. Furthermore, we have shown that the effect of ACM can depend 
on both the cell type and extracellular matrix binding moieties, with potential integrin 
dependence (Chapter 3). We provide evidence that these effects occur through MMPs 
present in the ACM, and through a ROCK-mediated signaling pathway in tumor cells. 
However, ACM did not appear to be a tumor cell chemoattractant (Chapter 3).  In 
summary, we have identified a novel mechanism by which biochemical factors 
secreted by astrocytes may act on tumor cells (e.g., through the extracellular matrix) 
to promote breast cancer metastasis to the brain (Chapter 3). 
Because the brain extracellular matrix is rather unique in its composition and 
biophysical properties, we aimed to investigate the biophysical interactions of 
metastatic breast tumor cells with a brain-relevant extracellular matrix, along with a 
monolayer of brain endothelial cells (Chapter 4). Specifically, we investigated the 
migration, morphology, and incorporation mechanisms of metastatic breast tumor 
cells on HA/gelatin films and human brain microvascular endothelial cell (HBMEC) 
monolayers (Chapter 4). We discovered that while tumor cells respond differently to 
varying degrees of HA/gelatin crosslinking, the extracellular matrix crosslinking did 
not significantly affect tumor cell incorporation into HBMEC monolayers (Chapter 
4). Additionally, we showed that tumor cells could be potentially incorporating not 
only paracellularly, but also transcellularly into HBMEC monolayers (Chapter 4).  
Metastasizing tumor cells also undergo a non-random process known as 
“organotropism,” where tumor cells are distributed preferentially to various distant 
sites [16]. This process can be regulated by various factors, ranging from cancer 





tissue [16]. It is possible that phenotypical properties of the tumor cells or their 
interaction with the extracellular matrix result in tumor cells crossing the BBB 
(Chapter 5). Here, we examined the differences in morphology and stiffness of 
regular, brain-, and bone-seeking metastatic breast tumor cell clones as they respond 
to substrate stiffness. We aim towards an understanding of whether morphological 
differences in tumor cell phenotype and tumor cell-extracellular matrix interactions 
could allow us to differentiate between the tumor cell clones (Chapter 5). We showed 
that while the different breast tumor cell clones do not vary in stiffness, they do vary 
in morphology (Chapter 5). 
 Since one of the key issues with tumor cell metastasis to the brain is the lack 
of successful therapies, we also examined the novel potential cancer therapeutic 
known as CAP (Chapter 6). Upon careful review of literature, we found that there are 
some critical gaps in cell-related CAP experiment consistency (Chapter 6). Thus, we 
aimed to provide a systematic examination of the effect of various experimental 
parameters on the effectiveness and selectivity of CAP-treated media as a potential 
cancer therapeutic (Chapter 6). We found that some common experimental 
parameters, such as media formulation and plasma source, significantly affect 
outcome of CAP-based cancer treatments, indicating that more work should be done 
to optimize the conditions before the treatment could potentially be introduced in vivo 
(Chapter 6).  However, with further development, CAP or CAP-treated liquids could 
become a new potential therapy that can be used to either destroy tumor cells in 
circulation, be applied directly to secondary tumors, or potentially even cross the 





nitrogen species (ROS/RNS) which could potentially cross the BBB via channel or 
member transport [11].  
 Together, our results show that physico-chemical cues from the BBB 
microenvironment and the phenotype of tumor cells could be playing a 
significant role in the progression of brain metastases. Additionally, show that 










2.1.1 Clinical presentation of brain metastases  
Cancer is one of the deadliest diseases and the second most common cause of 
death in the United States [17]–[19]. It is characterized by the uncontrolled growth of 
cells and can occur at many different sites in the body [18]. It is not fully understood 
why and how cancer occurs, although various risk factors such as smoking, obesity, 
and alcohol consumptions can significantly increase ones changes of the disease [18], 
[19]. While cancer statistics are lagging 2 - 4 years behind in the US, it is projected 
that 1.7 million new cancer cases and 606,880 cancer deaths will occur in 2019 in the 
US, which is the equivalent of 1,660 deaths per day [18], [19]. Some cancer are 
particularly prevalent, such as breast cancer and prostate cancers which are expected 
to make up 30% of new cancer cases in women and 20% of new cancer cases in men, 
respectively in 2019 [18], [19]. These cancers are expected to lead to 15% and 10% 
of deaths among women and men respectively [18], [19]. On the other hand, primary 
brain cancer is relatively rare, leading to only 3% of expected cancer deaths among 
both men and women [18], [19]. This is despite the fact that brain and nervous system 
tumors are the leading cause of mortality in the US in men below the age of 40 and 
women below the age of 20, while breast cancer is the leading cause of death among 
women between ages 20 and 59 years [18], [19]. Since this dissertation focuses on 
breast cancer metastasis to the brain, it is noteworthy that for 2019 it is estimated that 





US, and 2,670 cases of invasive breast cancer are projected to be diagnosed in men in 
the US [18], [19]. In the US in 2019, 42,260 people are expected to die from breast 
cancer [18], [19].  
When breast cancer is diagnosed prior to the spread of tumor cells to other 
parts of the body, it’s 5-year survival rate is 99% [18]. However,  the deadliest aspect 
of cancer is metastasis, where cells from a primary tumor intravasate into the 
circulatory or lymphatic systems, travel to distant organs, such as the brain, 
extravasate, and form secondary tumors (Figure 2.1) [20], [21]. Indeed, 90% of 
cancer deaths are due to metastasis [4]. Metastasis to the brain is one of the more 
deadly complications of primary tumors, with 10 - 35% of adult cancer cases 
resulting in brain metastasis [22],[23]. Various cancers, such as lung and breast 
cancers and melanoma, which account for 67% - 80% of all cancers [22], commonly 
Figure 2.1: Metastatic cascade.  Process of tumor cell dissemination from a primary tumor, 
into the blood stream, and to distant sites forming secondary tumors. Image used with 
permission from publisher (Open Access article distributed under the terms of the Creative 
Commons Attribution License (http://creativecommons.org/licenses/by/3.0)). J. L. Albritton 
and J. S. Miller, “3D bioprinting: improving in vitro models of metastasis with heterogeneous 





and preferentially metastasize to the brain [22],[6]. While in the past five years 
treatment and subsequent survival of brain metastases patients has improved [23], it is 
still extremely deadly and there is no consistently effective treatment. Metastasis has 
been recognized as a tremendous hurdle to survivability for a long time. In fact, as 
early as 1889, Dr. Stephen Paget suggest an breakthrough new theory, suggesting that 
metastasis is governed not just by patterns of circulatory flow, but by cross-talk of 
tumor cells and surrounding tissue [24], [25]. In the case of brain metastasis, breast 
cancer is the second most common cancer to metastasize to the brain (after lung 
cancer), and this leads to a worse diagnosis, more difficult treatment, and more 
devastating prognosis [26].  
2.1.2 Historic “seed and soil” hypothesis  
In 1889, Dr. Stephen Paget proposed in a seminal paper that tumor cells 
follow a “seed and soil” theory when spreading through the body to distant organs 
[24], [25]. Specifically, Dr. Paget asked himself what are the determinants directing 
to which organ tumor cells will spread during metastasis [24], [25]. His clinical 
findings disproved the earlier theory that tumor cells spread simply by passive blood 
flow and settle in whichever tissue they passed [24], [25]. Dr. Paget suggested that 
based on his clinical data, primarily on breast cancer and melanoma, in order to 
metastasize the tumor cell “seed” and the secondary organ “soil” need to be 
compatible, which is likely determined by the specific properties of each [24], [25]. 
While this theory has been extensively studied and revised over the past over 100 
years, it still remains widely accepted that tumor cells rely heavily on cross-talk, both 





prior work has explored the effects of several microenvironment cues, such as tumor 
cell response to tissue stiffness and matrix composition [27]–[32], in many cancers 
they remain unknown or unclear. For example, in tumor metastasis to the brain it has 
still not been established what properties of tumor cells and the BBB or brain 
microenvironments result in metastasis across the BBB and to the brain. This 
dissertation seeks to shed light on a small subset of these cues, in the hopes of 
contributing to the understanding of the brain metastasis mechanisms and eventually 
the development of effective therapies to address those mechanisms.  
2.1.3 Mechanism of metastasis 
In order to colonize a secondary tissue, tumor cells have to extravasate from 
the blood vessels into surrounding tissue. If the “seed and soil” hypothesis, described 
in Section 2.1.2, holds true, then both the tumor cells (“seed”) and the surrounding 
microenvironment (“soil”) have to be favorable for metastasis to occur. In order to 
extravasate, tumor cells have to attach to the wall of the blood vessel, and in some 
cases incorporate into the vessel’s endothelium prior to subsequent extravasation 
[33], [34]. In the very small vessels of the brain, the diameter of tumor cells is larger 
than that of the vessel, and thus tumor cells can become trapped in the vessels, 
leading to increased extravasation [34].  Certain biochemical and biophysical factors 
have been observed to be involved in tumor cell extravasation. For example, it is 
suspected that the presence of VEGF receptors on tumor cells contributes to 
metastasis. Furthermore, since tumor cells have to interact with diverse extracellular 
matrix proteins during metastasis, the presence of matrix metalloproteinase (MMPs) 





The physical aspects of the microenvironment can also influence tumor cells. 
Mechanical forces surrounding primary tumors, metastatic tumor cells, and secondary 
tumors are extremely important for understanding the underlying disease 
mechanisms. Two components are particularly important: the viscoelastic properties 
of the extracellular matrix and the cells themselves, as well as the physical 
composition of cells’ microenviornment. Increased extracellular matrix stiffness 
alters the structure of tumor cells’ cytoskeleton and their integrin clustering, resulting 
in increased invasiveness of tumor cells [36], [37]. For example, it has been shown 
that breast tumor cells become more invasive as their surrounding collagen matrix 
stiffens, promoting metastasis [38]. As the stiffness of cells’ extracellular matrix 
changes, cells are also able to change their own viscoelastic properties [39]. It has 
been shown that increased metastatic potential correlates with increased compliance 
of single tumor cells, which correlate with their invasiveness [40]. For example, using 
ovarian cancer cells it was shown that cancer cells have a lower stiffness than non-
malignant cells of the same type [41].   
 Interestingly, some tumor cells still readily metastasize to the brain, despite its 
unique microenvironment which does not share many characteristics with a typical 
tumor environment. For example, the brain microenvironment is very soft and is not 
made up of collagen and fibronectin proteins that are common in tumors and other 
parts of the body. In order to be able to effectively treat or event prevent devastating 
brain metastases, it is crucial to first understand what guides tumor cells to spread to 
the brain in the first place and how tumor cells are able to cross the BBB. This 





biophysical properties of the BBB as well as the intrinsic phenotypical properties 
of tumor cells in order to begin to understand which cell and 
microenvironmental properties direct brain metastasis.  
2.2 Blood-brain barrier (BBB) and brain microenvironment  
In order to understand how tumor cells cross the BBB, it is first crucial to 
understand what makes the BBB and brain microenvironments unique. Overall, the 
neurovascular unit includes the brain endothelium, astrocytes, pericytes, neurons, 
microglia, basal lamina, and extracellular matrix and space [11], [42]. Brain 
capillaries range in size, but are overall extremely small with an average diameter of 
7 - 10 µm [11] and they are lined with the highly impermeable BBB. Despite the 
small capillary size, the BBB creates a very large surface area for transport between 
the brain and circulatory systems [7], with a total surface area of approximately 15 - 
25 m2 [11].  
Structurally, the BBB consists of brain endothelial cells, connected by tight 
junctions with proteins such as zonula occludens (ZO), occludin, and claudin as well 
as adherens junctions with proteins such as vascular endothelial (VE)-cadherin, that 
line brain capillaries and are supported by other cells of the neurovascular unit, such 
as astrocytes, pericytes, and neurons (Figure 2.2) [7], [12]. There are two separate 
basal lamina supporting cells of the BBB: the endothelial basal lamina and the 
parenchymal basement membrane, separated by pericytes [43]. In a healthy BBB 
state, the two basal lamina layers cannot be told apart [43]. In general, the basal 
lamina is a sheet of organized proteins, and is only 50 – 100 nm thick. It consists 






somewhat different from the structure and composition of the brain extracellular 
matrix, which is a dense network of glycoproteins such as tenascins, hyaluronic acid 
(HA), and chondroitin sulfate proteoglycans [43], [44].  
Together with tight junctions and adherens junctions, all of these structural 
features create a barrier that separates the brain from the circulatory system and only 
transports select molecules, such as lipid soluble molecules, glucose, small peptides, 
and amino acids [7]. Tight junctions of brain endothelium regulate paracellular 
transport between the blood and the brain, while transporters, pumps, and receptors 
regulate the transcellular transport [11]. The BBB has an high electrical resistance 
between 1000 and 2000 Ω-cm2, which might guard against polar and ionic molecules 
[9]. Some of the transport mechanisms across the BBB include passive diffusion (eg. 
lipid soluble non-polar molecules), active efflux carriers (eg. lipid soluble non-polar 
molecules and conjugates), carrier-mediated influx via solute carriers (eg. glucose, 
Figure 2.2: Blood-brain barrier physiology.  Blood-brain barrier structure with main 
physical components from the brain microenvironment. BL: basal lamina. Image reprinted 
from Neurobiol. Dis, vol. 21, no. 4, N. J. Abbott, A. A. Patabendige, D. E. M. Dolman, S. R. 
Yusof, and D. J. Begley, Structure and function of the blood-brain barrier, pp. 13–25, 2010, 





amino acids, nucleosides, small peptides, organic anions and cations, 
monocarboxylates), receptor and adsorptive-mediated transcytosis (eg. lipoproteins, 
insulin, amyloid β), and mononuclear cell migration (eg. leukocytes) [7].  
Beyond the BBB, the brain is extremely soft (0.1 kPa – 1 kPa) and has a 
unique extracellular matrix composition [45], [46].  It contains little collagen, 
fibronectin, vitronectin, and laminin, which are abundant in other organs, but is rich 
in heparan sulfate and chondroitin sulfate proteoglycans, tenascins, and HA [45], 
[46]. Since the stiffness of the extracellular matrix and its composition play a role in 
metastasis [29] and tumors are typically stiffer than normal tissue [36], especially the 
brain, and are made up of the more common extracellular matrix proteins such as 
collagen and fibronectin, it is surprising that tumor cells still preferentially 
metastasize to the brain, despite its unique environment. While it is known that the 
structure of the BBB can be altered in the presence of tumor cells [47], the exact 
mechanisms by which tumor cells interact with the BBB are still not known [6]. The 
open question that remains is: which aspects of the BBB microenvironment or 
tumor cells motivate tumor cells to preferentially metastasize to the brain? 
Chapters 3 – 5 of this dissertation address several biochemical, biophysical, and 






2.3 Biochemical interactions of tumor cells with BBB via astrocytes and 
astrocytes secreted factors 
While tumor cells can interact with their microenvironment both via direct 
physical contact, they can also do so via indirect biochemical signaling. It is 
important to consider the indirect biochemical interactions that take place between 
tumor cells and the BBB microenvironment, since biochemical cues could be some of 
the first factors encountered by the tumor cells during the metastatic cascade, 
especially if the BBB is already damaged. Astrocytes, in particular, have been 
implicated in affecting tumor cells at the BBB, especially due to their proximity to the 
brain vasculature (Figure 2.2) [15]. In healthy physiology, astrocytes and their 
perivascular end-feet play a crucial role in maintaining the brain’s ionic, amino acid, 
neurotransmitter, and water homeostasis as well as supporting neuronal function [12]. 
Additionally, astrocytes upregulate various features of the BBB and help form and 
maintain tight junctions [12].  However, in the case of cancer, it has been shown that 
astrocytes can actually enhance cancer proliferation, chemoprotection, invasion, and 
immunoprotection [14]. More work has been necessary to fully understand the extent 
to which tumor cells and astrocytes interact, and which pathways are involved.  
Prior research has implicated astrocyte-secreted serpins in tumor cell survival 
during metastasis across the BBB using in vivo assays [15], attributed an increased 
BBB invasiveness of tumor cells to astrocyte secreted matrix metalloproteinases 
(MMPs) [48], and shown that  astrocytes and tumor cells can form gap-junctions [49]. 
It has been reported that extracellular vehicles (EVs) secreted by astrocytes carry 





(VEGF) [50], which have been shown to enhance tumor cell proliferation [51]. 
Furthermore, certain lipopolysaccharide (LPS)-activated microglia secrete chemical 
factors, such as tumor necrosis factor-α, that help destroy lung tumor cells in the brain 
[52]. However, astrocytes can also help tumor cells be resistant to chemotherapy [6] 
and microglia can increase the invasiveness of breast tumor cells via the Wnt and 
inflammatory signaling pathways [53]. In fact, astrocytes themselves can have 
different phenotypes in vivo which could affect their interaction with tumor cells.  
An additional consideration is that while in healthy physiology, astrocytes 
provide support for the brain and the BBB [12], during traumatic brain injury, 
astrocytes become reactive, forming glial scars that primarily consist of chondroitin 
sulfate proteoglycan (CSPG) [54]. During this process, CSPG and the fibrillary acidic 
protein (GFAP) are upregulated in astrocytes and astrocytes show signs of 
hypertrophy [54], [55]. It has been shown in vivo that fibrinogen-bound TGFβ 
infiltrates the brain through a damaged BBB and TGFβ activates the astrocytes [54]. 
Since astrocytes become reactive in response to injury, reactive astrocytes have been 
implicated in neurodegenerative diseases, such as Alzheimer’s disease, and some 
effect on tumor cells [55], [56]. Based on one study, during inflammation, astrocytic 
sphingosine-1 phosphate receptor 3 (S1P3) is upregulated and it helps tighten the 
blood-tumor barrier formed as a result of brain metastasis [57], [58]. Thus, it is 
evident that astrocytes and their different activation states could play a key role in 
the successful progression of brain metastasis. Two unanswered question that still 
remain is: how do tumor cells interact directly and indirectly with astrocytes in 





reactive in order to influence tumor cells? Chapter 3 of this dissertation will 
address the biochemical interaction of astrocytes and tumor cells as well the effect of 
astrocytes on tumor cell extracellular matrix and touches upon the activation of 
astrocytes in vitro. The next step after investigating the effect of biochemical cues, is 
to explore the physical interactions of tumor cells and the BBB extracellular matrix 
and endothelial cells, since in order to invade the brain, tumor cells have to inevitably 
physically cross the endothelial barrier. 
2.4 Transmigration and incorporation of tumor cells into endothelia 
2.4.1 General transmigration and incorporation of tumor cells 
Gaining a better understanding of tumor cell transmigration into the BBB 
endothelium will shed light on the most crucial step in the metastatic cascade which 
actually allows tumor cells to read their secondary tumor site. As described in Section 
2.2, the brain is particularly soft, and is abundant in unusual extracellular matrix 
molecules, such as HA. Yet, it has been previously shown that stiffer extracellular 
matrix can alter a cell’s migration, morphology, cytoskeletal arrangement, and focal 
adhesion and integrin density [36], [59], [60]. Thus, it remains to be understood how 
tumor cells interact with the brain’s extremely soft extracellular matrix and why 
certain cells preferentially metastasize to the brain, despite this potentially less than 
favorable environment [10]. One factor that could begin to address this dilemma is 
the fact that while the brain is abundant in HA, both tumor cells and brain endothelial 
cells express a specific HA receptor, CD44, a cell-surface glycoprotein [61], [62]. In 





endothelia and increased metastatic phenotype [63]. Studies have also shown that HA 
availability and CD44 expression could mediate transmigration of neural precursor 
cells across endothelia [64], leukocytes, and likely cancer cells [61]. CD44 can also 
bind to collagen, laminin, and fibronectin [61].  
Prior work comparing the transmigration of tumor cells across peripheral 
endothelia with the transmigration of the immune cells, leukocytes, showed that 
tumor cells implement an additional step in the process and displace endothelial cells 
[33]. However, the study also showed that there are significant differences in the 
mechanisms employed by tumor cells from different cancers and their reaction to 
different extracellular matrix [33].  
2.4.2 Transmigration across BBB-relevant endothelia  
Furthermore, some cancers, such as breast cancer, express genes that facilitate 
their adhesion to the BBB endothelium and further transmigration [65]. One study has 
shown, using a Transwell model of the BBB with porcine brain endothelial cells and 
astrocytes, that the metalloproteinase-disintegrin proteinase ADAM8 expression is 
related to higher brain metastasis incidence as well as an increased ability of tumor 
cells to transmigrate across a BBB model endothelium [66]. Furthermore, the study 
showed that blocking ADAM8, MMP-9 and β1 integrins reduced breast tumor cells’ 
transmigration across a BBB-like endothelium [66]. An additional study has shown 
that breast cancer cells and melanoma cells interact differently with the brain 
endothelium [67]. Utilizing a microfluidic device and rat brain endothelial cells the 
study shows that melanoma cells have a greater ability to attach and transmigrate 





to disrupt tight junctions, as evidenced by claudin-5 localization [67]. The study also 
implicated the tumor cells’ Rho/ROCK pathway in their ability to transmigrate 
effectively through a brain-like endothelium [67]. Similarly, a study has shown that 
ROCK inhibition in melanoma cells, but not brain endothelial cells, enhances 
transmigration [68]. Additional studies have shown that the adhesion of melanoma 
cells to a brain-like endothelium could also be cell-dependent based on the 
mechanical properties of the specific cell or cell type [69]. Interestingly, an additional 
study has shown that breast tumor cells are able to incorporate into brain-like 
endothelial via paracellular and transcellular pathways in an N-cadherin independent 
manner, while the transmigration of melanoma cells was limited to the paracellular 
pathway in an N-cadherin dependent manner [70]. These studies were carried out 
both in vivo and in vitro [70]. Furthermore, it has been suggested that endothelial-
mesenchymal transition of brain endothelial cells induced by tumor cells via TGF-β 
could be an essential part of successful tumor cell transmigration [71].  
2.4.3 Open questions in studying transmigration across the BBB  
To complicate matters further, tumor cells are highly heterogeneous, making it 
difficult to find a mechanism that can be generalized to an entire cell line or cancer 
type [6]. While prior studies shed light on tumor cell extravasation through non-BBB 
endothelia [72] as well as several important aspects of melanoma and breast tumor 
cells transmigration across brain-like endothelia, the following open question 
remains: how do various aspects of the microenvironment affect how tumor cells 
cross the BBB?  Chapter 4 of this dissertation address the incorporation of tumor 





understand whether the process is different from peripheral endothelia. However, 
understanding the interactions of tumor cells with biochemical and biophysical cues 
at the BBB leaves the question as to whether the tumor cell phenotype plays a role in 
preferential metastasis across the BBB.  
2.5 Brain- and bone-seeking clones of metastatic breast tumor cells 
  Sections 2.2 – 2.4 have addressed portions of the “soil” portion of the “seed 
and soil” hypothesis introduced in Section 2.2. However, the “seed” portion, or the 
tumor cells themselves, could prove to be similarly important in explaining tumor cell 
metastasis to the brain. In order to study the phenotype of the tumor cells in brain 
metastasis, different metastatic clones of the same cell lines have been generated. 
Specifically, to study the driving forces behind tumor cells from the same primary 
tumor type traveling to different distant metastatic sites, Yoneda et al. established two 
stable clones from the MDA-MB-231 parental metastatic tumor cell line [73]. The 
two established clones were repeatedly passaged through a mouse model until each 
clone metastasized solely to either the bone or the brain, creating the bone- and brain-
seeking MDA-MB-231 clone lines [73]. The final clones metastasized with 100% 
efficiency to their respective metastatic sites [73]. While the three different cell 
clones (parental, brain- and bone-seeking) exhibited similar tumorigenicity at the 
orthotopic site, they showed various biological differences. For example, the brain-
seeking cells produced more parathyroid hormone and their anchorage-independent 
growth was not dependent on TGF-β, unlike the brain-seeking and parental 
phenotypes [73]. The brain-seeking cells were also more sensitive to insulin-like 





much higher adhesion to bone matrix, than brain-seeking and parental clones [74]. 
Furthermore, it has been shown that exosomes from brain-, lung-, and liver-tropic 
tumor cells can actually be taken up by cells of the host tissue and thus the tumor 
cells in a way prepare a new niche [75]. 
 These tumor cell clones created an opportunity for the understanding of what 
separates tumor cells of the same type that preferentially metastasize to very 
physiologically distinct sites, such as the brain and bone. One study has performed a 
genomic analysis of the brain-seeking clone and determined that there are substantial 
changes in protein expression between brain-seeking clones and parental MDA-MB-
231 tumor cells, with the majority of the altered proteins being responsible for 
signaling and cell motility, cell cycle, metabolism, and transcription and translation 
[76]. Furthermore, it has been shown that brain-seeking MDA-MB-231 tumor cells 
show a higher migration and invasion potential in a transwell system and express a 
higher amount mRNA for MMP-1 and MMP-9 than bone-seeking and parental cells 
[77].  
While some work has been done to understand what differentiates the various 
clones, an open question remains: are there unique biophysical properties in 
brain-seeking clones that are absent in bone-seeking clones and the parental 
tumor cells which could be used to differentiate cell clones and determine the 
future metastatic destination of cells in a sample population? Chapter 5 of this 
dissertation begins to address some of the phenotypic differences in the different 
tumor cell clones. Phenotypic differences could allow us, in the future, to determine 





various engineered environments. Additionally, the phenotype of tumor cells can be 
crucial in the process of metastasis, including properties such as migration and 
morphology of tumor cells in different microenvironments. A better understanding of 
the physical response of these tumor cell clone to various components of a 
physiological microenvironment could be key to understanding more about what 
makes certain cells prefer metastasizing to the brain, despite it lacking many of the 
commonly preferred properties, such as high stiffness and collagen and fibronectin-
based extracellular matrix. While Chapter 5 addresses exclusively morphological 
differences, future work will focus on addressing additional phenotypic parameters. 
2.6 Therapeutic approaches 
2.6.1 Current therapeutic challenges 
Sections 2.1 – 2.5 have introduced some current gaps of knowledge in cancer 
research, while Chapters 3 – 4 of this dissertation seek to address a few of these gaps 
to improve the current understanding of the mechanisms behind tumor cell metastasis 
across the BBB. However, the ultimate goal of cancer research is to not only 
understand its mechanisms, but to cure the cancer or stop its progression. Thus, an 
essential part of cancer research is also to address potential therapies that could 
improve upon or provide an advantage in addition to current cancer treatment 
methods.  
The most common anti-cancer therapies include surgery, radiation, 
chemotherapy, and some newer drugs such as biologics or targeted therapies [78]. 





are still many downsides to most of the commonly used treatments. For example, 
surgery is commonly used in combination with other therapeutic methods and does 
not work effectively on cancer that has metastasized [78]. Additionally, some tumors 
are located in hard to access areas, such as some delicate parts of the brain, and 
surgery is not always an effective option and some cancers are chemoresistant [49]. 
Radiation and chemotherapy both have been very effective in treating certain cancers, 
however they result in significant and often long-term side effects due to damage to 
normal cells and organs [78]. While some novel therapies sometimes have fewer 
unpleasant side-effects, they often have to be administered in conjunction with more 
traditional methods leaving patients open to the same negative side effects [78]. Thus, 
novel therapies are always in high demand, especially for difficult to treat cancers and 
cancer complications, such as brain metastasis.  
While the impermeability of the BBB is crucial for maintaining healthy brain 
physiology, it becomes an unwanted barrier to drugs and therapeutics during disease 
treatment [79]. Currently, the state-of-the-art treatments for secondary metastatic 
brain tumors include antibody-based and chemotherapy drugs [79]. Recently, those 
drugs have been coupled with stereotactic radiosurgery and whole-brain radiotherapy, 
which can also be used independently, in order to decrease the tumor burden and 
allow drugs to cross through the BBB [79]. Furthermore, magnetic resonance imaging 
and Raman spectroscopy have helped make significant advances in the accuracy of 
cancer therapies and thus minimized damage to surrounding brain tissue [79]. New 
studies have also shown that focused ultrasound can be used to temporarily disrupt 





therapies that would help stop tumor cells prior to invading the brain or target cells in 
the brain without damaging health cells. However, in order to use a promising therapy 
in vivo to target the complex process of metastasis, especially to the brain, it has to be 
fully understood and optimized. Thus, Chapter 6 of this dissertation addresses a new 
potential cancer therapy, cold-atmospheric plasma (CAP) and study its ability to 
selectively destroy tumor cells without damaging surrounding normal cells.  
2.6.2 Cold-atmospheric plasma (CAP) 
CAP has been proposed by several researchers as a potential selective 
treatment that can damage or destroy tumor cells while leaving normal cells 
unharmed [81]. CAP itself has been long used in the physics and materials 
engineering fields; however, its application in biomedicine is relatively recent. 
Plasma in general is formed during an increase in the energy of atoms [82], [83]. As 
the energy of atoms increases, matter transforms from a solid, to a liquid, to a gas, 
and subsequently to plasma, which is formed by a process known as ionization where 
the high energy results in an electron breaking away and creating a free electron and 
positively charged atom (Figure 2.3 A) [82], [83]. Thus, plasma is a high energy 
ionized gas, that is on average neutral, consisting of positively charged ions, 
electrons, and neutral particles [81]. As matter changes states, its temperature also 
changes [81]. Due to the frequent collisions of electrons and heavy particles in the 
plasma a thermal equilibrium is reached and most common plasma is of very high 
temperature [81]. However, CAP is a special category of plasma where the plasma 
discharge is very fast and does not reach thermal equilibrium, thus the temperature 






from 25°C to 45°C and this type of plasma is preferred for use in biomedical 
applications, since the temperature range is physiologically appropriate [81]. CAP 
results in the formation of reactive oxygen and nitrogen species (ROS/RNS) which in 
turn then can become important for biological applications [81], [82]. It is important 
to note that while some of the reactive species have been identified, it is still not fully 
understood what specific combinations of reactive species are generated upon plasma 
treatment of various media, such as a liquid [84]. Thus, plasma treatments provide a 
unique modification of a surface or liquid which could not easily be replicated with 
other chemical or biological modifications. Furthermore, the species generated by 
plasma reactions are highly susceptible to modifications via changes in treatment 
type, time, gas types, and many other known and unknown parameters. 
There exist various CAP devices which have become key for plasma medicine 
applications. They are generally separated into direct and indirect CAP categories 
[81], [82]. In a direct system, the sample being treated serves as one of the electrodes 
or is part of the dielectric and thus is a part of the discharge  [81], [82]. In an indirect 
Figure 2.3: Cold Atmospheric Plasma (CAP). A) Plasma as a state of matter. Figure 
taken from [83] with permission from publisher (Creative Commons Attribution-
NonCommercial-ShareAlike 4.0 License). B) Atmospheric pressure plasma jet (APPJ) 







system, a gas (air or added gas) is used to carry the plasma generated reactive species 
to the sample [81], [82]. One example of an indirect plasma source is as a plasma jet 
(Figure 2.3 B) where the plasma is formed between an anode and a cathode, one of 
which is covered by a dielectric material [81], [82]. In the jet system, gas, such as 
argon, can be introduced and the continuous flow of the gas results in a needle-like 
projection of plasma [81], [82]. Another example of an indirect plasma source is the 
surface micro discharge (SMD), where there is no carrying gas present just air and 
plasma is applied over a much larger area [85]. In a jet source, convection is the 
primary transport mechanism with a small degree of diffusion, while the SMD is 
entirely based on diffusion [85]. In an SMD source that uses room air as the working 
gas, the main reactive species produced are O3, N2O5 , N2O, and HNO3 [86], while for 
a jet that uses argon as the working gas, the reactive species produced are also 
ROS/RNS but their exact composition is not fully known [84]. Other plasma sources 
fall into the hybrid category, where they incorporate some elements of direct and 
indirect sources [82].  
Recently, CAP has been shown to selectively destroy tumor cells while 
preserving normal cells [82], [87]–[90]. While the process by which this occurs is still 
being investigated, one theory is that while a small amount of ROS/RNS might 
actually increase cell proliferation, once the levels cross a certain threshold, cell death 
occurs [91]. In tumor cells, the baseline amount of ROS/RNS is greater due to a lack 
of redox homeostasis, and thus when additional ROS/RNS are introduced, tumor cells 
are more likely to cross the threshold necessary for cell death (Figure 2.4) [91]. Thus, 





tumor cells and not harm normal cells (Figure 2.4) [91]. However, with some CAP 
treatment conditions, even healthy cells become damaged by CAP [84]. Furthermore, 
it has been suggested in prior studies that CAP affects tumor cells through aquaporin 
and integrin based mechanism [82], [92]. Additionally, a study has shown that CAP 
does not significantly damage astrocytes as compared to tumor cells [93] and 
increases or restores chemotherapy sensitivity in glioma cells [94], indicating that it 
could work as an additional therapy along with currently existing treatments brain-
related applications. In vivo it is expected that direct CAP treatment could be effective 
for surface tumors, such as melanoma or other cancers that form closer to the surface 
of the skin. CAP-treated media, on the other hand, is proposed as a potential 
mechanism for treating tumor cells deeper in the body through administration into 
bodily fluid or catheterization. In fact, such a method could potentially be used to 
address circulating tumor cells in the circulatory and lymphatic systems, or could be 
adapted to be administered at or near the brain without significant damage to 
Figure 2.4: ROS and cell death. ROS from sources such as plasma can cause tumor cell 
death without destroying normal cells. Figure reprinted by permission from Springer 
Nature Customer Service Centre GmbH: Spring Nature, Nat. Rev. Drug Discov., 
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?, D. 





surrounding sensitive tissue. CAP has been using for biomedical applications both 
directly, and through the use of CAP-treated media or buffer solution. Extensive 
literature exists discussing the biomedical implications of CAP in cancer therapy [82], 
angiogenesis [95]–[97], wound healing [98] and more. However, there is still a long 
road ahead to clinical translation of CAP in the cancer therapeutics field. In fact, in 
order to achieve successful translation and a potential future application in treating 
brain metastasis, the current in vitro methods for CAP cancer treatments have to be 
systematically optimized, which is still missing from plasma literature. Specifically, 
the generation of CAP-treated media has shown a lot of promise; however, since 
bodily fluids do not correspond exactly to any buffer or media condition, it is 
important to understand how CAP interactions with its in vitro culture environment 
affect CAP study outcomes, in order to understand how it will potentially be 
translated into a significantly less controlled and predictable in vivo setting. One of 
the important open questions in the plasma medicine, and specifically plasma cancer 
treatment field is: which experimental parameters can alter the outcomes of CAP-
based cancer treatment experiments and how does that relate to future in vivo 
applications? Chapter 6 of this dissertation addresses some cell culture parameters 
that can affect the outcomes of CAP-based tumor cell treatment studies in order to 
establish some parameters that need to be considered when setting up CAP-based 
experiments.  
2.7 Conclusion 
 Cancer metastasis is a devastating outcome of an already serious illness. Yet, 





metastasis as a whole, a lot of the information necessary for developing successful 
therapies remains unknown. That is particularly true about metastasis to the brain, 
which can involve tumor cells crossing the highly impermeable BBB, and it remains a 
mystery how exactly that process occurs. Fortunately, there have been multiple 
successful studies that have shed light on some parts of the process, opening a path 
for further research into this field. This dissertation addresses some of the gaps in 
understanding of the physico-chemical interactions at the BBB during tumor 
metastasis. This dissertation focuses on biochemical cues from astrocytes (Chapter 3), 
biophysical interactions during incorporation (Chapter 4), and morphology of 
different metastatic clones (Chapter 5). Furthermore, this dissertation addresses the 
optimization of potential therapeutic approach, CAP, which has been tested for 
various cancer therapy applications, but optimization and validation is necessary 





3 Astrocytes from the brain microenvironment alter migration 
and morphology of metastatic breast cancer cells† 
3.1 Introduction 
Metastasis to the brain is one of the most deadly aspects of breast cancer, 
leading to a particularly poor prognosis for patients [99]. As described inuring 
metastasis, breast tumor cells break away from the primary tumor, travel through the 
circulatory system, preferentially infiltrate the brain, and form secondary tumors, 
which are notoriously difficult to treat [99]. During metastasis, tumor cells encounter 
many heterogeneous microenvironments containing an array of biochemical and 
physical cues [100], both of which regulate the migration, mechanobiology, and 
signaling mechanisms used by tumor cells to navigate these environments [4]. In the 
case of brain metastasis, it has been shown that that astrocytes in the brain 
microenvironment promote brain metastasis and facilitate tumor cell invasion [15], 
[48], [49], [56], [101]. Here, we hypothesize that astrocyte-secreted biochemical cues 
regulate the morphology and migration of metastatic breast tumor cells, and that this 
effect depends on the astrocyte activation state, as well as the mechanical 
microenvironment of the tumor cells.  
† This chapter is republished with permission of Fedn of Am Societies for Experimental 
Bio (FASEB) from M. A. Shumakovich, C. P. Mencio, J. S. Siglin, R. A. Moriarty, H. 
M. Geller, and K. M. Stroka, “Astrocytes from the Brain Microenvironment Alter 
Migration and Morphology of Metastatic Breast Cancer Cells,” FASEB J., vol. 31, no. 
11, pp. 5049–5067, 2017; permission conveyed through Copyright Clearance Center, 
Inc. C.P.M provided astrocyte conditioned media, J.S.S and R.A.M assisted with 





In healthy physiology, astrocytes provide support for neurons by maintaining 
an ionic, neurotransmitter, amino acid, and water balance in the brain [12]. The end-
feet of astrocytes support the blood-brain barrier (BBB) by assisting with the 
exchange of chemical signals between the circulatory system and the brain [12] and 
modulating the physiology of brain endothelial cells [12]. While astrocytes are 
important regulators of brain homeostasis, they also play a role in brain metastasis. 
Recently, it was reported that astrocyte-secreted serpins are involved in tumor cell 
survival during metastasis across the BBB in vivo [15]. Other reports have 
demonstrated an increased invasiveness of tumor cells in response to astrocyte-
conditioned media (ACM), and they attributed this response to astrocyte-secreted 
matrix metalloproteinases (MMPs) [48]. Others yet have shown that astrocytes and 
tumor cells can form gap-junctions, which then transport molecular messages 
between the two cell types [49]. Furthermore, it has been reported that extracellular 
vesicles (EVs) secreted by astrocytes carry fibroblast growth factor-2 (FGF-2) and 
vascular endothelial growth factor (VEGF) [50], which have been shown to enhance 
tumor cell proliferation [51]. Together, these reports suggest that astrocytes interact 
with metastasizing tumor cells and thus influence brain metastasis.  
While there exists evidence that astrocytes are involved in tumor cell 
metastasis across the BBB, it is unclear whether tumor cells react to signals from 
quiescent astrocytes or altered molecular signals from tumor cell-affected astrocytes. 
Interestingly, secretion of MMPs by astrocytes does not necessarily require two-way 
communication between tumor cells and astrocytes [48], and thus could be a part of 





MMPs are secreted by various cell types including both astrocytes and tumor cells, 
function to degrade the extracellular matrix, and are known to promote tumor cell 
splitting from a primary tumor, intravasation into the vasculature, and extravasation 
across capillary endothelial cells and the BBB [102]. Thus, MMPs secreted by 
astrocytes could act on breast cancer cells, or their extracellular matrix (ECM), to 
potentiate the metastatic phenotype.  
Tumor metastasis across the BBB likely causes BBB damage, which may be 
similar to BBB damage following traumatic brain injury. A damaged BBB permits 
the infiltration of fibrinogen-bound TGF-β, which then activates astrocytes [54], 
leading to formation of glial scars that primarily consist of chondroitin sulfate 
proteoglycans (CSPGs) [54], and altering the astrocyte secretome [103]. The 
secretome of activated astrocytes is enriched in pro-inflammatory cytokines and other 
small molecules [104]. In the case of cancer, similar activation of fibroblasts supports 
cancer cell growth, motility and invasion [105], which suggests that astrocyte 
activation may also have a role in brain cancer metastases. Thus, we hypothesize that 
there would be differential effects of adding conditioned media from untreated 
astrocytes versus TGF-β-activated astrocytes to tumor cells.  
In addition to biochemical cues, physical cues, such as physical confinement, 
also affect tumor cell migration. Metastasizing tumor cells encounter confined 
microenvironments when migrating through microtracks within tissues, through 
narrow brain capillaries which can be as small as 10 µm in diameter [106], through 
the brain endothelium, and along the blood vessel post extravasation across the 





metastasis across the BBB is crucial. Prior studies by our lab demonstrated that an 
Aquaporin 5 (AQP5)-based mechanism drives the migration of metastatic breast 
tumor cells in confined channels [108], suggesting that tumor cell migration in 2D 
and in confinement utilizes different mechanisms. Thus, the effects of astrocyte-
secreted factors on tumor cells could be different depending on the mode of migration 
employed by the tumor cells. Hence, we hypothesize that physical confinement alters 
the effects of ACM on tumor cell migration in a microfluidic model where ACM 
serves as a potential chemoattractant. 
In order to test our aforementioned hypotheses regarding the effects of 
astrocyte-secreted factors on metastastic breast tumor cell migration and morphology, 
we applied ACM (from untreated or TGF-β-treated astrocytes) to tumor cells or their 
extracellular matrix and quantified cell migration and morphology parameters on 2D 
substrates or in confined microchannels. We show that ACM increases tumor cell 
migration and alters their morphology towards a more elongated and larger 
phenotype, with enhanced actin stress fiber organization. Furthermore, we show that 
pre-treating collagen substrates with ACM prior to seeding tumor cells results in 
significantly increased tumor cell velocity as compared to control cells, with increases 
in velocity that are more drastic than treating cells directly with ACM. Additionally, 
we show that ACM affects tumor cells differently depending on the relative activation 
state of the astrocytes, and that MMPs are likely to be at least partially responsible for 
the ACM-dependent increases in tumor cell migration. Interestingly, the effect of 
astrocyte-secreted factors is contingent on the physical microenvironment of the 





3.2 Materials and Methods 
3.2.1 Cell Culture 
Human breast adenocarcinoma highly metastatic cells (MDA-MB-231), 
human breast adenocarcinoma metastatic cells (MDA-MB-468), human breast 
adenocarcinoma tumorigenic cells (MCF7), and human mammary gland non-
cancerous epithelial cells (MCF10A) were purchased from American Type Culture 
Collection (Manassas, VA, USA). MDA-MB-231 and MCF7 cells were cultured in 
media consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) with high 
glucose and pyruvate (ThermoFisher Scientific, Waltham, MA, USA), 10% Fetal 
Bovine Serum (FBS; HyClone Characterized GE Healthcare, Pittsburgh, PA, USA or 
ThermoFisher Scientific), and 1% Penicillin-Streptomycin 10,000 U/mL. MDA-MB-
468 cells were cultured similarly, but with DMEM/F12, HEPES (ThermoFisher 
Scientific) instead of DMEM. MCF10A cells were cultured in media consisting of 
DMEM/F12, HEPES, 100 µg/ml endothelial growth factor (Sigma Aldrich, St. Louis, 
MO, USA) in 10 mM acetic acid, 1 mg/ml hydrocortisone (Sigma Aldrich) in 95% 
ethanol, 4 mg/ml insulin (ThermoFisher Scientific), 5% horse serum, New Zealand 
origin (ThermoFisher Scientific), and 1% Penicillin-Streptomycin 10,000 U/mL.  
Cells were washed with Phosphate-Buffered Saline (PBS) (VWR, Radnor, PA, USA), 
and detached with 0.25% Trypsin-EDTA (ThermoFisher Scientific). MDA-MB-231 
and MCF7 cells were used up to a passage of 30 post-purchasing, and MDA-MB-468 
and MCF10A cells were used up to passage 10 post-purchasing. All cells were 





3.2.2 Extracellular matrix Proteins and Coatings 
In order to study the role of different extracellular matrix proteins on the 
effect of ACM on cells, several extracellular matrix conditions were examined. Cells 
were grown on glass coated with 300 μL of 20 μg/ml of the following extracellular 
matrix proteins: type I collagen from rat tail (Sigma Aldrich, St. Louis, MO, USA), 
type IV collagen from human cell culture (Sigma Aldrich), fibronectin from human 
plasma (Sigma Aldrich), laminin from human fibroblasts (Sigma Aldrich), or 20 
μg/ml Poly-D-Lysine hydrobromide (PDL; stored at 1 mg/ml and dissolved in sterile 
MilliQ water) (Sigma Aldrich) for 1 hour at 37˚C, depending on the type of 
experiment. Following the incubation, wells with collagen type I or IV, fibronectin, or 
laminin, were washed three times with PBS, wells with laminin were washed with 
Hank’s Balanced Salt Solution (HBSS) (ThermoFisher Scientific), and wells with 
PDL were washed with sterile MilliQ water. 
3.2.3 Astrocyte Conditioned Media 
Prepared by Dr. Caitlin Mencio, NIH. 
All animal care and procedures were approved by the Institutional Animal 
Care and Use Committee at the National Heart, Lung, and Blood Institute and 
performed in accordance with their guidelines by Dr. Caitlin Mencio. None of the 
animal work was carried out by Marina Pranda or at the University of Maryland, 
College Park. Pregnant C57Bl/6 mice were procured from Charles River Laboratories 
(Wilmington, MA, USA). Primary cortical astrocyte cultures were prepared from 





the cerebral cortices were dissected out and dissociated into single cell suspension. 
Dissociated cells were seeded into T75 flasks and grown in DMEM with high glucose 
and pyruvate, 10% FBS, and 1% Penicillin-Streptomycin 10,000 U/mL, at 37°C and 
5% CO2:95% air atmosphere until cells grew to confluency (10–14 days later). Flasks 
were shaken for 20 hours (120 rpm, 37°C) to detach microglia, oligodendrocytes, and 
neurons from the more adherent astrocytes. After shaking, the medium was replaced 
with fresh media. This occurred again 24 hours after the end of shaking. After the 
second complete change of media, astrocyte conditioned media (ACM) was harvested 
every 48 hours and frozen until utilized. To harvest conditioned media from reactive 
astrocytes, the purified astrocytes were plated onto 6-well plates or T-25 flasks in 
serum containing medium. After once again reaching confluence, astrocytes were 
incubated in one of three conditions: 1) serum-free media overnight and then treated 
with 10 ng/mL TGF-β (Peprotech, Rocky Hill, NJ, USA) in serum-free media for 5 
days before harvest; 2) serum-free media overnight and treated with 10 ng/mL TGF-β 
in serum-containing media for 5 days before harvest; 3) serum-containing media 
overnight and treated with 10 ng/mL TGF-β in serum-containing media for 5 days 
before harvest. Activation of astrocytes was confirmed (data not shown) in astrocytes 
cultured in serum-free media overnight and then treated with TGF-β (condition 1) by 
western blots for GFAP in astrocytes and CSPG in ACM performed as previously 
described [109]. The different conditioned medias collected from astrocytes were 
centrifuged at 300 g for 10 minutes and the supernatant was filtered using a 40 μm 
nylon cell strainer (VWR, Radnor, PA, USA) based on a published protocol [93]. The 





3.2.4 MMP inhibition 
To inhibit MMPs in ACM, the broad spectrum MMP inhibitor batimastat 
(BB94) (Sigma Aldrich, St. Louis, MO, USA) was used [110], [111]. Batimastat was 
diluted to 50 mM in Dimethyl Sulfoxide (DMSO) (Sigma Aldrich) and frozen in 
aliquots. For experiments, the 50 mM stock of batimastat was diluted to 0.1 μM, 1 
μM, or 5 μM in ACM. DMSO was used as a vehicle control.  
3.2.5 Addition of Exogenous MMP-2 and MMP-9 
For some experiments, MMP-2 from humans (Sigma Aldrich, St. Louis, MO, 
USA) was diluted to 5 mg/ml in water and then diluted to 100 and 40 ng/ml in control 
media (25, 26).  MMP-9 from humans (Sigma Aldrich) was diluted to 50 µg/ml in 
PBS and then diluted to 100 and 40 ng/ml in control media (25, 26). The extracellular 
matrix was pre-treated with MMP-2- or MMP-9-containing media. To increase cell 
numbers for the control condition (no MMPs), control data was pooled from both 
vehicle controls (water and PBS) since they were run on the same well plate and 
displayed no significant differences between them.  
3.2.6 ROCK inhibition 
For some experiments of the 10 μM Y27636 (Cayman Chemical, Ann Arbor, 
MI, USA) ROCK inhibitor was used. Y-27632 was added at the same time as ACM 
(for direct treatment of cells with ACM) and incubated with the cells for the duration 
of the time lapse experiment, or it was added when the cells were plated (for cells on 
ACM-treated collagen I) and incubated with the cells for the remainder of the time 





3.2.7 2D Migration Assays 
Glass bottom 24-well cell culture plates (MatTek, Ashland, MA, USA) were 
coated with type I collagen, type IV collagen, fibronectin, laminin, or PDL, 
depending on the experiment. MDA-MB-231, MDA-MB-468, MCF7, or MCF10A 
cells (1×104 total) were plated in each well in experiments where cells were directly 
later treated with ACM, depending on the type of experiment. All experiments 
comparing cell morphology and migration on different extracellular matrix molecules 
were performed using MDA-MB-231 cells only. All experiments comparing the 
response of different cell lines to ACM were performed using type I collagen 
extracellular matrix. All other experiments were performed using MDA-MB-231 cells 
and a type I collagen extracellular matrix. Cells were incubated at 37˚C, 50% 
humidity, and 5% CO2:95% air overnight. The next day, media was changed to ACM, 
control media, or control media or ACM with batimastat, TGF-β, DMSO, water, 
PBS, MMP-2, or MMP-9, depending on the type of experiment. In some experiments, 
10 ng/ml of TGF-β was directly added to ACM, control media, and serum free media 
in order to compare results to the ACM from TGF-β-treated astrocytes. For ACM 
pre-treatment of extracellular matrix protein or PDL, ACM or control media with 
DMSO, water, PBS, MMP-2, or MMP-9, depending on the type of experiment, was 
added directly to the extracellular matrix and incubated overnight at 37˚C, 50% 
humidity, and 5% CO2:95% air. On the following day, the extracellular matrix was 
washed three times with PBS, HBSS, or water, depending on the extracellular matrix, 
and 1×104 MDA-MB-231, MDA-MB-468, MCF7, or MCF10A cells were plated, 





were allowed to attach for three hours prior to imaging. MDA-MB-231, MDA-MB-
468, MCF7, or MCF10A cells (5×104 total) were plated in the same conditions as 
discussed above on extracellular matrix-coated glass bottom dishes for staining with 
phalloidin, as discussed below.  
3.2.8 Timelapse and Phase Imaging 
Images were acquired on an Olympus IX83 microscope (Olympus, Center 
Valley, PA, USA) using a 10× objective. In order to maintain the cells alive during 
the imaging, a chamber calibrated to 37˚C, 50% humidity, and 5% CO2:95% air was 
used on the microscope stage. Images were taken at 5 - 10 minute intervals (as 
described in detail in figure captions). On the following day, a collection of phase 
contrast images was taken using a 20× objective.  
3.2.9 Microfabrication 
We have previously reported the procedure to fabricate microfluidic devices 
containing channels of varying width [108],[112],[113]. All fabrication was carried 
out in the University of Maryland microfabrication facility using photolithographic 
methods. Briefly, a mask was designed in AutoCAD (AutoDesk, San Rafael, CA, 
USA). Four-inch diameter silicon wafers (University Wafer, Boston, MA, USA) were 
spin coated with SU-8 (negative photoresist) 3010 and 3025 in two layers 
(MicroChem, Westborough, MA, USA) for the cell seeding and confinement 
channels, respectively. For each layer, an EVG620 Mask Aligner (EVG Group, 
Albany, NY, USA) was used to crosslink the photoresist with ultraviolet light (UV) 





fabrication, the wafer surface was silanized with tridecafluoro 1,1,2,2,tetrahydrooctyl- 
1-trichlorosilane (97%) (Pfaltz & Bauer, Waterbury, CT, USA) overnight. This 
process resulted in a silicone wafer with raised channels of 50, 20, 10, 6, and 3 μm 
widths (data shown for 50, 10, and 3 μm widths), 200 μm length, and approximately 
10 μm height. Polydimethylsioloxane (PDMS) was mixed to a 10:1 ratio of elastomer 
base and elastomer curing agent from a Silicon Elastomer Kit (Robert McKeown 
Company, Branchburg, NJ, USA), degassed in a vacuum chamber for approximately 
one hour, and baked at 80ºC until cured, approximately two hours. The PDMS 
devices, along with 35 mm by 75 mm #1.5 glass coverslips, were then cleaned with 
ethanol, reverse osmosis treated water, and then ethanol again. They were then treated 
by plasma using a plasma cleaner (Harrick Plasma, Ithaca, NY, USA) and pressed 
together for bonding. The fabrication process resulted in a chemotactic device with 4 
inlet wells. Cells were seeded in the bottom-most well, and a chemoattractant was 
added to the top-most well, as described in the following section. 
3.2.10 Microchannel Assay 
Microfabricated devices containing microchannels were incubated with type I 
rat tail collagen (20 μg/mL) for one hour at 37˚C and then washed three times with 
PBS. MDA-MB-231 cells (1x105 cells suspended in 25 μL of either serum free media 
or full media, depending on the experimental condition) were then seeded into the 
inlet of the microfluidic device and incubated for 5-10 minutes to allow the cells to 
loosely attach. Then, the remaining media was taken out and replaced by 60-80 μL 
(per well) of either serum-containing media in all wells of the device, or serum-free 





top channel contained either serum-containing control media or ACM. The following 
chemoattractant conditions were considered: serum alone (positive control since 
serum is a chemoattractant for MDA-MB-231 cells), serum-containing ACM alone, 
serum-containing ACM with serum as additional chemoattractant, and no 
chemoattractant (all wells with serum-containing control media as a negative control). 
Two general set-ups were used: 1) tumor cells were seeded in serum-free media, and 
serum-containing ACM or serum-containing control media was used as a 
chemoattractant in the topmost channel. In some cases, cells were pre-incubated in 
ACM for 1-4 days and seeded similarly with serum-containing ACM as the 
chemoattractant. 2) tumor cells were seeded in serum-containing control media and 
either serum-containing ACM or serum-containing control media was used as the 
chemoattractant or negative control, respectively, in the topmost channel. The cells 
were then imaged live using time lapse microscopy at 37˚C, 50% humidity, and 5% 
CO2:95% with 10 minute intervals. 
3.2.11 Cell Staining 
Cells were washed once with PBS and fixed with 3.7% formaldehyde 
(FisherScientific, Fair Lawn, NJ, USA) for 10 minutes. Following fixation, cells were 
washed three times with PBS. Cells were then permeabilized with 1% Triton X-100 
(Sigma Aldrich) for 5 minutes at room temperature. Cells were washed again three 
times with PBS. Cells were then blocked for non-specific binding with 2.5% bovine 
serum albumin (BSA) (Sigma Aldrich) for at least an hour. Cells were then incubated 





1:2500 Hoechst 33342 (ThermoFisher Scientific) in PBS for one hour at room 
temperature. After staining, cells were washed three times with PBS.  
3.2.12 Confocal Microscopy 
Stained samples were imaged via either a Zeiss LSM 710 confocal 
microscope (Zeiss, Oberkochen, Germany) using a 60× oil immersion objective, or an 
Olympus FV3000 confocal microscope (Olympus) in resonance scanning mode with 
deconvolution using an appropriate filter and a 100× silicone immersion objective. 
Confocal images were reconstructed in ImageJ software (https://imagej.nih.gov) into 
a three-dimensional image using a maximum intensity projection. Intensities of 
corresponding control media-ACM image pairs were adjusted equally in ImageJ, as 
noted in the figure caption. 
3.2.13 Data Analysis 
Data were analyzed using the ImageJ software. Morphology of cells was 
measured by first manually tracing the outlines of cells imaged via phase contrast 
microscopy using a 20× objective, as we have previously described in Stroka et al, 
2016[114]. Briefly, cell “inverse aspect ratio” was calculated by dividing the length 




, where A is the area of the cell and P is the perimeter of the cell, both 
of the cell projections in phase contrast images. Cell solidity was defined as the ratio 
Acell
Aconvex
,  where Acell is the area of the cell and Aconvex is the convex area of the cell. 





 Positions of cells both in 2D and in confinement were evaluated by tracking 
cells using the “Manual Tracking” ImageJ plug-in. The approximate centroid of each 
cell was tracked over 300-670 minutes (for 2D assays, as stated in detail in figure 
captions) or 15 hours (for confinement assays). 5-10 minute time intervals were used 
between images, as stated in figure captions. Cells were not tracked if they divided, 
went out of the frame, or were significantly obstructed by an artifact or another cell. 
MCF7 and MCF10A cells that formed clusters were not analyzed and only single 
cells were selected for analysis. Migration analysis was started on the frames where 
cells appeared to have attached. A custom MATLAB (Mathworks, Natick, MA, 
USA) code was used to calculate velocities of the cells using output from the ImageJ 
tracking. The average velocity of cells in 2D was quantified by calculating the 
instantaneous velocities between every set of two points and then averaging the 
individual instantaneous velocities over all timepoints. The mean square displacement 
(MSD) was reported for 500 minutes and the diffusion coefficient was obtained from 
a Langevin-type fit [115] carried out in MATLAB to the mean square displacement 
curve over 200-268 minutes. MSD was calculated as the average of the square of the 
distance traveled using a sliding time average, and as described in Appendix B [115]. 
The sliding time average was obtained by averaging the MSD values for every time 
interval and thus obtaining the MSD at each time point [115]. The Langevin-type 
equation used was as follows: r2 = 4D t − 1− e−1/( )( ), where D is the diffusion (or 
random motility) coefficient, r2 is the two-dimensional MSD, t is time, and τ is the 
persistence time, and as described in Appendix B [115]. In confinement, speed was 





is moving toward or away from the chemoattractant. The chemotactic index (CI) was 
calculated by dividing the end-to-end distance of a cell from the beginning and end of 

















 and as described in Appendix B. The 
chemotactic index ranges from 0 to 1, where 1 indicates that the cell is moving 
completely straight (i.e., persistently). To compare the increase in velocities of ACM-
treated conditions when cells were treated directly and when collagen was pre-treated 
with ACM, the percent change was calculated as by obtaining the difference between 
the velocities of cells in the ACM-treated conditions and the velocities of cells in the 
control media-treated conditions and dividing by the reference value, which is the 
control media-treated condition. These parameters are further described in Appendix 
B. This was carried out for each of three trials for the ACM-treated cells and collagen 
sets of data as follows: % change = 
VACM −VControl
VControl
x100% , where V is velocity.  
3.2.14 Statistics 
Three independent trials were conducted for each experiment unless otherwise 
stated in the caption. Cells from all three experiments were pooled. Normality was 
assumed due the large sample size, which allows for parametric statistical analyses. 
For comparison of more than two groups of data, a one-way Analysis of Variance 
(ANOVA) test was performed in GraphPad (GraphPad, San Diego, CA), with a 
Tukey post-hoc test for multiple comparisons. A two-sided Welch’s t-test was used to 





GraphPad was used to generate histograms. A 95% confidence interval with P<0.05 
was used as the significance cutoff for all statistical tests. Cumulative distribution 
functions were tested for statistical significance using the two-sample Kolmogorov-
Smirnov test with P<0.05 indicating significantly different distributions. 
3.3 Results 
3.3.1 ACM alters metastatic breast tumor cell morphology and migration 
Astrocyte-secreted factors can reportedly enhance tumor cell invasion and 
metastatic potential[48], though the details of these effects are poorly understood. In 
order to corroborate previous reports regarding ACM-induced cell migration and 
identify whether these effects are accompanied by changes in tumor cell morphology, 
MDA-MB-231 cells were seeded on type I collagen-coated glass, allowed to attach 
overnight, and on the following day, culture media was replaced with ACM and 
incubated overnight (~16 hours) (Figure 3.1 A). Type I collagen was chosen as a 
substrate for preliminary experiments due to the fact that cell migration and  
Figure 3.1: Morphology and migration of ACM-treated tumor cells. For all images and 
plots: Black=Control Media; Red=ACM A) Diagram of experimental set-up, showing MDA-
MB-231 cells plated on type I collagen on glass on day 1, and media replaced with ACM on 
day 2. B) Representative phase contrast images of MDA-MB-231 cells treated with control 
media (left) or ACM-treated cells (right). Scale bar represents 20 µm and applies to both 
images. C) Cell areas and D) circularities, inverse aspect ratios, and solidities of the MDA-
MB-231 cells treated with control media or ACM. n(control)=1800 cells; n(ACM)=2045 
cells. E) Trajectories of all the cells treated with control media or ACM (5-minute time 
intervals). F) Cumulative distribution function plot of cell velocities when treated with 
control media or ACM. n(control)=272 cells; n(ACM)=300 cells, G) Average cell velocities 
tracked for 500 minutes with a 5-minute time interval, H) mean square displacement over 500 
minutes, and I) diffusion coefficients obtained from a Langevin-type fit to the mean square 
displacement plot over 200 minutes, of cells treated with control media or ACM. 
n(control)=272 cells; n(ACM)=300 cells. 5-minute time interval. Statistical analysis carried 
out using an unpaired t-test using a Welch’s t-test with p<0.05 (* p<0.05; ** p<0.01; *** 
p<0.001; ****p<0.0001). In all plots, bars indicate mean of pooled data from N≥3 





























morphology on this extracellular matrix have been well characterized in the literature 
[116]–[119]. Phase contrast images revealed that ACM-treated cells were larger and 
more elongated than control cells (Figure 3.1 B); this observation was confirmed 
quantitatively, with ACM-treated cells having significantly larger cell areas (Figure 
3.1C) and aspect ratios (Figure 3.1 D).  
The trajectories of tumor cells treated with control media or ACM overnight 
on type I collagen-coated glass indicated that the population of ACM-treated cells 
migrated over a larger area than control media-treated cells (Figure 3.1 E).  
Cumulative distribution functions of velocities for control and ACM-treated cells 
were significantly different when tested with the two-sample Kolmogorov-Smirnov 
test, with a shift towards increased velocity for cells treated with ACM (Figure 3.1 F). 
Further, the average velocity of ACM-treated cells was significantly greater (Figure 
3.1 G) than those of control media-treated cells, and the ACM-treated cells also had 
larger MSD versus time (Figure 3.1 H), and diffusion coefficient (Figure 3.1 I) in 
comparison with control cells.  
Media conditioned by astrocytes could be depleted of nutrients, including 
serum, in addition to being enriched in other soluble factors produced by the 
astrocytes. To evaluate the possible effects of the concentration of soluble factors in 
ACM on tumor cell morphology and migration, ACM was diluted to 5, 10, 20, 50, 
and 75% using serum-containing control media. Serum-free media was included as a 
control in order to test a nutrient deficient condition. Tumor cells were seeded on type 
I collagen-coated glass, allowed to attach overnight, and on the following day, culture 





free media, and incubated overnight. Tumor cell areas increased with increased ACM 
concentration (Figure 3.2 A), suggesting the presence of a soluble factor influencing 
tumor cell morphology. Areas (Figure 3.2 A), circularities, inverse aspect ratios, and 
solidities (Figure 3.2 B) were all significantly different from the control media at 
ACM concentrations above 20% ACM. The velocities of the tumor cells were higher 
in concentrations of 50% ACM and above compared to the control (Figure 3.2 C). 
The diffusion coefficient of ACM-treated cells also tended to increase with ACM 
concentration, though this relationship was not statistically significant (Figure 3.2 D). 
While tumor cells treated with serum-free media had similar morphologies to 100% 
ACM (Figure 3.2 B), they did not display increased migration potential, and further 
showed no differences in velocity or diffusion coefficient in comparison with cells 
treated with serum-containing control media (Figure 3.2 C, D). Hence, we conclude 
that the effect of ACM on cell migration is likely due to soluble factors present in 
ACM and not due to serum depletion. 
3.3.2 ACM-induced changes in extracellular matrix alter metastatic breast 
tumor cell migration 
Our results herein and the work of others indicate that ACM applied directly 
to MDA-MB-231 tumor cells can increase tumor cell migration potential. However, 
no studies have yet evaluated the effects of astrocyte-secreted factors on the 
extracellular matrix. Thus, type I collagen was pre-treated with ACM prior to seeding 
MDA-MB-231 cells (Figure 3.3 A). In these experiments, the area of the tumor cells 










Figure 3.2: Morphology and migration of ACM-treated tumor cells with different 
ACM dilutions. A) Areas and B) circularity, inverse aspect ratio, and solidity (right) of the 
MDA-MB-231 cells (on type I collagen) treated with control media or 5-100% ACM. 
n(serum free) = 682; n(0% ACM)=1010; n(5% ACM)=689; n(10% ACM)=663; n(20% 
ACM)=634; n(50% ACM)=1025; n(75% ACM)=476; n(100% ACM)=896 cells. C) 
Velocities and D) diffusion coefficient (right), obtained from a Langevin-type fit to a mean 
square displacement curve over 200 minutes. n(serum free) = 96; n(0% ACM)=157; n(5% 
ACM)=102; n(10% ACM)=109; n(20% ACM)=83; n(50% ACM)=165; n(75% ACM)=54; 
n(100% ACM)=187 cells. 5-6.7 minute time intervals. Statistics carried out using a one-way 
ANOVA and Tukey’s post-hoc analysis with p<0.05. (* p<0.05; ** p<0.01; *** p<0.001; 
****p<0.0001). In all plots, individual points indicate mean of pooled data from N≥3 
independent experiments, and error bars represent standard error of the mean. Note that 
some error bars not visible because the size of the point marker is larger than the error bars. 





directly with ACM. Of additional morphology parameters, inverse aspect ratio 
significantly increased when the collagen was pre-treated with ACM (Figure 3.3 C), 
which was opposite the effect when cells were treated directly with ACM. 
Meanwhile, area (Figure 3.3 B) and other morphology parameters (Figure 3.3 C) did 
not change significantly. However, most notably, we observed a substantial increase 
in tumor cell migration on ACM-treated type I collagen substrates, with cell 
trajectories showing tumor cells on ACM-treated type I collagen migrating over a 
larger area than cells on control media-treated type I collagen (Figure 3.3 D). 
Cumulative distribution functions of velocities for cells migrating on control and 
ACM-treated extracellular matrix were significantly different when tested with the 
two-sample Kolmogorov-Smirnov test, with a shift towards increased velocity for 
cells on ACM-treated extracellular matrix (Figure 3.3 E). Quantitatively, there was a 
significant increase in tumor cell average velocity (Figure 3.3 F), MSD (Figure 3.7 
G), and diffusion coefficient (Figure 3.7 H); this increase in migration was even 
greater than when cells were treated directly with ACM, as indicated by the 
comparison of a percent increase in velocity of 36% for ACM-treated cells versus 
92% for ACM-treated type I collagen as compared to control-media treatments 
(Figure 3.7 I).  
3.3.3 Cells of varying tumorigenic and metastatic potential respond uniquely to 
ACM 
To determine whether cell response to ACM is conserved over multiple cell 
lines, we repeated migration and morphology experiments on several additional cell 






Figure 3.3: Morphology and migration of tumor cells on ACM-treated extracellular 
matrix. For all images and plots: Black=Control Media; Red=ACM A) Diagram of 
experimental set-up, showing type I collagen plated and treated with ACM on day 1, and on 
day 2 MDA-MB-231 cells plated in control media. B) Quantification of cell areas and C) 
circularity, inverse aspect ratio, and solidity of MDA-MB-231 cells plated on control media 
or ACM-treated type I collagen. n(control)=716 cells; n(ACM)=742 cells. D) Trajectories of 
all the cells on collagen treated with control media (left) or ACM (right). n(control)=223 
cells; n(ACM)=201 cells. E) Cumulative distribution function plot of cell velocities on 
control- or ACM-treated type I collagen. Also shown is quantification of F) average cell 
velocities, G) mean square displacement with 5 minute intervals over 500 minutes, and H) 
diffusion coefficient, obtained from a Langevin-type fit to the mean square displacement 
curve over 200 minutes, of MDA-MB-231 cells on control media or ACM-treated type I 
collagen. I) Comparison of percent increase in velocity between ACM-treated and control 
media-treated conditions of the ACM-treated cells and ACM-treated type I collagen 
experiments. Statistical analysis carried out using an unpaired t-test using a Welch’s 
correlation with p<0.05. (* p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001). In all plots, 
bars indicate mean of pooled data from N≥3 independent experiments, and error bars 

























468; (2) the tumorigenic but non-metastatic breast tumor cell line, MCF7; and (3) the 
normal breast epithelial cell line, MCF10A. We selected these additional cell lines to 
(a) evaluate the effects of ACM on an additional metastatic breast tumor cell line, and 
(b) evaluate whether ACM can alter the morphology and/or increase the migration of 
non-metastatic breast tumor cells, or even normal breast epithelial cells. Migration 
assays on both type I collagen (and also on fibronectin; data not shown) revealed that 
MCF7 and MDA-MB-468 cells were non-migratory (velocities less than 10 µm/hr, 
which is mostly due to small random displacements in place rather than true 
migration), and addition of ACM to either the cells or their extracellular matrix did 
not promote migration. Meanwhile, direct treatment of MCF10A cells with ACM led 
to a statistically significant increase in cell migration velocity (Figure 3.4 A), while  
Figure 3.4: Morphology and migration of cells of varying metastatic potential either 
treated with ACM or on ACM-treated extracellular matrix. For all images and plots: 
Black=Control Media; Red=ACM. Velocities of MCF10A cells on type I collagen when the 
cells were A) treated with control media or ACM (n(control)=100 cells; n(ACM)=110 cells) 
and B) seeded on type I collagen pre-treated with control media or ACM (n(control)=118 
cells; n(ACM)=118 cells). Statistical analysis carried out using an unpaired t-test using a 
Welch’s correlation with p<0.05. (* p<0.05). C) Percent change in velocities of cells of 
MCF10A cells when treated with control media or ACM or seeded on type I collagen that 
was pre-treated with control media or ACM. Cell migration was analyzed over 5 hours with 
10 minute intervals between frames. D) Areas and E) corresponding circularities, inverse 
aspect ratios, and solidities of MCF10A, MCF7, and MDA-MB-468 cells on type I collagen 
when the cells were treated with control media or ACM (n(control, MCF10A)=120 cells; 
n(ACM, MCF10A)=69 cells; n(control, MCF7)=206 cells; n(ACM, MCF7)=161; n(control, 
MDA-MB-468)=492 cells; n(ACM, MDA-MB-468)=380 cells). F) Areas and G) 
corresponding circularities, inverse aspect ratios, and solidities of MCF10A, MCF7, and 
MDA-MB-468 cells seeded on type I collagen that was pre-treated with control media or 
ACM (n(control, MCF10A)=158 cells; n(ACM, MCF10A)=139 cells; n(control, MCF7)=562 
cells; n(ACM, MCF7)=389 cells; n(control, MDA-MB-468)=646 cells; n(ACM, MDA-MB-
468)=700 cells). Note that for all experiments, only single cells were analyzed and cells that 
formed clusters were excluded. Statistical analysis was performed using a Tukey’s multiple 
comparison post-hoc test with p<0.05. (* p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001). 
In all plots, bars indicate mean of pooled data from N=2 independent experiments, and error 
bars represent standard error of the mean with p<0.05. (* p<0.05; ** p<0.01; *** p<0.001; 
****p<0.0001). In all plots, bars indicate mean of pooled data from N≥3 independent 
experiments, and error bars represent standard error of the mean. Rebecca Moriarty assisted 










MCF10A cells plated on ACM-treated type I collagen substrates demonstrated no 
change in cell migration velocity (Figure 3.4 B). Thus, for MCF10A cells, the percent 
change in velocity from control to ACM was significantly more positive for the 
condition in which cells were directly treated with ACM, in comparison with ACM-
treated extracellular matrix (Figure 3.4 C). These results differ from MDA-MB-231 
cells (Figure 3.3 I), suggesting that the effects of ACM (either directly on cells or 
treatment of extracellular matrix) on cell migration may be dependent on cell type 
and degree of tumorigenicity or metastatic potential. 
  Meanwhile, for all additional cell lines, we observed mostly similar trends in 
morphological changes (i.e. same trends as MDA-MB-231 cells on type I collagen in 
Figures 3.1 and 3.3) in cells treated directly with ACM, and also cells plated on 
ACM-treated type I collagen substrates (Figure 3.4 D, E, F, G). More specifically,  
direct treatment of cells with ACM resulted in statistically significant increases in cell 
area, along with decreases in inverse aspect ratio, circularity, and solidity for 
MCF10A and MDA-MB-468 cell lines (similar to MDA-MB-231 cells in Figure 1 B, 
C, D) (Figure 3.4 D, E). Meanwhile, direct treatment of MCF7 cells with ACM 
resulted in no difference in cell area or solidity, but decreased inverse aspect ratio and 
circularity (Figure 4 D, E). We also observed some minor (or no) changes in cell 
morphological parameters in cells plated on ACM-treated type I collagen substrates, 
but these were much less significant than in cells treated directly with ACM (Figure 
3.4 F, G), which is also consistent with what we observed for MDA-MB-231 cells 






treatment of the collagen substrate) on cell morphology seem to be conserved across 
multiple breast cell lines and cell lines with varying tumorigenic and metastatic 
potential. 
3.3.4 Cell response to ACM is conserved on multiple extracellular matrix 
proteins 
In order to test whether the response of cells was unique to type I collagen, or 
whether it was conserved across multiple extracellular matrix proteins, we repeated 
the morphology and migration experiments using MDA-MB-231 cells plated on 
several additional extracellular matrix proteins that are present in the BBB  
microenvironment, including fibronectin, laminin, and type IV collagen. The 
migration assays demonstrated that there was no significant increase in MDA-MB-
231 cell velocity when cells (on fibronectin, laminin, or collagen IV) were treated 
directly with ACM (Figure 3.5 A), unlike on type I collagen, where an increase in cell  
migration velocity was observed (Figure 3.1 G). However, for fibronectin and 
laminin, there was a statistically significant increase in cell migration velocity on 
substrates pre-treated with ACM (Figure 3.5 B). The more pronounced increase in 
migration on ACM-treated fibronectin and laminin substrates (in comparison with 
cells directly treated with ACM; Figure 3.5 C) is consistent with our migration results 
on type I collagen (Figure 3.3 I). Interestingly, we did not observe any statistically 
significant changes in migration velocity for any conditions on collagen IV (Figure 
3.5 A, B), suggesting that there may be differential migration-induced effects of the 
ACM on various extracellular matrix or basement membrane proteins. Notably, 





and treated directly with ACM demonstrated significant morphological changes 
(similar to results on type I collagen), including increases in cell area and decreases in 
inverse aspect ratio, circularity, and solidity (Figure 3.5 D, E). Meanwhile, 
morphological changes in MDA-MB-231 cells plated on ACM-treated fibronectin, 
laminin, and type IV collagen substrates were either not significantly different, or less 
so than for the case of cells directly treated with ACM (e.g., p-value closer to 0.05) 
(Figure 3.5 F, G). These results are also consistent with our results for type I collagen 
(Figures 3.3 B, C). 
  
Figure 3.5: Morphology and migration of ACM-treated tumor cells and tumor cells 
on ACM-treated extracellular matrices with varying binding moieties. For all images 
and plots: Black=Control Media; Red=ACM. Velocities of MDA-MB-231 cells on type IV 
collagen, fibronectin, laminin, and PDL when the cells were A) treated with control media 
or ACM (n(control, type IV collagen)=127 cells; n(ACM, , type IV collagen)=152 cells; 
n(control, fibronectin)=133 cells; n(ACM, fibronectin)=142 cells; n(control, laminin )=118 
cells; n(ACM, laminin)=131 cells; n(control, PDL )=73 cells; n(ACM, PDL)=58 cells) and 
B) seeded on extracellular matrix pre-treated with control media or ACM (n(control, type 
IV collagen)=131 cells; n(ACM, , type IV collagen)=155 cells; n(control, fibronectin)=141 
cells; n(ACM, fibronectin)=151; n(control, laminin )=116 cells; n(ACM, laminin)=129 
cells; n(control, PDL )=62 cells; n(ACM, PDL)=83 cells). C) Percent change in velocities 
of cells of MDA-MB-231 cells when seeded on type IV collagen, fibronectin, laminin, or 
PDL and treated with control media or ACM or seeded on extracellular matrix that was 
pre-treated with control media or ACM. Cell migration was analyzed over 5 hours with 10 
minute intervals between frames. D) Areas and E) corresponding circularities, inverse 
aspect ratios, and solidities of MDA-MB-231 cells on type IV collagen, fibronectin, 
laminin, and PDL when the cells were treated with control media or ACM (n(control, type 
IV collagen)=578 cells; n(ACM, type IV collagen)=578 cells; n(control, fibronectin)=704 
cells; n(ACM, fibronectin)=559 cells; n(control, laminin )=436 cells; n(ACM, 
laminin)=363 cells; n(control, PDL )=220 cells; n(ACM, PDL)=208 cells). F) Areas and 
G) corresponding circularities, inverse aspect ratios, and solidities of MDA-MB-231 cells 
seeded on extracellular matrix pre-treated with control media or ACM (n(control, type IV 
collagen)=560 cells; n(ACM, type IV collagen)=642 cells; n(control, fibronectin)=526 
cells; n(ACM, fibronectin)=733 cells; n(control, laminin )=556 cells; n(ACM, 
laminin)=585 cells; n(control, PDL )=162 cells; n(ACM, PDL)= 225 cells). Statistical 
analysis was performed using a Tukey’s multiple comparison post-hoc test with p<0.05. (* 
p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001). In plots for type IV collagen, 
fibronectin, and laminin, bars indicate mean of pooled data from N≥3 independent 
experiments while in plots for PDL bars indicate mean of pooled data from N≥2 
independent experiments, and error bars represent standard error of the mean. Rebecca 













We also performed morphology and migration experiments on substrates 
coated with poly-D-lysine (PDL), which enhances electrostatic interactions between 
cells and the surface but does not promote integrin binding. We added this coating 
into the experimental setup to (indirectly) test the hypothesis that ACM treatment of 
the extracellular matrix or basement membrane alters integrin binding to the 
substrate. MDA-MB-231 cells plated on PDL and treated with ACM demonstrated 
statistically significant changes in morphological parameters, including increased area 
and decreased inverse aspect ratio, circularity, and solidity (Figure 3.5 D, E). 
Meanwhile, cells plated on ACM-treated PDL demonstrated no changes in any 
morphological parameter (Figure 3.5 F, G). Therefore, we speculate that ACM-
induced changes in cell morphology are not integrin-dependent. Intriguingly, MDA-
MB-231 cells plated on PDL and treated directly with ACM demonstrated no change 
in cell migration velocity (Figure 3.5 A), and trended towards decreased velocities 
(though not statistically significant) on ACM-treated PDL (in contrast with the 
increased velocities observed on other ACM-treated extracellular matrix substrates) 
(Figure 3.5 B, C). Hence, we speculate that the migratory response of cells to ACM 
treatment of the extracellular matrix may be dependent on integrin binding, though 






3.3.5 Direct treatment of cells with ACM alters actin cytoskeleton organization 
Given the significant alterations in cell morphology observed in response to 
direct treatment with ACM, we hypothesized that the actin cytoskeleton would also 
demonstrate concomitant changes in organization in response to ACM. Hence, cells 
were plated on extracellular matrix-coated glass substrates, fixed, permeabilized, 
stained for actin, and imaged via laser scanning confocal microscopy. Indeed, ACM-
treated MDA-MB-231 cells displayed more prominent actin stress fibers in 
comparison with control media-treated cells on type I collagen (Figure 3.6 A, B) and 
also on collagen IV, fibronectin, and laminin substrates (Figure 3.6 C). Meanwhile, 
ACM did not alter cell for both control and ACM-treated cells (Figure 3.6 C). There 
was also a (visual) actin organization on PDL, where only a diffuse actin network was 
observed for both control and ACM-treated cells (Figure 3.6 C). There was also a 
(visual) increase in actin stress fiber alignment in ACM-treated MCF10A cells and a 
minimal (visual) increase in stress fiber content in MCF7 cells (Figure 3.6 D). ACM 
did not appear to alter the actin organization of MDA-MB-468 cells (Figure 3.6 D). 
 
 
Figure 3.6: Cytoskeletal arrangement of ACM-treated cells of different metastatic 
phenotypes and tumor cells on ACM-treated extracellular matrix. A) Stitched images of 
a large area of MDA-MB-231 cells treated with control media or ACM and stained for actin 
(green) and the nucleus (blue) on type I collagen. B) Images of control media-treated (top) 
and ACM-treated MDA-MB-231 cells (bottom) stained for actin (green) and the nucleus 
(blue) on type I collagen. Images in panels (A) and (B) were taken using a 100x objective of 
an Olympus FV3000 confocal microscope. C) Images of control media-treated (left) and 
ACM-treated (right) MDA-MB-231 cells on type IV collagen, fibronectin, laminin, or PDL 
and stained for actin (green) and the nucleus (blue). D) Images of MCF10A, MCF7, and 
MDA-MB-468 on type I collagen, stained for actin (green) and the nucleus (blue). Images in 
panels (C) and (D) were taken using a 60x objective of a Zeiss LSM 710 
confocal microscope. The intensity of the images was adjusted equally between each set of 
conditions in order to best view the actin arrangement. Scale bars = 20µm and apply to all 













3.3.6 Astrocyte activation via TGF-β does not enhance the effect of ACM  
As discussed above, the astrocyte secretome changes when astrocytes become 
reactive, which occurs in response to injury or insult, such as cancer or stroke [120]. 
To date, no studies have systematically evaluated the effects of soluble factors from 
quiescent and activated astrocytes on tumor cell morphology and migration. We and 
others have previously shown that different serum conditions in conjunction with 
TGF-β treatment can be used to alter the activation state of astrocytes [103], [121], 
[122]. Specifically, we have shown that TGF-ß in combination with serum starvation 
induces a time-dependent increase in KCa3.1 protein expression, and at 5 days, 
induces expression of the glial fibrillary acidic protein (GFAP; marker protein of 
reactive astrogliosis) and the production of chondroitin sulfate proteoglycans 
(CSPGs). Thus, three ACM regimens were used with or without TGF-β treatment: 1) 
astrocytes were cultured in serum-free media overnight and then treated with TGF-β  
in serum-free media for 5 days; 2) astrocytes were cultured in serum-free media 
overnight and then treated with TGF-β in serum-containing media for 5 days; 3) 
astrocytes were cultured in serum-containing media overnight and then treated with 
TGF-β in serum-containing media for 5 days before harvest. The addition of serum 
was necessary since the ACM used for other experiments contained serum. We note 
that in each of the experiments, astrocytes remained attached to the substrate, 
maintained confluency, and appeared viable. Astrocytes demonstrate strong contact- 
inhibition and thus stop dividing once they reach confluency, and hence total 





cells were cultured on type I collagen-coated glass overnight, and on the following 
day, culture media was replaced with ACM from TGF-β-treated astrocytes, ACM  
from untreated astrocytes, or control media, and incubated overnight. Tumor cell 
morphology was not significantly different after treatment with ACM from a five-day 
culture of TGF-β-activated astrocytes, in comparison with ACM from untreated 
astrocytes (Figure 3.7 A, B). However, ACM from TGF-β-treated serum-starved 
astrocytes resulted in significantly decreased tumor cell velocities in comparison with  
ACM from untreated serum-starved astrocytes (Figure 3.7 C). Without astrocyte 
serum starvation, TGF-β treatment in astrocytes had no effect on tumor cell velocity 
(Figure 3.7 C). Meanwhile, there was no significant difference in tumor cell diffusion 
coefficient after tumor cells were treated with ACM from TGF-β-treated versus 
untreated astrocytes for any of the serum conditions (Figure 3.7 D).  
However, TGF-β itself can promote epithelial-mesenchymal transition and 
induce directional migration in breast cancer cells [123]. Thus, to confirm that the 
observed effects on tumor cell morphology and migration were not simply due to free 
TGF-β in the ACM, 10 ng/ml TGF-β was added to serum free media, control media, 
and two-day ACM, and migration experiments were performed on MDA-MB-231 
tumor cells cultured on type I collagen-coated glass. TGF-β addition resulted in 
increased circularity and inverse aspect ratio for tumor cells in serum free media and 
two-day ACM, and increased area for tumor cells in control media (Figure 3.8 A, B); 
however, the relative trends between TGF-β-treated and untreated tumor cells did not 
correspond to the changes seen in tumor cells treated with ACM from TGF-β -treated 






Figure 3.7: Tumor cells treated with ACM from TGF-β-treated astrocytes. Key: Serum 
Free: astrocytes were cultured without serum with or without TGF-β; Serum Free 
O/N+Serum: astrocytes were cultured without serum overnight and media was changed to 
media with serum with or without TGF-β; Full: astrocytes cultured in full media (with serum) 
with or without TGF-β. All ACM was conditioned for five days. A) Areas and B) circularity, 
inverse aspect ratio, and solidity of the MDA-MB-231 cells treated with control media or 
ACM. n(Serum Free – TGF-β)=626; n(Serum Free + TGF-β)=634; n(Serum Free O/N+Serum 
– TGF-β)=531; n(Serum Free O/N+Serum + TGF-β)=569; n(Full – TGF-β)=728; n(Full + 
TGF-β)=638 cells. C) Velocities (cells tracked for 670 minutes with 6.7 minute intervals) and 
D) diffusion coefficient, obtained from a Langevin-type fit to a mean square displacement 
curve over 268 minutes. n(Serum Free – TGF-β)=96; n(Serum Free + TGF-β)=93; n(Serum 
Free O/N+Serum – TGF-β)=73; n(Serum Free O/N+Serum + TGF-β)=69; n(Full – TGF-
β)=102; n(Full + TGF-β)=93 cells. Statistics carried out using a one-way ANOVA and 
Tukey’s post-hoc analysis with p<0.05. (* p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001). 
In all plots, bars indicate mean of pooled data from N independent experiments, and error 
bars represent standard error of the mean (N≥3 for all conditions, except Serum Free 






parameter for any condition (Figure 3.7 A, B). Furthermore, addition of TGF-β 
resulted in no changes in velocities (Figure 3.8 C) or diffusion coefficients (Figure 
3.8 D) of tumor cells in serum-free media, control media, or ACM. Thus, we 
conclude that free TGF-β did not cause the decrease in tumor cell velocity measured 
when tumor cells were treated with ACM from TGF-β-activated astrocytes (Figure 
3.7 C, D). Instead, changes in cell migration in response to ACM from TGF-β- 
activated astrocytes are likely a result of the altered astrocyte secretome in response 
to TGF-β.  
3.3.7 Inhibiting MMPs in ACM reverses its effect on metastatic breast tumor 
cells 
Previous studies have implicated MMPs in tumor cell migration changes [124] 
and also in the astrocyte secretome [48], [125].  Thus, MMPs could be one astrocyte-
secreted factor that might potentiate the observed phenotypic changes in tumor cells 
in response to ACM. In order to test this hypothesis, a broad-spectrum MMP 
inhibitor, batimastat, was used to inhibit all types of MMPs present in ACM. 
MDA-MB-231 tumor cells were cultured on type I collagen-coated glass overnight, 
and on the following day, culture media was replaced with control media with vehicle 
control, ACM with vehicle control, or ACM with varying concentrations of 
batimastat, and incubated overnight. In these experiments, as the concentration of 
batimastat in the ACM increased from 0.1 - 5 µM, the areas of tumor cells decreased 
to a similar size as the areas of cells treated with control media (Figure 3.9 A). 
Similarly, as batimastat concentration increased, tumor cells also returned to control-







Figure 3.8: Effect of exogenous TGF-β on ACM morphology and migration of ACM-
treated tumor cells. A) Areas B) circularity, inverse aspect ratio, and solidity of MDA-MB-
231 cells treated with control media, serum free media, or ACM with and without 10 ng/ml 
TGF-β. n(Serum Free – TGF-β)=264; n(Serum Free + TGF-β)=466; n(Control – TGF-
β)=284; n(Control + TGF-β)=408; n(ACM – TGF-β)=159; n(ACM + TGF-β)=383 cells. C) 
Velocities and D) diffusion coefficient, obtained from a Langevin-type fit to a mean square 
displacement curve over 200 minutes. n(Serum Free – TGF-β)=54; n(Serum Free + TGF-
β)=66; n(Control – TGF-β)=49; n(Control + TGF-β)=71; n(ACM – TGF-β)=33; n(ACM + 
TGF-β)=74 cells. 5-6.7 minute time intervals for 500-670 minutes. Statistics carried out using 
a one-way ANOVA and Tukey’s post-hoc analysis with p<0.05. (* p<0.05; ** p<0.01; *** 
p<0.001; ****p<0.0001). In all plots, bars indicate mean of pooled data from N independent 
experiments, and error bars represent standard error of the mean (N≥3 for all conditions, 





























Figure 3.9: Effect of MMP inhibition on morphology and migration of ACM-treated 
tumor cells. A) Areas and B) circularity, inverse aspect ratio, and solidity for MDA-MB-231 
cells treated with control media or ACM with DMSO as well as with ACM with 0.1, 1, and 5 
µM Batimastat. n(Control+DMSO)=445; n(ACM+DMSO)=343; n(ACM+0.1μM 
Batimastat)=328; n(ACM+1μM Batimastat)=325; n(ACM+5μM Batimastat)=360 cells. C) 
Velocities (cells tracked every 5 minutes for 500 minutes) and D) diffusion coefficients 
obtained from a Langevin-type fit to a mean square displacement curve over 200 minutes. 
n(Control+DMSO)=64; n(ACM+DMSO)=71; n(ACM+0.1μM Batimastat)=73; 
n(ACM+1μM Batimastat)=71; n(ACM+5μM Batimastat)=73 cells. Statistics carried out 
using a one-way ANOVA and Tukey’s post-hoc analysis with p<0.05. (* p<0.05; ** p<0.01; 
*** p<0.001; ****p<0.0001). In all plots, bars indicate mean of pooled data from N≥3 
independent experiments, and error bars represent standard error of the mean. Jonathan Siglin 





batimastat treatment also dose-dependently decreased the migration parameters of 
velocity (Figure 3.9 C) and diffusion coefficient (Figure 3.9 D) of cells treated with 
ACM. The results of MMP inhibition studies in ACM suggest that MMPs are 
implicated in the phenotypic changes of tumor cells treated with ACM. 
There exists evidence in the literature that MMP-2 and MMP-9 both can both 
cleave type I collagen [126], [127] and both of these MMPs are reportedly contained 
within ACM [48]. Thus, we added MDA-MB-231 cells to type I collagen-treated 
substrates that were pre-treated with exogenous MMP-2 or MMP-9 at 40 ng/ml or 
100 ng/ml. These concentrations were chosen based on previously published MMP-2 
and MMP-9 activity assay against gelatin [128] as well as previously published 
studies with exogenous MMP-2 and MMP-9 [129]. Treatment of cells on MMP-2- or 
MMP-9-treated extracellular matrix substrates resulted in similar increased (but not 
statistically significant) migration velocities as ACM (e.g., for 40 and 100 ng/mL 
MMP-2 and 40 ng/mL MMP-9) (Figure 3.10 A), while morphology was mostly 
unaffected by either MMP-2 or MMP-9 (Figure 3.10 B-C). These results suggest that 
MMP-2 and/or MMP-9 in ACM might be at least partially responsible for the ACM- 
Figure 3.10: Effect of exogenous MMP -2 and -9 on migration and morphology of tumor 
cells on ACM-treated extracellular matrix. A) Velocities of MDA-MB-231 cells on type I 
collagen that was pre-treated with control media, ACM, or control media with exogenous 
MMP-2 or MMP-9. (n(control)=80 cells; n(ACM)=120 cells; n(control+40 ng/ml MMP-2)= 
120 cells; n(control+100 ng/ml MMP-2)= 120 cells; n(control+40 ng/ml MMP-9)=80 cells; 
n(control+100 ng/ml MMP-9)=120 cells). Cell migration was analyzed over 5 hours with 10 
minute intervals between frames. B) Areas and C) corresponding circularities, inverse aspect 
ratios, and solidities of MDA-MB-231 cells seeded on type I collagen that was pre-treated 
with control media, ACM, or control media with exogenous MMP-2 or MMP-9 
(n(control)=321 cells; n(ACM)=449 cells; n(control+40 ng/ml MMP-2)=379 cells; 
n(control+100 ng/ml MMP-2)=366 cells; n(control+40 ng/ml MMP-9)=256 cells; 
n(control+100 ng/ml MMP-9)=317 cells). Statistical analysis was performed using a Tukey’s 
multiple comparison post-hoc test with p<0.05. (* p<0.05; ** p<0.01; *** p<0.001; 
****p<0.0001). In all plots, bars indicate mean of pooled data from N≥2 independent 
experiments, and error bars represent standard error of the mean. Rebecca Moriarty assisted 














induced effects on cell migration, for cells plated on ACM-treated type I collagen 
substrates, though the lack of statistical significance in velocity data (Figure 3.10 A) 
suggests other mechanisms are likely also at play. 
3.3.8 ROCK inhibition 
To begin to address the role of Rho/ROCK, we treated MDA-MB-231 tumor 
cells plated on collagen I with Y27632, a pharmacological ROCK inhibitor, and 
repeated morphology and migration experiments. We hypothesized that if ACM led 
to ROCK activation in either cells treated directly with ACM, or the cells on ACM-
treated extracellular matrix, then parallel treatment with Y27632 would attenuate the 
effects of ACM. We found that the addition of Y27632 enhanced migration overall, 
and negated the effect of ACM on velocity for both ACM-treated cells and 
extracellular matrix (Figure 3.11 A, B). However, morphological trends remained 
consistent between ROCK inhibited and control conditions, except for the inverse 
aspect ratio, where the effect of ACM was no longer apparent after ROCK inhibition 
(Figure 3.11 C, D, E, F).  Thus, these preliminary results seem to suggest that ROCK 
could be a player in the cross-talk between astrocytes and tumor cells, at least for the 
purposes of tumor cell migration.  
3.3.9 ACM does not serve as a chemoattractant for metastatic breast tumor 
cells in confined microchannels 
During metastasis across the BBB, tumor cells are exposed not only to 
biochemical cues, but also to physical cues such as confinement, since tumor cells 





work has suggested that tumor cells in confinement migrate via an alternate 
mechanism based on water permeation [108], as compared to cell migration in 2D 
which is drive by actin polymerization. Other recent work has continued to explore  
potential mechanisms guiding tumor cell migration in 3D matrices [130], [131]. Thus, 
an open question is whether ACM alters tumor cell migration differently in 
confinement versus 2D. In addition, it was also important to address whether ACM 
acts as a chemoattractant for tumor cells. Hence, here we used microfluidic devices 
containing microchannels of varying width to expose tumor cells to varying degrees 
of physical confinement and to a chemoattractant (e.g., serum or ACM). Two 
different conditions were used: (A) cells were seeded in serum-containing control 
media with no chemotactic gradient or with ACM as the sole chemoattractant (Figure 
3.12 A); or (B) cells were seeded in serum-free media with serum-containing control  
Figure 3.11: Effect of ROCK inhibition on tumor cells’ response to ACM. Velocities of 
MDA-MB-231 cells on type I collagen when A) treated with control media with DMSO, 
ACM with DMSO, control media with Y27632 (ROCK inhibitor), or ACM with Y27632 
(n(control+DMSO)=120 cells; n(ACM+DMSO)=75 cells; n(control+Y27632)=120 cells; 
n(ACM+ Y27632)=120 cells); and B) seeded on type I collagen pre-treated with control 
media or ACM and seeded in media containing DMSO or Y27632 (n(control+DMSO)=40 
cells; n(ACM+DMSO)=80 cells; n(control+ Y27632)=80 cells; n(ACM +Y27632)=80 
cells). Cell migration was analyzed over 5 hours with 10 minute intervals between frames. 
Areas of MDA-MB-231 cells on type I collagen when C) treated with control media with 
DMSO, ACM with DMSO, control media with Y27632, or ACM with Y27632 
(n(control+DMSO)=414 cells; n(ACM+ DMSO)=429 cells; n(control+Y27632)=198 cells; 
n(ACM +Y27632)=240 cells); and D) seeded on type I collagen pre-treated with control 
media or ACM and seeded in media with DMSO or Y27632 (n(control+ DMSO)=113 cells; 
n(ACM+DMSO)=257 cells; n(control+Y27632)=109 cells; n(ACM +Y27632)=134 cells). 
Corresponding circularities, inverse aspect ratios, and solidities of MDA-MB-231 cells on 
type I collagen when cells are E) treated with control media with DMSO, ACM with DMSO, 
control media with Y27632, and ACM with Y27632 and F) seeded on type I collagen pre-
treated with control media or ACM and seeded in media with DMSO or Y27632. Statistical 
analysis was performed using a Tukey’s multiple comparison post-hoc test with p<0.05. (* 
p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001). In all plots, bars indicate mean of pooled 
data from N≥2 independent experiments with just one replicate of the control+DMSO in the 
pre-treated collagen condition, and error bars represent standard error of the mean. Note, this 
figure was not included as part of the original paper. Rebecca Moriarty assisted with 












media or serum containing ACM on the other side of the channels, such that either 
serum or serum and ACM-containing soluble factors were the chemoattractants   
 (Figure 3.12 B). Condition (A) was used to determine whether ACM by itself acted 
as a chemoattractant. Condition (B) was used to determine whether ACM enhanced 
the effects of serum as a chemoattractant. In both conditions, cells were seeded in the 
collagen-coated devices and media was changed to one of the conditions described 
above. Cells migrated through the narrow channels towards the opposite side (Figure 
3.12 C), and cell velocity and chemotactic index were calculated as described in the 
Materials and Methods section, Appendix B, and in Figure 12 D. In both cases, tumor 
cells’ speed showed a biphasic relationship with channel width, with cells having  
Figure 3.12: Effect of ACM as a chemoattractant of tumor cells in microfluidic 
channels. A) Diagram of experimental set-up where ACM is serving as the sole 
chemoattractant (condition A). B) Diagram of experimental set-up where ACM and serum 
are chemoattractants (condition B). Cells cultured in control media or ACM. C) Example 
image sequence taken with 10 minute intervals of a single cell (indicated by arrow) traveling 
through a 6 µm channel with serum as a chemoattractant. The time step is labeled every 30 
minutes and the arrows indicate the same cell and are re-located from the leading to the 
trailing edge of cell due to space constraints at the end of the channel. D) Chemotactic index 
calculation. E) Speed and F) chemotactic index of cells traveling through microchannels with 
3, 10, 50 µm widths from control media towards ACM or control media (condition A). 
n(50µm channels with Control media everywhere)=152; n(50µm channels with ACM as 
chemoattractant)=212; n(10µm channels with Control media everywhere)=97; n(10µm 
channels with ACM as chemoattractant)=233; n(3µm channels with Control media 
everywhere)=18; n(3µm channels with ACM as chemoattractant)=57 cells. G) Speed and H) 
chemotactic index of cells traveling through microchannels with 3, 10, 50 µm widths from 
serum free media towards ACM or control media (condition B). n(50µm channels with 
Control chemoattractant)=200; n(50µm channels with ACM as chemoattractant)=158; 
n(50µm channels with ACM as chemoattractant and cells pretreated in ACM)=205; n(10µm 
channels with Control chemoattractant)=183; n(10µm channels with ACM as 
chemoattractant)=126; n(10µm channels with ACM as chemoattractant and cells pretreated 
in ACM)=122; n(3µm channels with Control chemoattractant)=18; n(3µm channels with 
ACM as chemoattractant)=23; n(3µm channels with ACM as chemoattractant and cells 
pretreated in ACM)=63 cells. The tracking time interval was 10 minutes for up to 15 hours. 
Statistical analysis was performed using a Tukey’s multiple comparison post-hoc test with 
p<0.05. (* p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001). In all plots, bars indicate mean 
of pooled data from N≥3 independent experiments, and error bars represent standard error of 

















smallest speeds in 50 and 3 μm channels and largest speeds in the 10 µm channels. 
However, when ACM was the sole chemoattractant (condition A), there was no 
significant difference in cell speed (Figure 3.12 E) or their chemotactic index (Figure 
3.12 F). On the other hand, when the ACM was used as a chemoattractant in 
conjunction with serum (condition B), tumor cells were significantly slower in 10 µm 
when migrating towards the serum-containing ACM from serum-free media (Figure 
3.12 G) but had similar chemotactic indices in all channels (Figure 3.12 H). 
Interestingly, when tumor cells were first cultured in ACM, they were no longer 
affected by the ACM and serum gradient and migrated from serum-free media at 
almost the same speed towards serum-containing ACM as towards serum-containing 
control media gradient (Figure 3.12 G). Together, these results suggest that ACM 
does not serve as a chemoattractant for the tumor cells, either with or without serum 
in the seeding media, since using ACM as a chemotactic source did not enhance the 
speed of the tumor cells in confinement, as it did in 2D. Furthermore, these results 
could suggest that the different migration modes utilized by tumor cells in 2D and in 
confinement are affected differently by astrocyte-secreted factors, which is important 
for understanding these interactions in physiological microenvironments.  
3.4 Discussion 
Mounting evidence suggests that astrocytes are implicated in increasing 
metastatic tumor cell invasiveness at the BBB [15], [48], [49], [56], [101]. Here, we 
investigated whether the one-way biochemical communication from astrocytes to 
tumor cells (and/or their extracellular matrix) influences tumor cell migration, and 





cytoskeletal organization. An additional goal was to probe the role of MMPs in the 
resulting phenotypic and behavioral changes of tumor cells.  
We found that (1) application of ACM  directly to MDA-MB-231 metastatic 
breast tumor cells or MCF10A normal breast epithelial cells increased cell velocity 
and induced an enlarged, elongated morphology; (2) pre-treating type I collagen, 
fibronectin, or laminin extracellular matrix substrates with ACM prior to seeding 
MDA-MB-231 tumor cells resulted in significantly increased tumor cell velocity as 
compared to control cells, with increases in velocity that were more drastic than 
treating cells directly with ACM; (3) a broad spectrum MMP inhibitor added to ACM 
reversed the effect of ACM on MDA-MB-231 tumor cell migration and morphology; 
(4) applying conditioned media from TGF-β-activated astrocytes reduced MDA-MB-
231 tumor cell migration velocity in comparison with media from untreated 
astrocytes; and (5) applying ACM as a sole chemoattractant did not affect MDA-MB-
231 tumor cell migration speed, but ACM in combination with serum as a 
chemoattractant reduced tumor cell migration speed in the 10 µm wide channels.  
Our results suggest that astrocytes have a significant effect on MDA-MB-231 
metastatic breast tumor cells prior to any potential signaling from tumor cells to 
astrocytes and reactive gliosis, indicating that astrocytes might play an important role 
in tumor cell recruitment and not just extravasation. Previous reports [132] have 
shown that changes in cell morphology on a 2D surface are correlated with metastatic 
potential. The specific trends seem to depend on tumor cell type, but they suggest that 
quantitative cell shape parameters can provide useful information about other aspects 





and MCF10A cell migration velocity and altered their morphology to be larger and 
more elongated, with enhanced stress fiber formation on 2D extracellular matrix-
coated substrates, all suggesting a more mesenchymal and metastatic phenotype[133]. 
Thus, ACM can enhance the migratory potential of (already) migratory metastatic 
breast tumor cells and also normal breast epithelial cells. Our migration results are in 
agreement with past studies where ACM increased tumor cell migration in wound 
healing and transwell assays [48]. Furthermore, we show that tumor cell morphology 
and actin cytoskeleton organization are also modulated by ACM, which could 
contribute to facilitation of migration in ACM-treated cells. We confirmed that serum 
depletion was not the cause of these results, since dilution of ACM with fresh serum-
containing media, down to 50%, also led to changes that were significantly different 
from control media. Thus, we conclude that there exist soluble factors secreted by 
astrocytes that increase tumor cell velocity and alter their morphology. The altered 
morphology and migration potential of tumor cells during exposure to ACM indicates 
that secreted factors by astrocytes could affect tumor cell phenotype, even without 
any exposure of the astrocytes to the tumor cell or injury. 
We found that ACM from astrocytes activated by TGF-β resulted in slower 
migration of tumor cells in comparison with untreated astrocytes, which is consistent 
with prior literature showing that ACM from interferon γ- and tumor necrosis factor 
α-activated astrocytes decreases the proliferation of tumor cells as compared to ACM 
from unreactive astrocytes [101]. Since astrocytes generally become reactive in 
response to injury and their secretome changes as a result, it is significant to note that 





though tumor cells are likely to cause injury and activate surrounding astrocytes. 
Since astrocytes need serum starvation in order for TGF-β to increase reactivity, as 
confirmed via western blot, and Wang et al. show no significant difference in tumor 
cell invasion and metastasis in ACM with and without serum [48], the fact that the 
most significant results occurred in the serum free activation conditions is still 
indicative of TGF-β-induced reactivity playing a role in astrocytes’ effect on tumor 
cells. We speculate that once astrocytes become reactive, they also become 
increasingly protective of the brain microenvironment by producing biochemical cues 
to reduce tumor cell migration. However, in other studies, activation of astrocytes via 
recombinant interleukin-1β (IL-1β) and subsequent co-culture with MDA-MB-231 
cells led to an enriched population of cancer stem cells in the culture. It is possible 
that the specific signaling leading to astrocyte activation, whether it is through injury-
modulated TGF-β stimulation, or through tumor cell-modulated activation of Notch 
signaling in astrocytes [56], leads to different effects on tumor cells, and future work 
could elucidate this relationship.  
The astrocyte secretome contains an array of biochemical factors [134], many 
of which can influence cell migration. Previous studies have implicated astrocyte-
secreted MMPs in ACM-mediated effects on tumor cells [48]. In order to further 
explore the mechanisms that alter tumor cell phenotype when exposed to ACM, we 
used a broad-spectrum MMP inhibitor, batimastat, to inhibit MMP activity in ACM. 
In these experiments, we observed a dose-dependent decrease in cell velocity with 
increased batimastat treatment, with the highest dose nearly reverting ACM-treated 





results are consistent with previous reports, where inhibition of MMPs using another 
broad spectrum inhibitor, ONO-4817, reduced cell invasion in a transwell assay in a 
dose-dependent manner [48]. Thus, we provide further evidence that MMPs produced 
by astrocytes could be at least partly responsible for the ACM-induced alterations in 
tumor cell migration and morphology. Furthermore, we provide preliminary evidence 
that addition of exogenous MMP-2 or MMP-9 to extracellular matrix substrates can 
produce similar effects to ACM on cell migration. However, since tumor cells also 
secrete MMPs, application of an MMP inhibitor to the ACM may also inhibit MMPs 
produced by the tumor cells, thus confounding interpretation of the results. It has 
been found that TGF-β1 increases MMP production by astrocytes [135], however the 
TGF-β treatment of astrocytes actually decreased the velocity of the subsequent 
ACM-treated tumor cells as compared to vehicle control-treated ACM. This suggests 
that MMPs are not the only, and potentially not the dominant, molecular mechanism 
at play in astrocyte-induced increased cell migration. Future analysis should be aimed 
at exploring the molecular interplay of the astrocyte-tumor cell signaling and the role 
of MMPs. Perhaps most notably, we discovered that pre-treating the extracellular 
matrix with ACM resulted in a significant increase in MDA-MB-231 tumor cell 
migration velocity in comparison with untreated extracellular matrix, which was even 
greater for type I collagen, laminin, and fibronectin substrates than the velocity 
increase when tumor cells were treated with ACM directly. Because the ACM was 
removed from the extracellular matrix prior to seeding cells, it seems that astrocyte-
secreted factors in the ACM in some way alter the extracellular matrix, leading to 





in the ACM degrade and/or reorganize the extracellular matrix, since MMPs have 
collagenase and gelatinase activity. However, minimal change in morphology was 
observed when the extracellular matrix substrates were pre-treated with ACM, 
suggesting that morphological changes alone are not responsible for the increased 
migration. This also suggests that there are different mechanisms involved in the 
ACM-induced phenotypical changes in tumor cell morphology and migration, 
respectively. Alternatively, it is possible that other biochemical factors, such as IL-6, 
tumor necrosis factor-α and IL-1β [136], within the ACM bind to the extracellular 
matrix and subsequently enhance tumor cell migration through adhesion-based 
signaling mechanisms. However, if this were the case, we would have expected to 
observe increased cell velocity over time during the overnight migration assays, since 
at later timepoints the extracellular matrix would have been coated in the same ACM 
factors. Instead, cell velocity was mostly consistent during the entire time lapse 
sequence (data not shown), suggesting this latter mechanism was not the case. 
Meanwhile, the fact that cells plated on PDL (which promotes adhesion through 
electrostatic interactions between cells and the substrate rather than through integrin 
binding) do not exhibit increased migration in response to ACM, in comparison with 
cells plated on extracellular matrix proteins (i.e., type I collagen, fibronectin, and 
laminin) suggests that integrin-based adhesions may be altered by ACM treatment. 
While it is unclear by which mechanisms the ACM alters the extracellular matrix to 
enhance migration, these findings do suggest that tumor cell-extracellular matrix 





logical link to the MMP pathways since MMPs are known to degrade extracellular 
matrix proteins.  
While MMPs are more commonly implicated in 3D migration, they also have 
several important effects in 2D. It is known that MMPs are primarily involved in 
proteolysis of extracellular matrix; however, it appears that MMPs also result in the 
rearrangement of extracellular matrix structure, in a MMP- extracellular matrix 
protein-dependent manner [137], [138]. This rearrangement could be responsible for 
ACM-induced changes in the 2D protein extracellular matrix that lead to changes in 
tumor cell migration and morphology. For example, MMP2 has been shown to induce 
epithelial migration on laminin by cleaving the laminin and exposing a pro-migratory 
site, even though MMP2 is not specifically known to degrade laminin [137], [139]. 
Thus, the specific interactions of different MMPs and extracellular matrix proteins 
could help explain the differences in the effect of ACM on tumor cells when seeded 
on different matrices. Furthermore, MMPs have been shown to interact with integrins  
[137] and since integrins are crucial in 2D migration, it is possible that this interaction 
could be involved in the effect of MMP-containing ACM on tumor cells and their 
extracellular matrix. Furthermore, it has been shown that the overexpression of some 
MMPs in epithelial cells activates other MMPs and also leads to reduced cell-cell 
contacts [137]. While this is primarily relevant to epithelial cells with strong cell-cell 
contacts, it could also speak to increased epithelial-to-mesenchymal transition and as 






While the studies observing the effect of MMPs in 2D show several 
interesting pathways by which MMP-containing ACM could be affecting tumor cells 
and their extracellular matrix, further experiments are necessary in order to fully 
understand how the presence of MMPs in ACM is affecting tumor cells. One way to 
achieve that would be to culture tumor cells in 3D collagen I or collagen IV gels and 
either pre-treat the scaffold with ACM or treat the tumor cells within the scaffold 
directly. Observing the migration and morphology of ACM-treated tumor cells in 3D 
would shed further light on the potential significance of MMPs in the effect of ACM. 
Furthermore, the MMP inhibition and addition experiments should be repeated in 3D. 
Future work will focus on delineating this relationship and also evaluate whether 
ACM can affect the extracellular matrix in a 3D matrix. 
Both in 2D and 3D it would be very interesting to study the structure of the 
extracellular matrix before and after ACM treatment. This could be achieved by 
scanning electron microscopy, simple harmonic generation imaging, or 
immunostaining for the appropriate extracellular matrix protein. Additionally, since it 
appears that MMPs are tied to the expression of integrins, immunostaining ACM-
treated tumor cells and tumor cells on ACM-treated extracellular matrix for the 
expression of paxillin or several different integrins could help shed light on further 
ACM-mediated mechanisms. This can also be carried out with MMP addition and 
inhibition in order to understand what the role of MMPs specifically is in the process.  
Additionally, we also inhibited ROCK in cells treated directly with ACM and 
cells cultured on ACM-treated collagen I. While we found that ROCK inhibition 





further examined. In the future, a more carefully investigation of the roles of the Rho 
family GTPases would help shed more light on the significance of the Rho/ROCK 
pathway in tumor cell – ACM interactions. 
Furthermore, we have previously shown that tumor cells can utilize an 
alternate, water permeation-based migration mechanism in confinement in 
comparison with 2D where migration is actin-driven [108]. Thus, we found it 
important to observe the interplay between effects of ACM and the physical cue of 
confinement. As discussed above, metastatic tumor cells experience confinement at 
the BBB when traveling through microtracks of the basement membrane in the brain, 
as well as when migrating through narrow brain capillaries which can be as small as 
10µm in diameter [106], through the brain endothelium, and along the blood vessel 
post extravasation across the endothelium [107]. The biphasic trend of tumor cell 
migration velocity with respect to channel width could be due to an optimal balance 
between effects of contact guidance and nuclear deformation in intermediate width 
channels. That is, in wide channels, no nuclear deformation is necessary, but cells are 
not completely contact guided by both walls of the channels. In narrow channels, 
cells are able to receive contact guidance from channel wall on both sides, but the 
nucleus must significantly deform in order for cells to squeeze through the channels. 
Interestingly, our work suggests that physical confinement and introduction of ACM 
as a chemoattractant contrasts the effects that ACM has in 2D, since cells exposed to 
ACM as a chemoattractant in confined microchannels were not preferentially 
attracted to the ACM over control media. Additionally, when the ACM gradient was 





towards the ACM in comparison with control media. Furthermore, pre-culturing cells 
in ACM resulted in them migrating towards ACM at a similar speed as towards 
control media. Future work will focus on which mechanisms (i.e. chemotaxis, 
confinement, contact guidance by edges of the channels) are responsible for the 
altered behavior of the tumor cells in the microchannels, since literature has shown 
that tumor cells can be attracted towards astrocytes in a Boyden chamber coculture 
assays [101]. Indeed, new assays are necessary to understand the physiologically 
relevant interaction of tumor cells and astrocytes and how cells respond to the 
complex interplay of biochemical and physical cues at the BBB.  
Overall, the observed changes in tumor cell migration and morphology as a 
result of ACM treatment of tumor cells and their matrix could potentially reflect on 
their ability to metastasize. Recent studies have shown that morphology and velocity 
of tumor cells are correlated with the cells’ metastatic potential [140]. Specifically, 
cells with a greater potential to metastasize tend be more migratory [140]. Those cells 
are also generally larger, more elongated, and with more protrusions and have a 
greater ability to form distant metastases in vivo [140]. Together, this suggests that 
the observed increase in speed and area of tumor cells treated with ACM and seeded 
on ACM-treated matrix could be potentially correspond to an increase in their 
metastatic potential and enhancing their ability to invade the brain.  
3.5 Conclusions 
This work demonstrates that astrocyte-secreted factors affect the migration, 
morphology, and actin cytoskeleton organization of metastatic breast tumor cells and 





astrocytes that have not been exposed to metastatic breast tumor cells could enhance 
metastasis at the BBB, although this effect could be abrogated if tumor cells 
experience physical confinement. When exposed to ACM, tumor cells become more 
elongated, larger, and faster, which suggests an increase in metastatic phenotype. 
Secretion of MMPs by astrocytes could be at least partially responsible for the 
changes observed in the tumor cell phenotype, and future work will continue to 
explore this hypothesis. Our work also found that ACM from TGF-β-activated 
astrocytes results in a lower tumor cell velocity than tumor cells treated with ACM 
from unreactive astrocytes, without significant changes in tumor cell morphology. 
Perhaps most notably, we found that treating the extracellular matrix substrate with 
ACM prior to seeding tumor cells has a greater effect on MDA-MB-231 tumor cell 
velocity than treating tumor cells directly with ACM, indicating that astrocyte-
secreted factors can alter the cells’ extracellular matrix. Finally, we showed that ACM 
may not serve as a chemoattractant to tumor cells in unconfined or confined 
microenvironments that also subject tumor cells to chemotaxis and contact guidance, 
suggesting that astrocytes may not attract tumor cells to the brain or help them move 
through confined spaces, but simply alter general morphology and migration 
properties. Regardless, our work provides support that astrocytes have a clear effect 
on tumor cell migration, morphology, and actin cytoskeleton arrangement in one way 
paracrine communication, and we show that astrocyte-secreted factors can also act 
indirectly on cells through their extracellular matrix to induce changes in morphology 
and migration. Further work should continue to examine the specific astrocyte-





molecular mechanisms and pathways by which astrocyte secreted factors act on 






4 Tumor cell mechanosensing during incorporation into the 
brain microvascular endothelium† 
4.1 Introduction 
Evidence in the literature, including in vivo imaging, has shown that tumor 
cells are capable of metastasizing to the brain via the circulatory and lymphatic 
systems [141], and that metastasis occurring through the circulatory system requires 
the tumor cells to traverse the BBB in order to reach the brain parenchyma [142]. 
However, the mechanisms governing how tumor cells cross the blood-brain barrier 
(BBB) are not well understood.  
In one study, close physical contact with the abluminal surface of the blood 
vessel was crucial for the spread of tumor cells, which actively transmigrated through 
gaps in the wall of the vasculature but also engaged in vascular remodeling during 
extravasation [143]. Unique to the BBB, tight junctions proteins (e.g., claudins, 
occludins) are overexpressed, and act in conjunction with adherens junctions (e.g., 
vascular endothelial cadherin, VE-cadherin) to regulate barrier integrity and 
permeability [144]. These junctional proteins link to the actin cytoskeleton through 
zonula occludens (e.g., ZO-1), which has been shown to regulate cell and junctional 
tension, cellular migration, barrier formation, and angiogenesis [145]. Disruption of 
these junctions is linked with increased permeability of the BBB to cells and 
† This chapter has been accepted for publication as M.A. Pranda*, K.M. Gray*, A J. L. 
DeCastro, G.M. Dawson, J.W. Jung, K.M. Stroka. “Tumor cell mechanosensing during 
incorporation into the brain microvascular endothelium”, CMBE Journal, 2019. Atomic 
force microscopy carried out by K.M.G. AJ.L.D and G.M.D helped out with 





molecules and is implicated in several diseases [146], including cancer metastasis 
[147]. Metastatic breast tum or cells reportedly secrete factors that  promote increased 
tumor cell-BBB adhesion and disrupt or rearrange junctions, weakening the barrier 
and leading to tumor cells transmigration [148], [149]. 
tumor cells-derived biochemical cues and physical interaction with brain 
endothelial cells can alter brain endothelial cell-cell junctions in such a way that 
directs the mode of trans-endothelial migration. For instance, melanoma cells are 
reported to disrupt junctions, presumably through protease secretion, and induce 
endothelial cell apoptosis leading to paracellular transmigration [150]. Other studies 
have shown that breast tumor cells can cross endothelial barriers utilizing both 
transcellular and paracellular pathways [151]. Tumor cells also secrete endothelial-
altering substances that can lead to an influx of calcium [152], glycocalyx 
degradation [151], and increased contractility [153], [154], of the targeted endothelial 
cells, all of which are associated with enhanced tumor cells transmigration at cell-cell 
junctions [151]–[154]. Furthermore, we and others have demonstrated that tumor 
cells can even physically displace endothelial cells and “incorporate” or “intercalate” 
into the endothelium [33], [155], [156], and we hypothesized that this process may 
also represent a distinct step in the extravasation of tumor cells through the brain 
endothelium. Hence, here we aimed to quantify how breast tumor cells biochemical 
factors and physical contact with the brain endothelium affect endothelial cell-cell 
junction organization, and ultimately, tumor cells incorporation into a biomimetic 





 In addition to cell-secreted factors, cell functionality is profoundly influenced 
by its surrounding extracellular matrix [157]. However, it is not yet well understood 
which aspects of the brain microenvironment play a role in cancer progression [158]. 
Hyaluronic acid (HA) is a glycosaminoglycan that serves as a major building block of 
the brain extracellular matrix, which, unlike other parts of the body, is not highly 
organized and consists mainly of loosely crosslinked networks [159]. HA in the brain 
is linked with small glycoproteins, as well as tenasins, the density of which plays a 
large role in the function of various neural processes. Thus, the disruption of these 
linkages [159] as well as extracellular matrix rearrangement [160] could play a large 
role in disease progression. Indeed, for other extracellular matrix models such as 
collagen gels, crosslinking (e.g., via lysyl oxidase) has been shown to increase 
extracellular matrix stiffness, making it more conducive to the progression of tumors 
and other diseases [31], [38], [161], [162]. While HA has important biological 
functions related to joint lubrication and wound healing, it also plays a role in the 
invasion of tumor cells, and, in the case of primary glioma tumors, HA is highly 
upregulated in the surrounding extracellular matrix [157].  
Because extracellular matrix structure (e.g., arrangement, stiffness, etc.) is 
known to play a significant role in healthy and diseased states of the brain, here we 
have investigated how the crosslinking of a brain-like extracellular matrix affects 
brain endothelial cells, tumor cells, and the interaction between the two cell types. We 
have used an HA/gelatin-based system with varying degrees of crosslinking to mimic 
the brain extracellular matrix and used live-cell microscopy and immunofluorescence 





and tumor cells incorporation into brain endothelial cell monolayers, thus providing 
insight into the interplay of extracellular matrix crosslinking and bi-cellular systems 
on breast cancer metastasis across the BBB.  
4.2 Materials and Methods 
4.2.1 Cell Culture 
Human breast adenocarcinoma cells, MDA-MB-231s (American Type Culture 
Collection, Manassas, VA, USA), were cultured, similarly to Chapter 3, in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose and L-glutamine 
supplemented with 1% Penicillin/Streptomycin 10,000 U ml-1 (Pen/Strep) and 10% 
Fetal Bovine Serum (FBS) (Thermo Fisher Scientific, Waltham, MA, USA) and used 
below passage 20 after purchase. Human brain microvascular endothelial cells, 
HBMECs (Cell Systems, Kirkland, WA, USA), were cultured under static conditions 
in flasks coated with 0.1% gelatin (VWR, Radnor, PA, USA) in RPMI-1640 
supplemented with 20% FBS, 1% Pen/Strep, 2mM L-Glutamine (Thermo Fisher 
Scientific), 30 μg ml-1 endothelial cell growth supplement (ECGS) (Millipore Sigma), 
and 100μg/ml heparin (Millipore Sigma) and used below passage 12. For VE-
cadherin-GFP adenovirus amplification, 293A cells (Thermo Fisher Scientific) were 
cultured in medium composed of high glucose DMEM, 10% FBS, 0.1 mM MEM 
Non-Essential Amino Acids (NEAA) (Thermo Fisher Scientific), 2 mM L-glutamine, 
and 1% Pen/Strep. All cells were cultured in a climate-controlled incubator at 37°C, 





4.2.2 HA/gelatin film formation 
HA/gelatin films were formed using the HyStem-C kit (ESIBIO, Alameda, 
CA, USA). The kit contained four components: DG water, Glycosil (thiolated HA), 
Gelin (thiolated Gelatin), and Extralink (thiol-reactive PEGDA crosslinker). 
Instructions from the kit were followed and were also described previously by 
Prestwich [163] . Briefly, all components were thawed for 30 - 60 minutes. Glycosil, 
Gelin, and DG water were then briefly heated at 37°C in a water bath to increase 
solubility. Glycosil and Gelin were then dissolved in 1 mL DG water, rocked for 1 
hour at room temperature, then briefly re-heated in the water bath. Extralink was 
dissolved in DG water to 10%, then was further diluted into aliquots of 6, 4, and 1%. 
24-well glass bottom plates (13 mm glass diameter) or 35 mm glass bottom dishes (14 
mm glass diameter) (MatTek, Ashland, MA, USA) were plasma treated using a 
plasma cleaner with a 5 minute pumping step to create a vacuum and a 2.5 minute 
treatment on the “High” RF power setting (Harrick Plasma, Ithaca, NY, USA, PDC-
001-HP (115 V)) to increase hydrophilicity. The plates were then treated with 
ultraviolet light for 5 - 10 minutes for sterilization. Gelin and Glycosil were mixed in 
a 1:1 ratio and then the Glycosil/Gelin solution was combined in a 4:1 ratio with the 
appropriate concentration of Extralink. The final concentration of Extralink within the 
films were 0.2, 0.8, 1.2, and 2%. Twenty microliters of solution were plated in each 
well, spread, and covered for gelation, the time of which varied by Extralink 
concentration (2%: 2 - 5 minutes, 1.2%: 3-6 minutes, 0.8%: 4 - 7 minutes, 0.2%: 6 - 9 
minutes). Once crosslinked, medium was added, and the films were incubated at 37°C 





4.2.3 Atomic force microscopy (AFM)  
Written, analyzed, and carried out by Kelsey Gray. 
 
To measure the stiffness of the HA/gelatin, films were formed on 50 x 9 mm 
petri dishes. After the films had polymerized, the dishes were filled with PBS and an 
Asylum MFP-3D-BIO Atomic Force Microscope was used to perform AFM. The 
“Get Real” approach provided by Asylum Research was used to calculate the inverse 
optical lever sensitivity and the cantilever spring constant of the TR400PB(L) probes 
used for measurement. The cantilever spring constants were within the nominal range 
of 0.01 to 0.05 N m-1 (measured range: 0.026 to 0.028 N m-1) and within a factor of 
1.37 to Asylum’s nominal value of 0.02 N m-1. Four film samples of each 
composition were measured via five 100-curve force maps each (20 force maps in 
total). The force map specifications were as follows: 10 μm x 10 μm area, 2 μm force 
distance, 1 V trigger point (~1.57 nN), and a 0.99 Hz scan rate. The Hertz models was 







) ⋅ √𝑟  ⋅ 𝛿3/2 where the fitting parameter, 𝐸, is the Young’s modulus, and 
𝛿, is the measured indentation of the sample. The Poisson’s ratio, 𝜈, and tip radius of 
curvature, 𝑟, were assumed to be 0.45 and 30 nm, respectively. The results are shown 
in Figure 4.1 and indicate that all HA/gelatin films are in the physiological brain 
stiffness range.  
4.2.4 Tumor cell morphology and migration assays 
HA/gelatin films were prepared as described above in 24-well glass bottom 





plated on top of the films and set-up to image as soon as the cells settled to the bottom 
of the plate. Images were collected via time-lapse phase-contrast microscopy and 
analyzed as described below in the data analysis section.  
4.2.5 Tumor cell immunofluorescence staining  
For CD44 staining, 2x104 MDA-MB-231 cells were plated on HA/gelatin 
films formed with 0.2, 0.8, 1.2, and 2% Extralink in glass bottom dishes, or on dishes 
incubated with 20 μg ml-1 type I collagen for at least 1 hour at 37°C and washed three 
times with PBS. The next day, the cells were fixed in 3.7% formaldehyde (Millipore 
Sigma) for 10 minutes at room temperature, washed three times with PBS for 5 
minutes each on a rocker, and permeabilized with 0.5% Triton-X 100 (Millipore 
Sigma) for 5 minutes. The samples were then washed again three times in PBS for 5 
minutes each and blocked in 2% Bovine Serum Albumin (BSA) (Millipore Sigma) 
for one hour at room temperature. Cells were then incubated at 4°C overnight with 
CD44 antibody (monoclonal CD44 antibody (156 3C11) Mouse mAb #3570, Cell 
Figure 4.1: AFM measurements of HA/gelatin gel stiffness. Young’s modulus 
measurements of HA/gelatin films as a function of HA/gelatin film crosslinking. Each 
point represents the average Young’s modulus of a 100-curve force map covering a 10 μm 
x 10 μm area. Five measurements were taken across 4 different samples for each film 
composition. The ROUT method (Q=1%) was used to identify and remove 1 outlier. The 
numbers next to each bar represent the average modulus for that film composition. Data 
obtained, analyzed, and figure generated by Kelsey Gray. 





Signaling Technologies, Danvers, MA, USA), which was dissolved in 2% BSA at a 
1:100 ratio. Next, cells were rinsed with PBS and again blocked with 2% BSA for 
one hour at room temperature and washed with PBS. Cells were then incubated with 
1:500 Phalloidin - Alexa Fluor 488 (Thermo Fisher Scientific), 1:100 of secondary 
antibody (Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody Alexa 
Fluor 568, Thermo Fisher Scientific, A-11004), and 1:2500 of Hoechst 33342 
(Thermo Fisher Scientific) diluted in PBS for 1 hour at room temperature. HBMECs 
transfected with the VE-cadherin-GFP adenovirus and tumor cells stained with Cell 
Tracker (described below) were also fixed for 10 minutes in 3.7% formaldehyde, 
washed with PBS, and stained with 1:2500 of Hoechst 33342 for one hour at room 
temperature. Finally, all samples were washed with PBS and stored at 4°C until 
imaging via confocal microscopy. 
4.2.6 Adenovirus amplification  
The VE-cadherin-GFP adenovirus was a generous gift from Dr. William 
Luscinskas (Harvard Medical School), whose lab has previously described the 
construction of this vector [164]. For amplification of VE-cadherin-GFP adenovirus, 
293A cells cultured to ~80% confluency in 100 mm dishes. The 293A cells were then 
infected with the adenovirus and cultured until ~80-90% of all cells lifted off the dish. 
The cells were then collected and centrifuged at 1000 rpm. The resultant pellet was 
frozen at -80°C for 30 minutes and then thawed at 37°C for 15 minutes. The freeze-
thaw was repeated a total of three times. The lysed cells were centrifuged at 3000 rpm 
and the supernatant was saved and frozen at -80°C. This supernatant was then used to 





4.2.7 Tumor cell incorporation assay  
HA/gelatin films were prepared as described above in 24-well, glass bottom 
plates with 0.2, 0.8, 1.2, and 2% Extralink as well as a 1:1 mixture of gelatin and HA 
without Extralink (0%). 5x104 - 1x105 HBMECs were plated on the HA/gelatin films. 
For experiments fluorescently visualizing live VE-cadherin-GFP-expressing 
HBMECs’ cell-cell junctions, freshly plated and barely-attached HBMECs were 
transfected with 10 𝜇L of the VE-cadherin-GFP adenovirus, as previously described 
by Hamilla et al. [33], and incubated for two days. To investigate the percent 
incorporation of MDA-MB-231 cells into HBMEC monolayers, live MDA-MB-231 
cells were first stained with CellTracker Orange CMRA Dye (Thermo Fisher 
Scientific) per the manufacturer’s instructions. CellTracker Orange CMRA Dye is 
stated in product specifications to only transfer from parent cell to daughter cell and 
not in between neighboring cells. Since staining was carried out in the complete 
absence of HBMECs, transfer of dye between the two cell types is highly unlikely. 
Briefly, MDA-MB-231 cells were cultured in 6 well plates and equilibrated in 
HBMEC medium for two hours. The cells were washed with PBS and then incubated 
with 2 mL of 0.5 𝜇M CellTracker Orange dye in RPMI-1640 and 1% Pen/Strep for 15 
minutes. Cells were then washed again with PBS and incubated for 30 minutes in full 
HBMEC medium. The stained cells were then trypsinized and 1x104 - 2.5x104 MDA-
MB-231 cells were plated on top of HBMECs that had been cultured on HA/gelatin 
films and allowed to form monolayers for two days prior to MDA-MB-231 cell 
seeding. These samples were imaged using time-lapse phase-contrast and 





4.2.8 Time-lapse microscopy  
Similarly to Chapter 3, live-cell phase contrast and fluorescence images were 
captured using an IX83 microscope (Olympus, Center Valley, PA, USA) with a 10x 
objective (tumor cell migration assays on bare films), 20x objective (tumor cell 
morphology assays on bare films, incorporation assays with non-transfected 
HBMECs and CellTracker-stained tumor cells), and 60x oil objective (incorporation 
assays with VE-cadherin-GFP-expressing HBMECs and CellTracker-stained tumor 
cells). The Olympus cellSens Software (Olympus) was used to acquire the images. 
Phase contrast images of tumor cells on bare films were collected every 5 to 15 
minutes for migration analysis, and additional images were captured at the end of the 
time-lapse on the second day for morphological analysis. The imaging regions for 
transmigration experiments were selected based on best monolayer coverage and the 
presence of MDA-MB-231 cells. The live-cell imaging chamber was maintained at 
37°C, 50% humidity, and 5% CO2:95% air surrounding the microscope stage.  
4.2.9 Confocal microscopy 
A PerkinElmer confocal spinning disk microscope (PerkinElmer, Waltham, 
MA) was used to obtain 3D images of fixed cells using a 40x water immersion 
objective. Vertical z-stacks were taken using appropriate filters using the Volocity 3D 
Image Analysis software. All acquisition settings were kept consistent between 
images within each experiment for CD44 imaging and slightly adjusted for best 
visualization for transmigration imaging. The ImageJ software (NIH; 





maximum-intensity and interpolated projections. Brightness of each channel in 
images of tumor cells stained for CD44 was adjusted separately but identically 
between each image to ensure that intensities could be compared. Brightness of each 
channel in images of tumor cells incorporating into HBMEC monolayers were 
adjusted separately for best visibility of appropriate parts of the cells; thus, intensities 
cannot be directly compared for these images. 
4.2.10 Data analysis 
Tumor cell morphology and migration: tumor cell morphology was analyzed 
using ImageJ by manually tracing phase contrast images of live cells captured during 
or after time-lapse experiments in ImageJ. Cell circularity, solidity, and inverse aspect 
ratio were calculated as described in Appendix A. To track tumor cell migration on 
bare films, phase-contrast time-lapse images were acquired in 5-minute intervals. The 
ImageJ Manual Tracking plugin was used to track the approximate centroid of each 
cell starting with frame 60 (when cells appeared to have attached) and continuing up 
to 100 frames. Cells were not tracked if they went out of frame, divided during the 
tracking time, or were otherwise obstructed or hard to track. A custom Matlab 
(MathWorks, Natick, MA, USA) code was used to calculate cell speed, mean square 
displacement, and diffusion coefficient of the migrating cells, as described in detail in 
Appendix B. One hundred frames (495 minutes) were used for speed calculation, 90 
frames (445 minutes) were used for MSD calculation, and 40 frames (195 minutes) 
were used for diffusion coefficient calculations. Analysis commenced once cells 





 Tumor cell incorporation: To quantify the time that tumor cells take to 
incorporate into HBMEC monolayers, and the percent of the tumor cells that 
incorporate into the monolayers, CellTracker-stained tumor cells were tracked on 
HMBEC monolayers by capturing images in 15-minute intervals. First, the total 
number of tumor cells per frame was recorded at the start of each time-lapse 
sequence. Tracking was carried out for 40 frames (585 minutes). Cells that went out 
of frame before frame 40 were excluded from analysis, as well as cells deemed 
“untrackable” due to clumping, visual obstructions, or migration to areas of large 
gaps in the monolayer. An incorporating cell was subjectively identified based on the 
disappearance of a white halo surrounding the cell and transition to a 2D-flattened 
morphology in phase contrast images. If a cell was spread, but retained a halo and 3D 
appearance, it was counted as not incorporating and instead was likely spreading on 
top of the monolayer. Percent incorporation was calculated by dividing the total cells 
that incorporated into the monolayer by the total number of cells tracked in each 
frame. The start time for a cell to incorporate was marked as the first frame where the 
cell appeared to be spreading into the monolayer, or the very first frame if it was 
already spread. If cells incorporated and then exited the monolayer, only the first 
instance of incorporation was counted. If a cell divided before incorporating or before 
frame 40, it was counted as two separate cells. If cells divided after incorporation, it 
was counted as one cell. Cumulative percent incorporation was calculated by 
averaging the total percent of cells that had incorporated at each 15 minute timepoint 





 For migration analysis pre- and post-incorporation, select cells were manually 
traced in ImageJ. If cells remained completely rounded for 40 frames, they were 
tracked for 20 frames (285 minutes) and characterized as “non-incorporating.” Cells 
that incorporated were tracked for 6 frames (75 minutes) prior to spreading (i.e. “pre-
incorporation”) and 6 frames (75 minutes) after they had fully incorporated (i.e. 
“post-incorporation”). If a cell started to incorporate within the first 6 frames (i.e., did 
not have a sufficient pre-incorporation phase to track) or rounded up again post-
incorporation in less than 6 frames, the cell was omitted. Tumor cells that appeared to 
be spread-out but maintained a white halo, indicating a higher focal plane, and did not 
incorporate within 40 frames were interpreted as cells adhered to, and migrating on, 
the surface of the monolayer, and were entirely excluded from analysis. Three 
randomly selected HBMECs per frame were also traced for up to 8 frames (105 
minutes) for three experiments (36-66 cells total). The average absolute value of the 
change in area or speed between each time point was calculated for a given cell by 
subtracting the area or speed at the previous time point from the area or speed at the 
current time point and taking the absolute value of the difference. These differences 
were then averaged for the time points analyzed for each cell.   
4.2.12 Statistical Analysis 
GraphPad Prism 8 (GraphPad, La Jolla, CA, USA) was used for all statistical 
analysis and graph preparation. Data was tested for normality using a D'Agostino-
Pearson normality test, and it was found that the majority data within the same set did 
not follow a normal distribution. Thus, non-parametric tests were used for statistical 





comparison post-hoc test was used with P > 0.05 indicating not statistically different, 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. A linear regression was used 
to compare the number of tumor cells at the start versus monolayer quality. Errors 
bars represent standard error of the mean. All data represents pooled values from 
three independent trials unless otherwise noted in the figure captions. 
4.3 Results 
4.3.1 MDA-MB-231 cells become smaller and slower with increased 
HA/gelatin crosslinking   
Extracellular matrix crosslinking has been shown to alter tumor cell 
phenotype and invasiveness, and HA is known to be one of the primary components 
of the brain’s extracellular matrix [38], [159], [161], [162]. Hence, we aimed to 
evaluate the migration and morphology response of MDA-MB-231 tumor cells to 
varying degrees of HA/gelatin film crosslinking by altering the concentration of  
Extralink, a PEGDA-based crosslinker, during film formation [165]. We found that 
with increased Extralink concentration from 0.2% to 2%, tumor cells became 
significantly smaller (Figure 4.2 A, B) and more circular (Figure 4.2 A, C) and 
increased in inverse aspect ratio, circularity, and solidity (Figure 4.2 A, C). 
Furthermore, cells plated on HA/gelatin films with increased Extralink concentrations 
demonstrated more homogeneous morphologies as evidenced by a decreased spread 
of the data with higher Extralink concentrations (Figure 4.2 B, C). Additionally, 
tumor cell speed decreased with increased crosslinking of HA/gelatin films (Figure 





explored smaller areas with increased crosslinking of HA/gelatin films (Figure 4.2 E), 
with a non-statistically significant decrease in diffusion coefficient with increased 
crosslinking of HA/gelatin films (Figure 4.2 F). Because a mesenchymal, metastatic 
phenotype is typically associated with highly migratory, elongated cells [166], these 
changes in cell morphology and migration could be relevant to the cells’ 
functionality.  
Cell attachment to HA is mediated by CD44, which also has been implicated 
in transducing HA stiffness cues and associated with brain tumor progression and 
invasion [157], [167]–[169]. For breast tumor cells, CD44 increases tumor cell 
adhesion to and invasion of the endothelium, increasing the efficiency of distant 
metastasis [170]. Hence, we explored whether the morphological and migratory 
behavior with altered HA/gelatin film crosslinking were also associated with 
differences in CD44 binding. Interestingly, MDA-MB-231 cells immunostained for 
CD44 on HA/gelatin films with varying degrees of crosslinking, as well as type I  
collagen-coated glass, did not present observable differences in CD44 expression 
(Figure 4.2 G). 
Figure 4.2: MDA-MB-231 morphology and migration parameters on HA/gelatin films 
with varying degrees of crosslinking. A) Phase contrast images of MDA-MB-231 cells on 
HA/gelatin films with 0.2, 0.8, 1.2, and 2% Extralink. Scale bar is 50 μm and applies to all 
images. B) Areas, C) inverse aspect ratio, circularity, and solidity, D) speed, E) mean square 
displacement, and F) diffusion coefficient of MDA-MB-231 cells on HA/gelatin films with 
0.2, 0.8, 1.2, and 2% Extralink. Means of columns that do not share a lower-case letter are 
significantly different with P < 0.05 via a non-parametric Kruskal-Wallis ANOVA test with a 
Dunn’s multiple comparison post-hoc test. B,C: 529 ≤ N ≤ 582, D,F: 142 ≤ N ≤ 228 where N 
is the number of cells. E: N = 3, where N is the number of trials. All error bars represent 
standard error of the mean. All values are pooled from three independent trials. G) 
Reconstructed confocal z-stacks of MDA-MB-231 cells immunostained for CD44 (red) and 
stained for actin (green) on HA/gelatin films with 0.2, 0.8, 1.2, and 2% Extralink, as well as 
on glass coated with type I collagen. Scale bar on first image is 50 μm and applies to all 
images. Scale bar in the zoomed in inserts is 25 μm. Green: actin; red: CD44, blue: DNA. All 
images were reconstructed from a z-stack in ImageJ and intensities were adjusted equally for 













Meanwhile, actin arrangement was altered, with tumor cells on type I collagen 
and HA/gelatin films with 0.2% Extralink displaying a somewhat fibrous actin 
arrangement (Figure 4.2 G) which became more diffuse with increased film 
crosslinking, especially on the films with 2% Extralink (Figure 4.2 G). Increased cell 
spreading and mesenchymal migration are typically correlated with a more stress 
fiber-rich actin arrangement [171], which is indeed in line with our observations. A 
stress fiber-rich actin cytoskeleton is also often linked with a high degree of cellular 
contractility, which also correlates with the stiffness of the underlying cellular matrix 
[172]. Since increased crosslinking typically results in increased material stiffness, 
changes in film stiffness could drive alterations in tumor cell contractility and actin 
filament arrangement. Hence, we used atomic force microscopy to probe the effect of 
Extralink concentration on the Young’s modulus of HA/gelatin films. The average 
modulus of the films formed with 0.2, 0.8, 1.2, and 2% Extralink were measured to be 
0.85, 1.1, 1.5, and 3.8 kPa, respectively (Figure 4.1). Interestingly, only the Young’s 
modulus of the film formed using 2% Extralink was statistically significantly 
different from the Young’s modulus of the other film compositions. Despite this, we 
still found significant differences in tumor cell phenotype and behavior on those film 
compositions (Figure 4.2 A).  
4.3.2 MDA-MB-231s incorporate into HBMEC monolayers, independent of 
HA/gelatin film crosslinking 
Because other work in our lab observed that tumor cell-derived biochemical 
cues can alter HBMEC junction morphology (data not shown), we next examined the 





monolayers. Phase contrast and fluorescence microscopy were used to evaluate 
CellTracker-stained MDA-MB-231 incorporation into HBMEC monolayers (Figure 
4.3 A). We found no statistically significant difference in the percent incorporation of 
tumor cells into HBMECs (Figure 4.3 B) or in the time from the start of the timelapse 
to complete incorporation (Figure 4.3 C) as a function of Extralink concentration 
under static conditions. The cumulative percent of tumor cell incorporation, or 
percent of incorporation at each time point, was generally similar for all films, 
regardless of Extralink concentration under static conditions (Figure 4.3 D). 
Furthermore, we found that the plot of percent tumor cell incorporation at ~10 hours 
versus the average number of tumor cells at the start of the time-lapse had a slope that 
was not significantly non-zero (Figure 4.3 E).  
Tumor cells can utilize multiple modes of extravasation across endothelial cell 
barriers, and hence we used confocal and live-cell microscopy to image CellTracker-
stained tumor cells interacting with VE-cadherin-GFP-expressing HBMECs. We 
found that some tumor cells remained on top of or found their way underneath the 
HBMECs (Figure 4.4 A). As expected, many tumor cells simply squeezed 
paracellularly into gaps between HBMECs, with protrusions going above and/or 
underneath the monolayer (Figure 4.4 B, C (left insert)). We also found several 
interesting and unexpected interactions. In some cases, an HMBEC, identified by its  
VE-cadherin-GFP expression, contained an extra nucleus and internal CellTracker 
stain that should have exclusively stained the tumor cells (Figure 4.4 C (right insert), 
E, F). We note that CellTracker Orange CMRA is transformed into a cell-impermeant 











Figure 4.3: MDA-MB-231 cell incorporation into HBMEC monolayers on HA/gelatin 
films with varying degrees of crosslinking. A) Phase contrast images of an incorporating 
(blue arrow) and a non-incorporating (green arrow) CellTracker-stained MDA-MB-231 cell 
(red) on an HBMEC monolayer. B) Percent of tumor cells that incorporate (12 ≤ N ≤ 22, 
where N is the number of time-lapse sequences analyzed), C) time from start of time-lapse 
to full incorporation, and D) the cumulative percent incorporation of tumor cells over time 
(65 ≤ N ≤ 184, where N is the number of incorporating cells) into HBMEC monolayers on 
HA/gelatin films with 0, 0.2, 0.8, 1.2, and 2% Extralink in a total time of 9.75 hours. For 
panels B and C, P > 0.05 via a non-parametric Kruskal-Wallis ANOVA test with a Dunn’s 
multiple comparison post-hoc test between all groups. E) Average percent incorporation as 
a function of the number of tumor cells in frame at the start of the time-lapse. All error bars 








Figure 4.4: Confocal images of various modes of tumor cell incorporation into HBMEC 
monolayers. Confocal z-stacks reconstructed in ImageJ into a 3D stack showing evidence of 
A) MDA-MB-231 cells on top of or underneath HBMECs, B) paracellular incorporation of 
MDA-MB-231 with long cell tail above HBMEC monolayer, C) paracellular and potentially 
transcellular incorporation, D) potentially transcellular incorporation or spread of MDA-MB-
231 cell material into HBMEC, E) and F) potentially transcellular incorporation of MDA-
MB-231 cells into HBMEC monolayer. Intensity of each channel in each image were 
separately adjusted for better visualization; thus, relative intensities should not be compared. 
Scale bars from bottom row (panel F) apply to all images above except for the zoomed 
images. Each zoomed image is scaled individually, and all scale bars on zoomed images are 
50 μm. All images were taken on HA/gelatin films with 0% Extralink. Green: VECadGFP 






to daughter cells but not neighboring cells, and thus we do not expect for HBMECs to 
be nonspecifically labeled with CellTracker. By observing the 3D and cross-sectional 
view as well as the orthogonal view of the cells, it appeared that a tumor cell had 
transcellularly incorporated into the HBMEC monolayer, becoming a part of the 
HBMEC (Figure 4.4 C (right insert), E, F). A different mode of tumor cell-HBMEC 
interaction was observed in HBMECs that appeared to contain CellTracker stain but 
retained solely one nucleus (Figure 4.4 D). The punctate nature of the CellTracker  
stain in these HBMEC leads us to speculate that there could be extracellular vesicles 
or other cellular material shed by tumor cells and internalized by HBMECs (Figure 
4.4 D).  
4.3.3 MDA-MB-231 tumor cells dynamically interact with HBMEC junctions 
To quantitatively capture the dynamics of tumor cell incorporation into 
HBMECs, we collected time-lapse images of GFP-VE-cadherin-expressing HBMECs 
and CellTracker-stained MDA-MB-231 tumor cells. We found that some tumor cells 
were able to migrate on top of HBMEC adherens junction and appear to 
morphologically “unzip” them (Figure 4.5 A, white arrow), such that the adherens 
junctions opened and then closed behind the tumor cell (Figure 4.5 A, yellow arrow). 
Additionally, we found that tumor cells could squeeze in between HBMECs, resulting 
in complete disruption of the surrounding adherens junctions (Figure 4.5 B, magenta 
and purple arrows). Similar to Figure 3 D, some image sequences suggested that 
HBMECs internalized cellular material shed by tumor cells, without damaging  
surrounding adherens junctions (Figure 4.5 B, blue arrow). These time-lapse 













Figure 4.5: Fluorescent live-cell imaging of VE-cadherin-GFP-expressing HBMECs 
and CellTracker-stained MDA-MB-231 cells. A) Example of MDA-MB-231 cell (white 
arrow) altering VE-cadherin-GFP (yellow arrow) between HBMECs as the tumor cell 
passes over the HBMEC junction. B) Examples of tumor cells squeezing between 
HBMECs (pink and purple arrows) and possible material transfer from tumor cell to 
HBMEC, or potential transcellular incorporation (blue arrow).  Intensity of each channel in 
each image was separately adjusted for better visualization, thus, relative intensities should 
not be compared. Scale bars from top row apply to all images in its series and are 50 μm. 
Starting time was selected for best visualization. All images were taken on HA/gelatin films 
with 0% Extralink. Green: VE-cadherin-GFP (HBMEC); red: CellTracker (MDA-MB-





findings, while simultaneously enabling us to observe tumor cell-adherens junction 
interactions.  
4.3.4 MDA-MB-231 tumor cell morphology and migration speed are altered 
during incorporation into HBMECs 
Tumor cell morphology and migration were clearly affected by the 
concentration of Extralink during migration on the bare HA/gelatin films (Figure 4.2); 
therefore, we explored the dynamics of tumor cell incorporation into HBMECs and 
whether this process depended on crosslinking of the HA/gelatin films. In some cases, 
tumor cells either remained rounded on top of the HBMEC monolayer and did not  
incorporate, or they spread into the monolayer (Figure 4.3 A). However, many tumor 
cells also spread and migrated on top of the HBMEC monolayer without 
incorporating. Therefore, we studied three specific cases over time: (1) MDA-MB-
231 cells that incorporated into the monolayer, separated into a pre-incorporation 
(i.e., exclusively rounded) and a post-incorporation (i.e., spread out) regime; (2) 
MDA-MB-231 cells that did not incorporate and remained rounded for the entire 
study; and (3) three representative HBMECs from each monolayer. First, we 
observed that the area (Figure 4.6 A) and speed (Figure 4.6 B) of HBMECs remained 
mostly constant over time at each Extralink concentration. There was no statistical 
difference between the absolute value of the average changes in HBMEC area or 
speed across all timepoints as a function of Extralink concentration (Figure 4.6 C). A 
similar trend was observed for non-incorporating tumor cells, where both their area  
(Figure 4.6 D) and speed (Figure 4.6 E) did not change significantly over time (Figure 





incorporating tumor cell area and speed occurred with the 1.2% Extralink 
concentration (Figure 4.6 F). However, the area of incorporating tumor cells 
increased during incorporation (Figure 4.6 G), while their speed decreased during 
incorporation (Figure 4.6 H). This increase in tumor cell size after incorporation is in 
line with a previous study that reported melanoma cells becoming more spread and 
elongated as they incorporated into endothelial monolayers [150]. For tumor cells 
pre- and post-incorporation, there were no significant differences between Extralink 
concentrations in the absolute value of the change in area or speed across timepoints;  
however, it was evident that area was generally more consistent between the different 
Extralink concentrations prior to incorporation and speed was generally more 
consistent post-incorporation (Figure 4.6 I).  
 To understand the statistical significance of this dynamic data, we calculated  
the area and speed of the cells averaged across multiple time points pre- or post-
incorporation. First, we found that there were no differences in HBMEC or MDA-  
Figure 4.6: MDA-MB-231 tumor cell area and speed profiles over time during 
incorporation into HBMEC monolayers. A) HBMEC area and B) HBMEC speed over 
time during incorporation experiments on HA/gelatin films with 0, 0.2, 0.8, 1.2, and 2% 
Extralink. 36 ≤ N ≤ 66 where N is number of cells. C) Absolute value of the average change 
in area and speed between each time point from panels A and B, respectively. D) Area and 
E) speed over time of non-incorporating MDA-MB-231 cells on HBMEC monolayers on 
HA/gelatin films with 0, 0.2, 0.8, 1.2, and 2% Extralink. 14 ≤ N ≤ 89, where N is the number 
of cells. F) Absolute value of the average change in area and speed between each time point 
from panels D and E, respectively. G) Area and H) speed over time for MDA-MB-231 cells 
pre-incorporation (while rounded) and post-incorporation (while spread out) into HBMEC 
monolayers. 30 ≤ N ≤ 78 where N is the number of cells. I) Absolute values of the average 
change in area and speed between each time point from panels G and H, respectively. 
Average J) area and K) speed of HBMECs, non-incorporating MDA-MB-231 cells, and 
incorporating MDA-MB-231 cells (pre- and post-incorporation) on HA/gelatin films with 
0, 0.2, 0.8, 1.2, and 2% Extralink. For panels J and K, each dot represents one cell. All data 
is pooled from three independent trials. Statistical significance was determined using a non-
parametric Kruskal-Wallis ANOVA test with a Dunn’s multiple comparison post-hoc test 
as follows: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. For all figures, error 













MB-231 tumor cell (incorporating and non-incorporating) area (Figure 4.6 J) or speed 
(Figure 4.6 K) as a function of HA/gelatin film crosslinking under static conditions. 
However, the area of the tumor cells was significantly larger pre-incorporation 
compared to post-incorporation on HA/gelatin films for all concentrations of 
Extralink (Figure 4.6 J), as was also observed in the plots over time (Figure 4.6 G). 
Meanwhile, there was a significant decrease in speed between pre- and post-
incorporation phases of the tumor cells on HA/gelatin films with 0, 0.8, and 2% 
Extralink (Figure 4.6 K). These results suggest that the process of incorporation into 
HBMECs changes the morphology and migratory behavior of the tumor cells and also 
abrogates the mechanosensitivity of tumor cells to the crosslinking density of the 
HA/gelatin films. 
We also note that for HA/gelatin films with 0.2% Extralink, the area of 
incorporating tumor cells (Figure 4.6 J) became similar to the area of tumor cells on 
bare films (Figure 4.6 B). However, due to the loss of a mechanosensation effect in 
the presence of HBMECs, tumor cells had much larger spreading areas and migration 
speeds during incorporation into HBMECs on the HA/gelatin films with 2.0% 
Extralink in comparison with tumor cells on the bare films.  
4.4 Discussion 
Extracellular matrix crosslinking and stiffness are known regulators of many 
cellular functions in the context of physiologic and pathologic conditions. In this 
work, we explored the effects of HA crosslinking on metastatic breast tumor cell 
migration and incorporation into the human brain endothelium. Interestingly, our 





crosslinked, and thus stiffer, HA/gelatin films is contradictory to frequent reports in 
literature, including our own, where cells spread more on stiffer extracellular matrix-
coated polyacrylamide gels [60], [114], [173]. Similarly, previous studies have shown 
that when utilizing HA-methacrylate gels crosslinked with dithiothreitol (DTT)  and 
functionalized with Arg-Gly-Asp (RGD) peptides for cell adhesion, increasing HA 
weight percent and crosslinking density, thus increasing stiffness, increased the 
spreading area and speed of glioblastoma cells [45]. Varying the concentration of 
DTT crosslinker in the same HA system was also found to alter the phenotype of 
brain-seeking clones of MDA-MB-231 cells, where they observed increased tumor 
cell area and speed with increased crosslinking and film stiffness [174]. Notably, the 
previous studies were performed on HA gels crosslinked using a different mechanism 
and with various coatings for cell adhesion, rather than gelatin incorporation as was 
used here. On the other hand, through chemical rather than mechanical signaling, soft 
HA gels can produce identical cellular responses to those on stiffer substrates [175].  
Hence, mechanosensitivity in this context likely involves a delicate balance between 
sensing of multiple parameters of the extracellular matrix, including stiffness, method 
and degree of crosslinking, method of adhesion molecule incorporation, and the 
specific composition of the matrix. 
One aspect of the HA/gelatin films that could have affected the response of 
tumor cells to changes in crosslinking is film porosity. Several studies in the past 
have observed that various different formulations of HA gels are structured as a mesh 
folded sheet which became dense with increased methacrylated HA polymer weight 





size of the pores gradually decreased with increased crosslinking [176]. The size of 
the pores was in the tens of microns range [176]. However, since the structure of the 
gels could be a result of either one of the two components in the gel, another study 
compared the structures of collagen gels, methacrylated HA gels, and gels that were a 
combination of both gels and found that while collagen itself had a fibrous structure, 
the HA gels had a sheet or flake-like structure, and the composite gels had elements 
from both types of gel and were highly porous [177]. Since in the case of this study 
the gelatin used can be expected to act similarly to collagen and form a tighter 
structure with increased crosslinking [178] it is expected that our films were 
comprised of both fibrous or sheet-like components as well as porous ones and 
increasing crosslinking decreases pore size and makes the mesh more dense. Based 
on literature, the pores of the films are likely of micron size and thus highly relevant 
to cell behavior since their size is of similar order of magnitude. This aspect of the 
HA/gelatin film structure could potentially play a role in the mechanosensitive 
response of the tumor cells.  
For example, the presence of larger pores and a more diffuse network could be 
facilitating tumor cell-matrix degradation via invadopodia. Invadopodia are a type of 
actin rich protrusion of carcinoma cells, similarly to podosomes on endothelial and 
other cells [179]. Invadopodia are able to not only help cells attach to a matrix, but 
also degrade it with greater efficiency than podosomes and invadopodia are also 
larger than podosomes, with a maximum size of 8 µm x 5 µm [179]. It is possible that 
the larger pores and the more diffuse network of HA and gelatin allows for deeper 





MMPs [179]. Invadopodia have been shown to be involved in cell migration and 
transmigration [179], which could explain some of the differences observed on the 
differently crosslinked HA/gelatin films. As the matrix becomes more crosslinked 
and the pore size decreases, it is possible that fewer invadopodia invade the matrix 
resulting in decreased matrix degradation, and cell migration. Increased involvement 
of invadopodia could also correspond to an increased integrin expression [179], 
which could explain the increased spreading of cells on less crosslinked HA/gelatin 
matrices.  
Our results suggest MDA-MB-231 are highly sensitive to HA/gelatin 
crosslinking despite the fact that the measured Young’s modulus of the films was in 
the relatively small range of 0.85 to 3.8 kPa. This could indicate that extracellular 
matrix crosslinking could actually have a greater effect on tumor cells than 
extracellular matrix stiffness. The observed changes in migration and morphology of 
tumor cells on bare HA/gelatin films could be indicative of mechanosensitive changes 
in metastatic potential of the cells. For example, tumor cells have been shown to be 
more migratory during pre-micrometastasis (when they first cross an endothelium but 
prior to formation of tumor cell-tumor cell contacts) as compared in micrometastasis 
(once tumor cells form contacts and begin to form secondary tumors) [180]. In fact, 
the migratory pre-micrometastsis regime has been suggested as a therapeutic target 
[180]. Studies have also shown, as discussed in Chapter 3, that more cells with higher 
metastatic potential tend to also be more migratory [140]. This suggests that the 
mechanosensitivity of tumor cells to HA/gelatin crosslinking could also be tied to the 





secondary tumors when they are initially more migratory, as they are on less-
crosslinked HA/gelatin films.  
Furthermore, our results suggest a lack of correlation between the number of 
tumor cells in the area of observation and propensity to incorporate. We note that if a 
tumor cell interacted directly with a gap between HBMECs in the monolayer, it was 
not included in the analysis. Therefore, once a monolayer of HBMECs was present in 
the system, tumor cells appeared to be significantly less sensitive to HA/gelatin 
matrix crosslinking than when they were on bare films. These results suggest that 
HA/gelatin crosslinking does not significantly affect tumor cell incorporation into 
HMBEC monolayers, and that matrix mechanics might become more important post-
extravasation, since tumor cells on the bare gels without HBMECs showed such 
dramatic differences in morphology and migration. Our observations are also 
consistent with our previous results, where percent tumor cell incorporation into 
HUVECs was independent of polyacrylamide gel stiffness [181].  
Our observations suggest that breast tumor cells have multiple mechanisms by 
which they can interact with and incorporate into HBMEC monolayers. This is 
consistent with our prior studies in non-brain extracellular matrix, where tumor cells 
incorporated into and physically displaced endothelial cells in monolayers [33]. Other 
studies have found that tumor cells can utilize cytoplasmic protrusions (i.e., 
invadopodia) to assist in extravasation across endothelial barriers and degrade the 
basement membrane [182]–[185], which has been previously thoroughly reviewed 
[186], [187]. It is possible that similar interactions are occurring here during 





Furthermore, the dynamic nature by which we observed HBMEC adherens junctions 
open and close due to tumor cell interaction is of particular interest, and suggest that 
HBMECs have a potential for self-repair. Indeed, our results are supported by prior 
reports where endothelial cells were able to rearrange their cytoskeleton to repair 
themselves post para- and trans-cellular invasion of tumor cells [188]. 
Despite the interaction of tumor cells with the HA matrix when squeezing in 
between brain endothelial cells, the degree of HA/gelatin film crosslinking did not 
play a significant role in the ability of tumor cells to incorporate. It is also possible 
that brain endothelial cells deposit their own extracellular matrix to an extent that 
masks the mechanical properties of the original HA/gelatin films to the tumor cells. 
Indeed, previous studies have demonstrated that endothelial cells are capable of low 
levels of extracellular matrix deposition after just one day of culture in favorable 
conditions [189], and thus HBMEC-matrix remodeling is plausible during the three-
day culture period.   
Interestingly, other studies have reported enhanced transmigration of MDA-
MB-231 cells in the presence of human brain endothelial cells, suggesting that the 
endothelial cells facilitate transmigration [190]. This could potentially explain the 
increase in tumor cell area and migration post-incorporation, where HBMECs are 
present, compared to their respective values on bare HA/gelatin films. Notably, 
though, this response was influenced by the extent of matrix crosslinking, since only 
minimal changes were observed on the films with 0.2% Extralink. Alternatively, as 
discussed above, HBMECs may be remodeling the underlying matrix and/or 





properties of the HA/gelatin films to the incorporating tumor cells and altering their 
interactions with the matrix post-incorporation. It is also possible that junctional 
proteins, which may potentially be linking tumor cells and HBMECs, could 
physically alter the migratory capacity of tumor cells within an HBMEC 
monolayer.While our experiments have provided interesting insights into the 
biochemical and physical interactions between tumor cells, the HA matrix, and the 
brain endothelium, we acknowledge several important limitations of our system. 
First, our models lack other cell types present at the in vivo BBB, including astrocytes 
and pericytes. There is a growing body of literature [191], [192] to support the 
hypothesis that the presence of these cells, and/or their secreted biochemical factors, 
would likely influence tumor cell migration and incorporation into the brain 
endothelium, cell-cell junctions in the HBMECs, and possibly also the extracellular 
matrix. Indeed, our own previous work has shown that astrocyte conditioned media 
applied to tumor cells directly, or to their extracellular matrix only, can result in 
increased tumor cell migration, as described in Chapter 3. Secondly, our models lack 
physiologic flow conditions. Shear stresses in the brain capillaries of rodent models 
have been measured to be in the range of 20-40 dyne cm-2 [193], which can influence 
endothelial barrier function, cell migration, tumor cell adhesion, and tumor cell 
proliferation [194]–[198]. Another limitation of our model is the lack of cylindrical 
geometry, which can influence endothelial cell elongation in the presence of shear 
stress [199]. Incorporation of these additional cells and mechanical cues will continue 






We have shown that MDA-MB-231 morphology and migration parameters 
were sensitive to the crosslinking density of HA/gelatin films, with a trend that was 
opposite of that typically observed for varying stiffness of extracellular matrix-coated 
polyacrylamide gels. HA/gelatin crosslinking, however, did not seem to affect MDA-
MB-231 tumor cell incorporation into the HBMEC monolayers. We also showed that 
MDA-MB-231 tumor cells were able to utilize multiple modes of incorporation into 
HBMECs, in addition to the commonly reported paracellular pathway, and that tumor 
cells dynamically modified their morphology and migration behavior, as well as 
HBMEC junctions, during incorporation into a biomimetic BBB. Overall, our 
quantitative results suggest that a combination of biochemical and physical factors 
promote tumor cell migration through the BBB, and suggest that extracellular matrix 
mechanics may become most significant once incorporation or transmigration is 
complete. Future work will continue to build upon these results by incorporating 











5 Morphological phenotyping of organotropic brain- and bone-
seeking clones of metastatic breast tumor cells 
5.1 Introduction 
 Yoneda et al. established organotropic brain- and bone-seeking clones from 
the MDA-MB-231 parental metastatic breast tumor cell line [73] which now can be 
used to study the different properties of the clones. Organotropic metastatic tumor 
cells have been shown to have several distinguishing properties, such as exosome 
secretion and molecular expression [16]. Breast cancer in particular is known to 
exhibit a significant level of organotropism [16]. A better understanding of the 
properties that make tumor cells organotropic, can inform further steps in targeting 
these specific cell phenotypes in the blood stream prior to transmigration, during 
transmigration, or as secondary tumors as well as could allow for earlier cancer 
detection [16]. Some, primarily biochemical, differences in the breast cancer cell 
clones have already been established. For example, brain-seeking tumor cells have 
been shown to produce more parathyroid hormone with TGF-β-independent growth 
while the bone-seeking and parental tumor cells did not have these properties [73]. 
Brain seeking tumor cell clones were also more sensitive to insulin-like growth factor 
I [73] and the bone-seeking tumor cells adhered more strongly osteoblast generated 
bone matrix, than brain-seeking and parental clones [74]. In fact, one study showed 
that adhesion properties of brain- and bone-seeking cells can be used to sort them 
based on their adhesion to brain and bone like extracellular matrix, as established via 





performed a proteomic analysis of the brain-seeking clones and compared them to the 
parental tumor cells, showing some major protein expression differences, and 
pathway analysis that revealed alterations in pathways related to cell signaling, 
division, movement, survival, protein synthesis, molecular transport, and cell-cell 
interaction, to name a few [76].  
Here, we seek to understand any morphological differences that differentiate 
brain- and bone-seeking tumor cells from parental tumor cells on niche-relevant 
substrates in order to determine whether the use of niche-relevant substrates could be 
used to differentiate the cell clones based on morphology. This understanding would 
begin the process to learning how one could distinguish the cell clones and predict 
tumor cells’ metastatic destination prior to colonization with the help of additional 
parameters. Since tumor cells are highly heterogenous, in addition to morphology, 
many additional parameters will need to be characterized such that a combination of 
various parameters can allow us to make an early determination of the metastatic 
destination of a population of metastatic tumor cells.  
5.2 Materials and Methods 
5.2.1 Cell Culture 
Human breast adenocarcinoma highly metastatic cells (MDA-MB-231) and 
their brain-seeking and brain-seeking clones were generously provided by Dr. 
Toshiyuki Yoneda’s laboratory in Osaka, Japan. Dr. Yoneda’s lab developed the 
brain- and bone-seeking clones based on a published protocol where the parental cell 





where the cells were collected and the process was repeated until a heterogenous 
population was obtained [73]. The cells were cultured in media consisting of 
Dulbecco’s Modified Eagle’s Medium (DMEM) with high glucose (ThermoFisher 
Scientific, Waltham, MA, USA), 10% Fetal Bovine Serum (FBS; HyClone 
Characterized GE Healthcare, Pittsburgh, PA, USA or ThermoFisher Scientific), and 
1% Penicillin-Streptomycin 10,000 U/mL, similarly to previous chapters. Cells were 
washed with Phosphate-Buffered Saline (PBS) (VWR, Radnor, PA, USA), and 
detached with 0.25% Trypsin-EDTA (ThermoFisher Scientific). All cells were 
cultured at 37˚C, 50% humidity, and 5% CO2:95% air.  
5.2.2 Polyacrylamide (PA) gel formation and collagen coated glass 
PA gels were formed as previously described [173], [201]. Briefly, 22 x 22 
mm coverslips (Thermo Fisher Scientific) were activated using sodium hydroxide 
(Sigma Aldrich, St. Louis, MO), 3-aminopropyltrimethoxy silane (Sigma Aldrich) 
to, and glutaraldehyde (Sigma Aldrich). To form 280 kPa and 1 kPa PA gels (as 
measured previously by Dr. Kimberly M. Stroka and Dr. Leann Norman via AFM), 
acrylamide and bisacrylamide (bis) (Bio-Rad Laboratories, Hercules, CA) were 
combined as follows: 15% acrylamide + 1.2% bis, and 3% acrylamide + 0.2% bis 
and mixed with 1 M HEPES buffer (Thermo Fisher Scientific) and water and then 
crosslinked with tetramethylethylenediamine (TEMED) (Bio-Rad Laboratories) and 
ammonium persulfate (Sigma-Aldrich). The gels were then activated with sulfo-
SANPAH (ThermoFisher Scientific) and treated with ultraviolet light (UV) for 
sterilization. They were then coated with 300 µl of 50 µg/mL collagen I (Sigma-





experiments with 50 µg/mL collagen I coated glass, cells were plated in 50 mm 
AFM grade glass bottom dishes (VWR) without activation. They were coated with 
780 µl of collagen I for 1 hour at 37 ˚C and 2.6 x 105 cells were plated on top. The 
difference in collagen volume and cell number was used to account for the 
difference in culture area.  
5.2.3 Varying extracellular matrix binding moieties on glass 
Experiments on varying extracellular matrix binding moieties were carried out 
the way as described in Section 3.2.2.  However, only the following extracellular 
matrix moieties were used: type I collagen from rat tail (Sigma Aldrich, St. Louis, 
MO, USA), fibronectin from human plasma (Sigma Aldrich), laminin from human 
fibroblasts (Sigma Aldrich), or Poly-D-Lysine hydrobromide (Sigma Aldrich). As 
described in Section 3.2.7, 24-well glass bottom plates (MatTek, Ashland, MA) were 
coated in the varying binding moieties and incubated as described in Section 3.2.2. 1 
x 104 cells (parental, brain- and bone-seeking) were plated on each substrate.  
5.2.4 Cells in suspension 
4 x 105 cells were plated in 6 well non-tissue culture treated plates (VWR) and 
imaged immediately. 10 μm diameter (9.94 μm exactly as per manufacturer for 
specific batch) Envy Green fluorescent beads (Bangs Laboratories, Inc, Fishers, IN, 
USA) were suspended in the same plates in order to validate imaging and analysis 





5.2.5 Live cell phase imaging 
Cells in suspension and beads were imaged immediately following seeding 
using an Olympus I.X83 microscope (Olympus, Center Valley, PA, USA) using a 
phase-contrast 20× objective, similarly to Section 3.2.8. Images of attached cells were 
taken following an overnight incubation of cells on all substrates. Imaging was 
carried out using a phase-contrast 10× objective. A climate-controlled chamber was 
calibrated to 37˚C, 50% humidity, and 5% CO2:95% air on the microscope stage for 
all experiments.  
5.2.6 Atomic force microscopy (AFM)  
Carried out and analyzed by Kelsey Gray. 
 
 Stiffness of tumor cells on PA gels and on glass was measured using AFM. 
AFM was performed using an Asylum MFP-3D-BIO Atomic Force Microscope with 
TR400PB(L) probes (Asylum Research) as previously described [201]. All AFM 
measurements were carried out by Kelsey Gray. Briefly, the coverslip with tumor 
cells on glass or PA gels was adhered to the bottom of a 50 x 9 mm petri dish. After 1 
day in culture, AFM was performed on live cells with the stage heated to 37 °C. 
Asylum’s “Get Real” approach was used to measure the spring constant and inverse 
optical lever sensitivity of TR400PB(L) probes via the Sader method and thermal 
noise method, respectively. The average spring constant of the cantilevers was within 
a factor of 1.33 to Asylum’s nominal value of 0.02 N/m and all within the nominal 
range of 0.1-0.5 N/m. One 100-curve force map covering a 5 μm2 area was collected 





and a scan rate of 0.99 Hz. The Hertz model was used to fit the force curves within 






∙ √𝑟 ∙ 𝛿3/2 , where 𝛿 
is the measured indentation of the sample and the Young’s modulus 𝐸 was the fitting 
parameter. The Poisson’s ratio 𝜐  of the sample was assumed to be 0.45 and the tip 
radius of curvature 𝑟 was approximately 30 nm. Three biological replicates were 
performed in which three cells per condition per trial were measured (n = 9 cells 
total).  
5.2.7 Data analysis 
 For cells in suspension and beads, images were modified in ImageJ for 
maximum brightness and contrast in order to get the sharpest contours. The image 
was then made black and white and binary. The ImageJ function to fill holes was used 
and the ImageJ built in particle analyzer was used with a cut off for size for area of 
300 - 1250 pixels2, and a cutoff circularity of 0.65 - 1. This was done in order to 
eliminate any aggregates from analysis.  ImageJ then generated a spread sheet with 
the necessary parameters, such as area for all cells in a given frame. This was 
repeated for all frames. Data analysis for attached cells was carried out similarly to 
Sections 3.2.9 and 4.2.9.  ImageJ was used to manually trace cells and calculate cell 
area, aspect ratio, circularity, and solidity (Appendix A).  
5.2.8 Statistical analysis 
Statistical analysis was carried out similarly to Section 3.2.10 and 4.2.10. 
GraphPad Prism (GraphPad, San Diego, CA) was used for all statistical analysis. The 





data was not normally distributed, the Kruskal-Wallis non-parametric test with a post-
hoc Dunn’s test was used to determine statistical significance. Between two and three 
independent trials were carried out for each experiment type, as indicated in figure 
caption). Histograms were generated using a frequency analysis in GraphPad. A 
Gaussian curve was fitted to a frequency distribution of cell and bead area and 
diameter in GraphPad as well. Statistical significance was determined with a 95% 
confidence interval with P < 0.05. Detailed statistical significance is indicated in 
figure captions. 
5.3 Results 
5.3.1 MDA-MB-231 metastatic tumor cell clone areas in suspension 
In order to determine whether the different MDA-MB-231 cell clones would 
vary in morphology while still in circulation, we studied their projected area and 
diameter in suspension (prior to attachment to a surface). In suspension, the analysis 
methods were validated by analyzing beads with known diameters and found 
consistent results within approximately 1.86 µm of the dimeter and 32.4 µm2 of the 
area (Figure 5.1 A, B). Thus, we proceeded to analyze cells in suspension. While 
based on images, there does not appear to be a great difference between the cells 
(Figure 5.1 C), upon quantification we determined that there were significant 
differences within the groups. The largest differences were in area and diameter 
between parental and bone-seeking cells as well as brain- and bone-seeking cells 
(Figure 5.1 D, E, F, G). A significant difference was also observed between parental 





is important to note that the populations are still highly heterogenous, even in 
suspension (Figure 5.1). Next, we chose to investigate whether these trends change 
once tumor cells become attached to an extracellular matrix. 
5.3.2 MDA-MB-231 metastatic tumor cell clone areas on different substrates 
Because some phenotypic differences were observed in suspension  
between the tumor cell clones, we decided to also examine them attached  
to extracellular matrix. Since tumor cells attach to different extracellular matrix 
molecules during metastasis to various distant sites, it is important to examine the 
tumor cell phenotypes on various extracellular matrix. Here, we considered two 
common extracellular matrix proteins, collagen I and fibronectin, as well as PDL, 
which unlike proteins, does not engage integrins and relies on electrostatic 
interactions for cell adhesion. When MDA-MB-231 metastatic breast parental tumor 
cells and brain- and bone-seeking clones were plated on collagen I, fibronectin, and 
PDL, some visual morphological differences became apparent (Figure 5.2 A). 
Specifically, bone-seeking clones were distinct from the parental and brain-seeking 
clones on collagen I, since they had more protrusions, and on fibronectin, where the 
cells are more spread (Figure 5.2 A). However, on PDL there were minimal 
observable differences between the three tumor cell clones (Figure 5.2 A). Because 
that all the cells appeared to attach to both extracellular matrix proteins and spread 
readily in an integrin-dependent fashion, further experiments were carried out to on 








Figure 5.1: Images of MDA-MB-231 parental cells and brain- and bone-seeking clones 
in suspension.  A), B) Proof of concept 9.94 µm beads in suspension.  606 beads analyzed. 
C) Images of MDA-MB-231 parental cells and their brain- and bone-seeking clones in 
suspension. Scale bar applies to all images. All images taken via 20x phase contrast imaging. 
D) Area and E) Gaussian distribution of MDA-MB-231 parental cells and their brain- and 
bone-seeking clones in suspension. F) Diameter and G) Gaussian distribution of MDA-MB-
231 parental cells and their brain- and bone-seeking clones in suspension. All cell numbers 
are: 1277 ≤ n ≤ 1695 cells. All data is pooled from three independent trials. (* p < 0.05; ** p 






Furthermore, the three tumor cell clones were seeded on surfaces coated with 
collagen I but of different stiffness, glass (~50 GPa), 280 kPa (similar to bone), and 1 
kPa (similar to brain) in order to further mimic biomechanical properties of the local  
extracellular matrix at various metastatic sites. With decreasing stiffness, all tumor 
cell clones became less spread (Figure 5.2 B). However, once again the bone-seeking 
clones stood out in morphology by having more protrusions and longer protrusions on 
all extracellular matrix stiffness than any of the other clones (Figure 5.1 B). 
 Upon quantification, significant differences in morphology parameters were 
observed among the different cell clones on collagen I coated glass and 280 kPa and 1 
kPa stiffness PA gels. Within each extracellular matrix stiffness, all cell clones had 
statistically different areas from each other, except on glass and the 1 kPa gels, where 
parental and brain-seeking cells’ areas were not different (Figure 5.3 A, B). On PA 
gels, bone-seeking cells had the largest area while on glass the brain-seeking cells 
were actually larger (Figure 5.3 A). The inverse aspect ratios were not significantly 
different between the three cell clones on 280 kPa gels, however, within glass and 1 
kPa stiffness gels all cell groups were significantly different (Figure 5.3 C, D). 
Similarly, for circularity parental and brain-seeking cells were not different on the 
280 kPa gels, while all other cells within each stiffness were statistically different 
(Figure 5.3 E, F). On the other hand, within each stiffness group all solidities were 
significantly different between the three different clones (Figure 5.3 G, H). Notably, 
the cell populations were all highly heterogeneous (Figure 5.3 B, D, F, H).  
These results suggest that altering the extracellular matrix stiffness and 









Figure 5.2: Images of MDA-MB-231 parental cells and brain- and bone-seeking clones 
on various substrates.  MDA-MB-231 parental cells and their brain- and bone-seeking 
clones on 20 µg/ml A) collagen I, fibronectin, and PDL coated glass, and 50 µg/ml collagen I 
coated B) glass, 280 kPa (bone-like), and 1 kPa (brain-like) stiffness PA gels. Scale bars on 
first zoomed out image apply to all images in the sequence. Scale bar on first zoomed in 
image applies to all images in sequence. Images taken at 10x via phase contrast imaging with 






Figure 5.3: Morphology of MDA-MB-231 parental cells and brain- and bone-seeking 
clones on collagen I coated glass. MDA-MB-231 parental cells’ (P) and their brain (Br) and 
bone-seeking (BO) clones’ A), B) areas, C), D) inverse aspect ratios, E), F) circularities, and 
G), H) solidities.  If no lack of significance is indicated, the groups are significantly different 
by P value indicated in plot. Legends apply to all plots. Data pooled from three independent 
trials. All substrates are coated with collagen I. All cell numbers are: 597 ≤ n ≤ 1532 cells. 
ns: not statistically significant, P > 0.05. Label and legend apply to all figures. Nathaniel 







bone-seeking cells, however it does not appear that by using different substrate 
stiffnesses one could easily identify the various cell populations. It does appear 
possible that the 1 kPa substrate could be used as a starting point to start separating  
the cell populations, since the greatest number of differences were observed there for 
all parameter and the bone-seeking cells appearing most distinct on that surface. This 
could have important functional implications as they undergo metastasis from the breast 
to brain or bone.  
5.3.3 MDA-MB-231 metastatic tumor cell clone stiffness on different 
substrates  
As TCs metastasize, they have to travel through various porous physiological 
structures, and thus have to be able to get through very narrow spaces and the softer a 
cell is, the more likely it is be able to get through differently shaped spaces. Thus, we 
evaluated the stiffness of each cell clone type on collagen I coated glass and 280 and 
1 kPa PA gels. Our data showed that all three cell clones do not have statistically 
different stiffness within each substrate (Figure 5.4). However, there are general 
differences between cells on different substrates, brain-seeking and bone-seeking 
cells on 1 kPa PA gels being the softest and parental and brain-seeking cells being 
stiffest on 280 kPa PA gels (Figure 5.4). This data suggests that cell stiffness is 
unlikely to be a primary determining factor in the preferential metastasis of the 






  This study begins to address the “seed” portion of the “seed and soil” 
hypothesis, focusing on the tumor cells themselves and not just the 
microenvironment. While the Chapter 3 and 4 examine cues exerted by the BBB  
microenvironment and surrounding cells on metastatic tumor cells, it is also crucial to  
study the tumor cells themselves in order to begin to understand whether there are 
some underlying driving forces within the cells themselves that result in preferential 
metastasis to the brain, versus other organs. As such, it is important to examine how  
brain-seeking tumor cells compare in their phenotype to parental or bone-seeking 
tumor cells and how all the cells respond to their microenvironments in order to begin 
Figure 5.4: Stiffness of MDA-MB-231 parental cells and brain- and bone-seeking 
clones’ collagen I coated glass and PA gels.  MDA-MB-231 parental cells’ (P) and their 
brain- (Br) and bone-seeking (BO) clones’ Young’s Modulus on 50 µg/ml collagen I 
coated glass, and 50 µg/ml collagen I coated 280 kPa and 1 kPa PA gels. All cell numbers 
are: 28 ≤ n ≤ 49. Data was pooled from at least three independent trials. Statistical 
analysis was performed using a Kruskal-Wallis multiple comparison test with a Dunn’s 
post-hoc test. (* p < 0.05; ** p < 0.01; *** p < 0.001). AFM measurements taken and 





to discover differences that would allow us to predict the metastatic destination of a 
given tumor cell.  
 While it is still unknown whether tumor cells’ metastatic site is controlled 
more by their intrinsic phenotypic and genotypic properties, or whether the properties 
of the tumor cells are altered as a result of metastasis to a particular organ, it is likely 
that the interaction of tumor cells with their microenvironment results in tumor cells 
that have different properties [76], [77], [202]. However, it is also important to note 
that the phenotype of tumor cells varies on surface versus traveling through the blood 
stream. Here, we seek to determine whether culturing tumor cell clones in different 
conditions could yield significant enough morphological differences to distinguish the 
three phenotypes.  
 We showed that parental and brain- and bone-seeking tumor cells exhibit 
different morphological properties both in suspension (Figure 5.1) and when attached 
to extracellular matrix (Figures 5.2 and 5.3). Visually, the bone-seeking cells are 
morphologically unique even when attached by showing greater protrusions (Figure 
5.2). Interestingly, there does not appear to be a direct correlation between cells with 
different organotrophic destinations having distinct morphologies between soft and 
stiff substrate that vary clone to clone. Overall, our data shows that seeding cells on 
substrates with different stiffness would not allow us to differentiate the different 
cells based on morphology alone. This is more promising within each stiffness, 
especially on 1 kPa, however the cell populations are too heterogenous for 
morphology to be a sufficient parameter for distinction even for statistically 





on all extracellular matrix substrates, suggesting that while morphology could be a 
potential future indicator of functional differences in the tumor cell clones when 
combined with additional factors such as migration or traction force generation, cell 
stiffness is unlikely to play a significant role. While the phenomena has to be further 
examined, this is consistent with prior studies showing distinct differences in the 
tumor cell clones, especially in response to different extracellular matrix [32], [200]. 
Prior studies have shown that larger tumor cells with more protrusions are more often 
more metastatic and have a greater ability to migrate through blood vessels to distant 
sites [140], [203], suggesting that  phenotypic differences between different cell 
clones can also be indicative of changes in their metastatic potential and ability to 
metastasize to particular distant sites.   
5.5 Conclusion 
 Based on this data we concluded that all tumor cells examined are more 
spread on stiffer substrates and less spread on the soft PA gels. However, there are 
distinct phenotypical differences between the different cell clones on all surfaces, 
suggesting that cell morphology could be one of the distinguishing characteristics of 
the different clones and could be either a result of functional changes or lead to 
functional changes in tumor cell metastasis. However, due to the heterogeneity of the 
tumor cell population on all surfaces, multiple additional characterization approaches 
need to be taken into account before the tumor clone populations can be effectively 
sorted based on phenotypical characteristics. Furthermore, tumor cell stiffness was 
not significantly different between clones on PA gels and glass, suggesting that this 





helpful in differentiating the cell clones. Future work will determine additional 
factors, such as migration, traction forces, or confined migration that can, together 
with morphology on various substrates, help distinguish the tumor cell populations. 
Additionally, functional significance of these any phenotypic differences and further 
investigate mechanobiological changes between brain- and bone-seeking phenotypes 






6 Sensitivity of tumor vs. normal cell migration and morphology 
to cold atmospheric plasma-treated media in varying culture 
conditions† 
6.1 Introduction  
Cancer is known to be an extremely devastating diagnosis. Most cancer deaths 
are due to metastasis, or the spread of cancer cells from a primary tumor to distant 
sites, where they then form more aggressive secondary tumors  [35]. Currently, the 
most common cancer therapies, such as surgery, chemotherapy, and radiation, often 
leave patients with severe side effects such as anemia, bleeding, bowel dysfunction, 
bone density loss, infertility, and immune suppression [204]. This is often a result of 
significant damage to normal cells during the cancer treatment. While new and 
improved cancer therapeutics are constantly being developed [205]–[207], there 
remains a need for therapies that cause minimal damage to normal cells in the body. 
One potential novel therapy that has been recently proposed is the use of cold 
atmospheric pressure plasma (CAP), which produces reactive oxygen and nitrogen 
species (ROS, RNS) with the capacity to selectively kill cancer cells [82], [208], 
[209]. While CAP has already been shown as a promising therapeutic for external 
wounds [98], [210], [211] and destroying certain cells while leaving others intact 
[82], [91], it remains unclear how CAP would be used in vivo in the presence of 
bodily fluids with highly variable compositions [212], [213]. In order to facilitate 
† This chapter is modified from manuscript submitted for publication as M.A Pranda, 
B.J. Murugesan, A.J. Knoll, G.S. Oehrlein, K.M. Stroka, “Sensitivity of tumor vs. 
normal cell migration and morphology to cold atmospheric plasma-treated media in 





potential future CAP delivery in vivo [212], [213], many in vitro studies that assess 
the effectiveness of CAP as a cancer therapy are conducted in cell culture media, 
water, or buffer solutions [209], [214]. Hence, it is critical to understand what effect 
various cell culture parameters have on the outcome of CAP-treated media-based 
cancer treatment studies. Otherwise, there is a risk that the data will be a function of 
cell culture condition, instead of a function of the effectiveness of the actual 
treatment.  
A thorough review of CAP-based cancer therapy literature (condensed 
version, Table 6.1) revealed that very different experimental conditions have been 
used between different laboratories, and even between different experiments in the 
same laboratory [212], [214]–[218]. While some studies solely examined the effect of 
CAP on one cell line [212], [217] [212], [217] others investigated CAP selectivity 
between normal and disease cells [90], [216], [219]. Many studies that utilized more 
than one cell line for CAP-based experiments used the same fluid for both cell lines 
(Table 6.1) [84], [90], [209], [214], [216], [218], [220], [221], while others used 
different media across different cell lines (Table 6.1) [213], [222]–[225]. 
Additionally, many studies that compared normal and tumor cells used cells from 
unmatched tissue samples [216], [220]. Furthermore, a majority of previous studies 
used cells grown on tissue culture plastic (Table 6.1) [84], [90], [213]–[218], [224] 
where cells primarily rely on polar interactions for adhesion [226]; however, this 
microenvironment is not representative of the in vivo situation, where cells typically 
adhere to extracellular matrix  proteins via integrins [227]. Finally, most studies 





Table 6.1: Literature review of CAP usage in biomedical research. Summary chart of 
several recent studies utilizing plasma for cancer cell treatment. This chart provides an 
overview of which treatment parameters and experimental conditions are commonly used in 
the field. References that discuss the effect of varying medias are highlighted in gray. 
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sources (Table 6.1), though other CAP sources exist. While these experiments have 
produced interesting and significant results, the translatability of future CAP 
treatments will rely on careful, systematic studies that optimize cell culture and CAP 
treatment conditions to ensure that reported tumor cell selectivity is not simply a 
function of cell culture conditions.  
Here, our goal was to gain an understanding of the effects of cell culture 
conditions (e.g., media type and cell-matrix binding moieties) on the effectiveness of 
CAP-treated media as a selective treatment that can damage tumor cells while leaving 
normal cells unaffected. We chose two complimentary cell lines from the breast 
tissue, including a normal breast epithelial cell (MCF10A) and a metastatic breast 
tumor cell (MDA-MB-231) line. CAP-treated media was selected over direct CAP 
treatment of cells because in vivo metastatic cells are generally deeper in tissue and 
thus it would be very difficult to reach them directly with a plasma source. We varied 
cell culture media because different cell lines generally have different recommended 
media compositions, and thus when one is comparing the selectivity of a potential 
therapy, it is essential to ensure that conditions are standardized. We also compared 
the complimentary cells’ response to CAP-treated media in the presence of different 
cell-matrix binding moieties, because CAP may affect cellular integrin expression 
and therefore could potentially act on cells via an integrin-dependent pathway [219]. 
Thus, here we show how varying CAP parameters, culture media, and cell-matrix 
binding moieties affects the ability of CAP-treated media to be selective in damaging 





6.2 Materials and Methods 
6.2.1 Cell culture 
  Human metastatic breast adenocarcinoma cells, MDA-MB-231 (American 
Type Culture Collection, Manassas, VA, USA), were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) with high glucose and L-glutamine 
(ThermoFisher Scientific, Waltham, MA, USA) supplemented with 1% 
Penicillin/Streptomycin 10,000 U ml-1 (Pen/Strep) (ThermoFisher Scientific) and 
10% Fetal Bovine Serum (FBS) (ThermoFisher Scientific or HyClone Characterized 
GE Healthcare, Pittsburgh, PA, USA). Human mammary gland normal epithelial 
cells, MCF10A (American Tissue Type Culture Collection), were cultured in 
DMEM/F12, HEPES (ThermoFisher Scientific) with 0.02 µg/ml epidermal growth 
factor (Millipore Sigma, Burlington, MA, USA; E-9644, in 10 mM acetic acid), 0.5 
µg/ml hydrocortisone (Millipore Sigma; H-0888, in 95% ethanol), 0.02 mg/ml insulin 
(ThermoFisher Scientific; 12585-014), and 5% horse serum of New Zealand origin, 
ThermoFisher Scientific), and 1% Pen/Strep.  Cells were washed with Phosphate-
Buffered Saline (PBS) (VWR, Radnor, PA, USA), and detached with 0.25% Trypsin-
EDTA (ThermoFisher Scientific). All cells were used at or below passage 12 post-
purchase. All cells were cultured in a climate-controlled incubator at 37°C, with 5% 







6.2.2 Cold atmospheric plasma (CAP) set-up 
Plasma treatments carried out by Andrew Knoll. 
Two different CAP sources were used to introduce reactive species into media 
liquid used for cell culture. First, we utilized an atmospheric pressure plasma jet 
(APPJ) (Figure 6.1 A). This source has been well characterized in terms of plasma 
behavior and production of reactive species densities under various operating 
conditions [80], [215] and interactions with polymer materials [230]–[232]. The 
source utilizes a 1 mm diameter high voltage tungsten pin electrode sharpened to a 
point mounted inside a quartz tube, which has a 1.5 mm inner diameter and 3 mm 
Figure 6.1: Plasma source diagrams. Schematic of A) a 13.56 MHz driven pin style APPJ 
source that operates using Argon gas fed through a quartz tube and produces an ionized 
plasma discharge extending several mm toward the treated area. The distance used for this 
source was 1 cm, with a plasma dissipated power of 1.5 W, and the reactive species are 
driven by convection to the sample surface. Also shown is a schematic of B) a 42 kHz 
driven SMD plasma source that operates in ambient air where the plasma forms around the 
grounded mesh below a quartz dielectric barrier. The distance used for this source is 3 mm, 
with a dissipated power of 0.25 Wcm-2, and there is no gas flow and the reactive species are 
primarily transported by diffusion to the sample surface. Figure created by A.J. Knoll. 







outer diameter. There is also a grounded electrode made of copper on the outside of 
the quartz tube which has a 5.3 mm length and fits snug around the quartz tube. The 
standard operating conditions for the plasma jet are 20 kHz modulated 13.5 MHz 
sinusoidal wave with a 20% on, 80% off cycle. The dissipated power is 1.2 W with a 
gas flow of 1.5 slm of Argon (Ar), which corresponds to an average gas velocity of 
14.15 ms−1. The jet nozzle was set to a standard distance of 1 cm above the media.  
Details of how this power is calculated can be found in previous work characterizing 
this plasma source [233]. Secondly, our work utilized a surface microdischarge 
(SMD) style plasma source (Figure 6.1 B). This source is based on a design by 
Morfill as previously described [234], [235]. The powered copper electrode on the top 
of the source has an area of 25 cm2, and a quartz plate with thickness 1.6 mm 
separates the high voltage electrode from the grounded stainless-steel mesh with a 
50% opening. The source operates at 42 kHz sinusoidal wave, 6 kVp-p voltage from a 
PVM500 power supply, at a total plasma dissipated power approximately 6.5 W over 
the 25 cm2 area, or a specific power of 0.25 Wcm-2. The operating conditions for this 
source are in open ambient air with no active gas flow set 3 mm above the media. 
6. 2.3 Experimental set-up (Figure 6.2 A) 
This study compared two cell types (Figure 6.2 B), three different adhesion 
molecules (Figure 6.2 C), four different media conditions (Figure 6.2 D), and a 
control and CAP-treated condition. The following adhesion molecules were 





plasma (Millipore Sigma), and Poly-D-Lysine hydrobromide (PDL) (Millipore 
Sigma) (Figure 6.2 C). The following media were compared: (1) native MDA-MB- 
231 medium, which consisted of DMEM + 10% FBS + 1% Pen/Strep; (2) native 
MCF10A medium, which consisted of DMEM/F12 + all supplements (DMEM + 
Supp.) (described in Figure 6.2 D and Cell Culture section);  (3)  DMEM/F12 +  10%  
FBS + 1% Pen/Strep (to verify the effect of the base media versus supplements); and 
(4) RPMI-1640 (ThermoFisher Scientific) +  10% FBS + 1% Pen/Strep + 3.56 mM L-
glutamine (ThermoFisher Scientific) (Figure 6.2 d), since RPMI is a very common 
base medium used in many CAP studies [90]. Cells that were seeded on fibronectin 
and PDL were treated only with DMEM, while experiments evaluating the effects of 
the four different media compositions were performed only on type I collagen (Figure 
6.2). This experimental set-up enabled a systematic evaluation of the effects of each 
individual cell culture parameter. Prior to cell-seeding, 24-well glass bottom plates 
Figure 6.2: Experimental set-up. A) Experimental layout starting with culturing cells, 
preparing plasma treated media, treating cells, and imaging and analyzing cell speed and 
circularity. Descriptions of B) the complimentary cancer and normal cells used in 
experiment, C) the surface coatings varied in experiments (when surface coatings were 
varied, DMEM was used), and D) the media varied in experiments (when media were 






with 13 mm diameter glass (MatTek, Ashland, MA, USA) were coated with 300 μL 
of 20 μg/ml type I collagen in PBS, 20 μg/ml fibronectin from human plasma in PBS, 
or 20 μg/ml PDL in MilliQ water for at least 1 hour at 37˚C. In each plate, 16 wells 
were coated with type I collagen, 4 wells were coated with fibronectin, and 4 wells 
were coated with PDL (Figure 6.2 A). Wells with type I collagen and fibronectin 
were washed three times with PBS and wells with PDL were washed with sterile 
MilliQ water. MDA-MB-231 or MCF10A cells (1x104 total per well), were seeded 
per well such that each cell type was cultured under the same conditions (Figure 6.2 
A). After plating, cells were grown in their native media overnight. On the second 
day, the experimental media were treated with CAP (described in “CAP-treated 
media preparation”), the cells were washed with PBS, and either 1 mL of CAP-
treated media or the corresponding untreated control media was added. The layout is 
shown in Figure 6.2.  
6.2.4 CAP-treated media preparation 
CAP-treated media was prepared in the lids of Falcon Disposable Petri 
Dishes, Corning (VWR) for the SMD and in Corning tumor cell-Treated Culture 
Dishes (ThermoFisher Scientific) dishes for the APPJ. 4 mL of media were pipetted 
into each lid or dish. The lids used for SMD treatment were 4 mm tall and filled to 3 
mm, and the inner radius was approximately 20 mm. The dishes used for APPJ 
treatment were 10 mm tall and filled to approximately 4.4 mm, and the inner radius 
was approximately 17 mm. Different lids/dishes were used for SMD and APPJ 
treatments due to the necessary distance of the plasma source from the surface of the 





conditions described in “CAP set-up” for 1 or 7 minutes. The media was then 
collected into clean tubes. Within approximately 1.5 hours of each treatment, the 
media was heated for 10 minutes to 37°C and then applied to cells as described in 
“Experimental set-up” and Figure 6.2.  
6.2.5 Live-cell imaging  
  Imaging of cells was started immediately after the media change to either 
CAP-treated or control media. Live-cell, time-lapse, phase contrast images were 
taken overnight every 10 minutes using an IX83 inverted microscope (Olympus, 
Center Valley, PA, USA) with a 10x objective. At the end of the time-lapse 
(approximately 15- 20 hours after switching to control or CAP-treated media), phase 
contrast images were taken of the live cells using a 20x objective. Images were 
acquired using cellSens Software (Olympus). The live-cell imaging chamber was 
maintained at 37°C, 50% humidity, and 5% CO2:95% air surrounding the microscope 
stage.  
6.2.6 Data analysis  
Image analysis was completed using ImageJ software 
(https://imagej.nih.gov/ij/). Cell centroids were manually tracked in the time-lapse 
sequences using the Manual Tracking plugin in ImageJ. Cells were excluded from 
analysis if they divided, went out of frame, or were otherwise obstructed during the 
sequence. Cells imaged with a 20x objective after the time-lapse were analyzed for 
morphology by manually tracing the cell outline using ImageJ. ImageJ then 





following definition: Circularity = 4*π*(Area / Perimeter2) as described in Appendix 
A. With this definition, circularity can span the range 0 to 1, with a value of 1 
corresponding to a cell with a very circular shape. A custom Matlab (MathWorks, 
Natick, MA, USA) code was used to calculate cell speed during cell migration by 
reading in the x and y coordinates of each cell centroid obtained through ImageJ 
tracking. For each individual cell, the instantaneous speed between every set of two 
points was calculated based on the x and y positions over time, and the instantaneous 
speeds were then averaged across all sets of two points to produce an instantaneous 
speed for that cell, as described in Appendix B.  
2.7 Statistical analysis 
All statistical analysis and graph preparation was carried out in GraphPad 
Prism 8 (GraphPad, La Jolla, CA, USA). A D'Agostino-Pearson normality test 
indicated that most data in each data set did not follow a normal distribution. Hence, 
non-parametric tests were used for subsequent statistical analysis. For all statistical 
analysis, a non-parametric Kruskal-Wallis test with a Dunn’s multiple comparison 
post-hoc test was used. Statistical significance was indicated as follows: NS P > 0.05, 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. Errors bars represent 







6.3.1 Selective and non-selective treatments 
To investigate tumor and normal cells’ response to different CAP-treated 
media utilizing different CAP sources, we examined the cells’ migration and 
circularity parameters as proxies for cell viability and functionality. Highly metastatic 
cells rely on their migration potential, as well as mesenchymal, elongated 
morphology for maximum invasion and thus metastasis, similarly to results shown in 
Chapter 3 [166]; therefore, more elongated cells (i.e., circularity <<1) with higher 
migration speed could be considered more viable or “functional.” Normal MCF10A 
cells are also highly migratory and highly spread as single cells in 2D assays, as 
shown in Chapter 3, and thus these parameters could similarly be used as proxies for 
cell viability. Upon cell death, cell circularity approaches a value of 1 as the cell 
rounds and detaches from the substrate. Cell migration speed, which assesses a 
critical cellular function, along with cell circularity, can provide useful information 
towards assessing cell viability. Here, we defined the term “selective” in reference to 
a CAP treatment that reduced tumor cell migration (possibly coupled with an increase 
in tumor cell circularity), while having minimal effect on normal cells. 
We determined that our treatments each had one of three outcomes: (1) the treatment 
was selective; (2) the treatment was not selective because both cell types migration 
(possibly coupled with an increase in tumor cell circularity), while having minimal 
effect on normal cells. showed reduced migration speed or increased circularity; and 





affected. Figure 6.3 provides several representative examples of these outcomes. One 
observed selective condition was the 1 minute APPJ treatment with DMEM-based 
medium (Figure 6.3 A). Based on cell morphology over time and cell trajectories, it 
was evident that when exposed to CAP-treated media, tumor cells became less 
migratory, rounder, and smaller, while the normal cells remained unaffected in terms 
of these parameters (Figure 6.3 A). However, when DMEM/F12-based medium with 
supplements was used with a 1 minute APPJ treatment, neither cell line changed 
visibility in migration or morphology post-exposure to CAP-treated media (Figure 6.3 
B), suggesting a non-selective treatment. On the contrary, in DMEM-based medium 
with a 7 minute APPJ treatment, both the normal and tumor cells were smaller, 
rounder, and less migratory (Figure 6.3 C), again suggesting a non-selective 
treatment. When these results were compared to the 7 minute SMD treatment, we 
found that the 7 minute SMD treatment was still selective in DMEM-based medium 
(Figure 6.3 D); however, when RPMI-based medium was used, both cell types were 
affected by CAP-treated media (Figure 6.3 E), while neither cell line was affected 
when the DMEM/F12+Supp.-based medium was used (Figure 6.3 D). Figure 6.4 
Figure 6.3: Images of CAP-treated cells over time. Phase contrast image sequences of 
representative MDA-MB-231 and MCF10A cells over time, along with trajectories of all 
cells analyzed for the corresponding condition. Shown are a) selective APPJ treatment 
condition: 1 minute APPJ treatment in DMEM, b) non-selective APPJ treatment 
condition where both cell types cells were unaffected by CAP: 1 minute APPJ treatment 
in DMEM/F12 + Supp. medium, c) non-selective APPJ treatment condition where both 
tumor and normal cells were affected by CAP: 7 minute APPJ in DMEM, d) selective 
SMD treatment condition: 7 minute SMD treatment in DMEM, e) non-selective SMD 
treatment condition where both cell types cells were unaffected by CAP: 7 minute SMD 
treatment in DMEM/F12 + Supp. medium, f) non-selective SMD treatment condition 
where both tumor and normal cells were affected by CAP: 7 minute SMD in RPMI 
medium. Scale bar applies to all images in the sequence and x-scale of last trajectory in 
sequence applies to all previous ones on that panel. Images were taken via phase contrast 
microscopy using a 10x objective. “0 min” corresponds to the time just after the media 














































































































Figure 6.4: Images of CAP-treated cells. Phase contrast images of MDA-MB-231 and 
MCF10A cells when exposed to DMEM/F12 + Supp. or DMEM treated with A) 1 
minute APPJ or B) 7 minute SMD. Scale bar applies to all images in the panel. Images 
were taken via phase contrast microscopy using a 20x objective approximately 15-20 








provides a side-by-side comparison of cells at higher magnification and shows the 
typical morphologies of both cell types after approximately 15-20 hours in  
various CAP-treated media. Together, these results show that the type of medium is  
critical in understanding CAP-tumor cell interactions. Although these media 
compositions have been routinely used in other studies, when they are compared side- 
by-side, the resulting conclusions about CAP-treatment selectivity could be 
completely different.  
6.3.2 Quantification of CAP-treated media selectivity with varying medium 
Next, we quantified the morphology and migration parameters and performed 
statistical analysis in order to understand which experimental parameters affected the 
interaction of CAP-treated media and tumor and normal cells to a statically 
significant degree. By analyzing cells treated with different CAP-treated and control 
media, we determined that the 7 minute APPJ treatment resulted in no selective 
conditions (Figure 6.5 A, B). In DMEM and RPMI-based media, the 7 minute APPJ   
 
Figure 6.5: Effect of varying cell media. Plots of speed (panels A, C, E) and circularity 
(panels B, D, F) and selectivity summary tables of MDA-MB-231 (red) and MCF10A (blue) 
cells on collagen I-coated glass when cells were exposed to different media treated with A, B) 
7 minute APPJ, C, D) 1 minute APPJ, and E, F) 7 minute SMD generated plasma. Speed was 
calculated from live-cell image sequences during exposure to control or CAP-treated media, 
taken with a 10 minute time-step, and tracked over 10 hours. Circularity was quantified from 
phase contrast images taken 15-20 hours after switching media to control or CAP-treated. 
Selectivity was determined via a non-parametric Kruskal-Wallis ANOVA test comparing all 
the data using a Dunn’s multiple comparison post-hoc test with ns P > 0.05, * P ≤ 0.05, ** P 
≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. (+) or (-) following statistical stars on summary 
tables indicates a trend opposite to that expected for a selective treatment. Appropriate pairs 
were picked out from test results for selectivity comparison. Each dot indicates the 
measurement for one cell, while the bar indicates the mean across all pooled cells. Errors bars 














treatment was so strong that both normal and tumor cells became significantly slower 
and rounder, while in the DMEM/F12 + Supp. medium, the speed remained 
unchanged while the circularity decreased, indicating an opposite trend of that 
expected in the case of cellular damage (Figure 6.5 A, B). With the 1 minute APPJ 
treatment, the DMEM-based medium treatments produced the sole, consistently-
selective result in terms of both migration speed and circularity, where the speed  
decreased and circularity increased for tumor cells but not normal cells (Figure 6.5 C, 
D). Interestingly, for the DMEM/F12-based medium condition, the speed increased 
after CAP-treated media treatment of normal cells (Figure 6.5 C). Additionally, when 
looking at circularity, there was evidence of selectivity for both DMEM and RPMI-
based media (Figure 6.5 D); however, only the DMEM-based medium condition had 
matching selectivity results for speed and circularity (Figure 6.5 C, D). Finally, with 
the 7 minute SMD treatment, the DMEM-based medium was the only treatment that 
was selective in terms of cell speed, where speed decreased for tumor cells in CAP- 
treated medium, while normal cells retained their speed (Figure 6.5 E). However, 
tumor cells unexpectedly became less circular with CAP-treated DMEM-based 
medium, while normal cells remained the same (Figure 5 F). Since only an increase 
in circularity is indicative of CAP-induced cell damage, this metric is not indicative 
of selectively for the 7 minute SMD treatment. Furthermore, in the RPMI-based 
medium, both the tumor and normal cells became significantly slower and more 
circular (Figure 6.5 E, F), suggesting that the effectiveness of CAP-treated media is 
highly dependent on the cell culture conditions. Overall, an important observation 





not using matched media between different cell lines could significantly skew 
selectivity results, thus reducing translatability of experimental interpretations to 
clinical use. 
6.3.3 Quantification of CAP-treated media selectivity with varying cell-matrix 
binding moieties 
As previously discussed above, CAP may affect cellular integrin expression 
and therefore could potentially act on cells via an integrin-dependent pathway [219]. 
Hence, we evaluated the selectivity of CAP when cells were plated on several 
different substrate coatings, including collagen I, fibronectin, or PDL. We note that 
these experiments were all performed in DMEM, which showed the greatest number 
of selective conditions (Figure 6.5) and thus was most promising to further evaluate 
variation of cell-matrix binding moiety. Results for cells plated on collagen I and 
treated with control or CAP-treated DMEM were already presented in Figure 6.5, but 
are repeated on Figure 6.6 for easy comparison. First, we found that normal and  
tumor cells exposed to DMEM with 7 minute APPJ treatment had reduced migration  
Figure 6.6: Effect of varying cell binding moieties. Plots of speed (panels A, C, E) and 
circularity (panels B, D, F) and selectivity summary tables of MDA-MB-231 (red) and 
MCF10A (blue) cells on collagen I, fibronectin, and PDL-coated glass when cells were 
exposed to DMEM treated with A, B) 7 minute APPJ, C, D) 1 minute APPJ, and E, F) 7 
minute SMD generated plasma. Speed was calculated from live-cell image sequences 
during exposure to control or CAP-treated media, taken with a 10 minute time-step, and 
tracked over 10 hours. Circularity was quantified from phase contrast images taken 15-20 
hours after switching media to control or CAP-treated. Selectivity was determined via a 
non-parametric Kruskal-Wallis ANOVA test comparing all the data using a Dunn’s 
multiple comparison post-hoc test with ns P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 
0.001, **** P ≤ 0.0001. (+) or (-) following statistical stars on summary tables indicates a 
trend opposite to that expected for a selective treatment. Appropriate pairs were picked 
out from test results for selectivity comparison. Each dot indicates the measurement for 
one cell, while the bar indicates the mean across all pooled cells. Errors bars represent 


































speeds along with increased circularity on all binding moieties (Figure 6.6 A, B), 
which was consistent with experiments where medium was varied (Figure 6.5 A, B). 
For media with 1 minute APPJ treatment, cell speed and circularity both showed 
selectivity when cells were plated on collagen, fibronectin, or PDL (Figure 6.6 C, D). 
For the 7 minute SMD treatment, all substrate coatings yielded a selective result 
based on speed, but not based on circularity (Figure 6.6 E, F). Based on these results, 
we conclude that the condition with DMEM-based medium with a 1 minute APPJ 
treatment on any surface, yielded the most consistently selective result (Figure 6.6). If  
only migration speed was considered as a significant cell viability predictor, then the 
7 minute SMD would also be an effective selective treatment for all coating types 
(Figure 6.6 E). Hence, the selection of the cell-matrix binding moieties may be less  
crucial to a consistent CAP-treatment outcome than the selection of the treatment 
media.  
6.4 Discussion  
 Overall, our results show that media compositions are crucial in the outcome 
of studies involving CAP-treated media on tumor versus normal cells, and media 
selection should be carefully considered when designing experiments. In fact, 
changing the type of media could entirely change the selectivity outcomes. 
Meanwhile, binding moieties seem to play a less significant role.  
Previous studies have investigated the effect of various culture conditions 
such as cell number, treatment time, medium volume, and treatment well size on the 
RNS/ROS concentration in CAP-treated media, as well as their effects on cells [236]. 





treatment selectivity was not considered, yet there was a difference in outcomes even 
between different types of tumor cells [236]. Another study has shown that the effect 
of CAP-treated liquid on cell viability is dependent on both the cell type and the type 
of liquid, such as medium versus buffer [209]. Yet another study has shown that 
higher FBS concentrations in media can reduce CAP treatment’s effects on 
glioblastoma cell viability [92]. However, that study did not address the selectivity of 
the treatment between normal and tumor cells. A few studies have found that altering 
media composition can alter the effects of CAP on cell viability  (Table 6.1, shaded) 
[84], [90], [222]; however, no systematic assessment of selectivity has been carried 
out to the best of our knowledge. Furthermore, these studies showed that RPMI-based 
medium generally provides the best conditions to effectively reduce tumor cell 
viability; however, it does not address how the results might change for normal cells, 
and in fact one study shows that a decrease in normal cell viability when treated with 
RPMI-based CAP treated media [84], [90], [222]. It is also important to note that 
when considering therapeutics intended for in vivo use, the media do not fully 
recapitulate any particular body fluid. Thus, if a therapy is effective in one medium 
but not in another, it remains uncertain whether it will be effective in the presence of 
blood or another bodily fluid. Thus, in our work, we aimed to systematically evaluate 
the effects of CAP-treated media (produced by two different CAP sources) on the 
migration and morphology of metastatic breast tumor cells and their normal breast 
epithelial cell counterparts, while varying several common cell culture media and 





Our work not only demonstrates that the treatment and medium type affect 
how CAP-treated media impacts cells, but perhaps more importantly, it also shows 
that these parameters can change the conclusions made about the selectivity of the 
treatment. Since cancer therapy toxicity remains a challenging and important aspect 
of drug development [237], treatment selectivity for tumor cells (versus normal cells) 
is an important outcome to achieve. Here, we show that, of the media tested, CAP 
treatment of DMEM-based medium appears to most consistently result in damage to 
tumor cells while not significantly affecting normal cells. Overall, the 1 minute APPJ 
treatment and the 7 minute SMD treatment of DMEM resulted in selective reduction 
of tumor cell migration speed, with the 1 minute APPJ treatment of DMEM also 
resulting in a selective increase of tumor cell circularity.  
Furthermore, the majority of previous reports involving CAP treatment of 
cells and media utilize tissue culture plastic surfaces, which bind cells via 
electrostatic forces. For our study, these surfaces are most similar to the PDL-coated 
glass, since that binding moiety also engages cells via electrostatic forces and does 
not activate integrins [238]. However, our results on PDL were mostly consistent with 
our results on collagen and fibronectin. These data suggest that cell-matrix binding 
moiety, whether via electrostatic interactions or integrin-extracellular matrix binding, 
has a negligible effect on the outcome of a CAP-treated media experiment; 
furthermore, our results do not support the hypothesis that CAP-treated media acts on 
cells through via integrin-mediated pathways.  
Finally, we found that the type of CAP treatment is an important factor. 





selectivity, with both normal and tumor cells being damaged by the CAP-treated 
media, as seen for the 7 minute APPJ treatment. Consideration of these results are 
important because they provide guidelines for future CAP-treated media-based 
studies, as CAP-therapy cancer technology progresses towards becoming more 
ubiquitous and suitable for human use.  
In this work we specifically observe tumor cell migration and morphology 
without evaluating cell death directly. This is motivated by the fact that tumor cells’ 
ability to migrate and their morphology are tied to both their health [239] and their 
metastatic potential [140], [180], [203]. When tumor cells are smaller, rounder, and 
appear to be blebbing they tend to be less healthy [239]. Similarly, healthy MDA-
MB-231 and MCF10A cells are highly migratory and thus a decrease in migration 
suggests some damage to the normal functioning of the cell [240]. When it comes to 
tumor cells’ ability to metastasize, tumor cells with a higher metastatic potential tend 
to be larger, more elongated, with more protrusions, and more migratory [140]. Thus, 
the observation of decreased cell speed and increased circularity corresponds to 
potentially decreased cell health as well as a decrease in metastatic potential. While 
we do not show whether tumor cells are destroyed by CAP, the selective decrease in 
tumor cell speed relative to normal health and the selective increase in tumor cell 
circularity relative to normal cells under certain treatment conditions suggests that the 
tumor cells become less metastatic and less able to spread to distant sites. 
Alternatively, the selective CAP treatments also could return the tumor cells to a state 
where they are less aggressive and more localized to a specific area and thus more 





This work contributes to the discussion of how plasma treatment of liquids 
leads to effects on biological systems. There has been a wealth of research on plasma-
liquid interactions for many purposes, from medical to waste water treatment, which 
has been summarized recently in work by Bruggeman et al.[241]. Specifically, the 
area of plasma medicine is interested in plasma-liquid interactions, as there is 
typically a liquid medium between the plasma species and the biological system, 
whether it could be bacteria or other cells [242]. RNS and ROS in the gas phase tend 
to cause reactions with the water which form different liquid-based reactive species. 
Some studies have investigated how different additives to the water or media 
influence the effect of plasma on biological systems. Wende et al. used the exact 
plasma source used in this work and investigated how buffered water impacts the 
species in the liquid, and how this liquid kills bacteria [84]. Specifically, they used 
catalase as a ROS scavenger to show that the plasma jet has no effect on cells when it 
is present through a liquid barrier, but has a significant effect on cells through water 
that is not buffered. In our experiments, it is possible that some compounds in the 
media solution, such as sodium pyruvate [243] or glutathione [244]. act similarly as 
reactive species scavengers which reduce the effectiveness of the plasma treatment on 
the cells. However, the simple presence of the ROS/RNS scavenger in media is not 
enough to explain the difference in results, since DMEM/F12 and RMPI contain 







We have found that the type of plasma source and media in which CAP-
treated media experiments are conducted are key parameters in achieving selective 
CAP-based treatments. As CAP technology is developed further and adapted for in 
vivo use, it is important to carefully consider the in vitro experimental parameters to 
ensure that the interpretation of results is based on CAP’s effects and not simple 
interactions with arbitrary media. In the future, it would be key to determine what 
method of CAP delivery will be used in vivo, and then the appropriate bodily fluid 
should be tested similarly to our comprehensive study, in order to properly account 







7 Summary and Conclusions, Contributions to the Field 
Metastatic tumor cells are able to cross the BBB and form devastating 
secondary tumors in the brain. However, the mechanism by which that occurs is not 
well understood and thus it is difficult to develop successful therapeutics, since many 
chemotherapeutic drugs cannot cross the BBB [245]. Thus, determining how tumor 
cells cross the highly impermeable BBB remains an important medically relevant 
problem, so that these mechanisms can either be targeted by therapies or the 
therapeutics could leverage the pathways to cross the BBB as well. This dissertation 
addresses this topic by looking at the physico-chemical interactions of tumor cells 
with the BBB microenvironment while also touching upon the optimization of a novel 
cancer therapeutic strategy.  
7.1 Tumor cells become more elongated and migratory when exposed to 
astrocyte-secreted biochemical cues. 
 In Chapter 3, this dissertation shows that when tumor cells are exposed to 
astrocyte-secreted factors, they became more elongated and faster, which could 
indicate a more mesenchymal, and thus more invasive phenotype. Most interestingly, 
we showed that astrocyte-secreted factors not only directly affected the behavior of 
tumor cells, but they actually interacted with the tumor cell’s extracellular matrix 
leading to an increase in tumor cell velocity. One of the potential biochemical cues 
that astrocytes secrete to alter tumor cell migration and morphology, could be MMPs, 
especially MMP-2 and -9. Specifically, the inhibition of MMPs in ACM led to a 





control media appeared to enhance tumor cell migration similarly to ACM. Since 
MMPs are known to degrade the extracellular matrix, the presence of MMPs in ACM 
could partially explain why ACM alters tumor cell behavior even when they are not 
treated directly but seeded on extracellular matrix treated with ACM. Similarly, we 
found that inhibiting ROCK in tumor cells somewhat attenuated their response to 
ACM, indicating a likely involvement of the ROCK-mediated contractility pathway 
in the tumor cell response to astrocyte secreted factors.  
 Another surprising finding was that astrocyte activation via TGF-β led to a 
decrease in tumor cell changes when treated with ACM, compared to ACM from 
untreated astrocytes. This finding is interesting since reactive astrocytes are more 
likely to be found in a diseased state, such as brain metastasis, and thus it would have 
been unsurprising if astrocytes from a diseased state were enhancing tumor cell 
migratory behavior. However, due to the opposite trend, it is possible that astrocytes 
actually develop a more protective phenotype in disease. Moreover, while we have 
observed an increase in tumor cell speed when treated with ACM, this does not 
necessarily correspond to increased metastatic potential [180]. It is possible that 
metastatic tumor cells are slower at a secondary site and actually slow down as part of 
the process of proliferating into a secondary tumor [180]. However, more motile cells 
prior to extravasation could serve as a potential therapeutic target since they are more 
likely to form micrometastases that then form secondary tumors [180]. Since tumor 
cells could be exposed to astrocyte-secreted factors on either side of the vasculature, 





 It is important to note that these results were relatively consistent across cell 
lines of varying metastatic potential but from the same tissue source for cells treated 
with ACM, however the effect of ACM was less evident when cells of lower 
metastatic potential were plated on ACM-treated extracellular matrix. The results 
were also consistent across multiple extracellular matrix molecules, including 
collagen I, fibronectin, and laminin, for certain parameters. However, the effects of 
ACM on cell migration did not hold on PDL, suggesting that in addition to MMPs, 
integrins are likely to play a role in tumor cell-ACM response.  
 Together, Chapter 3 of this dissertation sheds light on some key pathways 
involved in the biochemical interaction of tumor cells with the BBB 
microenvironment. This work elucidates one potential cell type within the BBB 
microenvironment that could actually be resulting in tumor cells’ enhanced 
invasiveness at the BBB, instead of serving in its protective role.  
7.2 Tumor cells become slower on more crosslinked HA-gelatin films; 
however, the effect is diminished during incorporation into HBMEC 
monolayers. 
 Following an understanding of some of the biochemical interactions of tumor 
cells with the BBB microenvironment in Chapter 3, Chapter 4 addressed the 
biophysical interactions of tumor cells with a BBB-like extracellular matrix made of 
HA-gelatin films. Both types of interactions are essential to understand in order to 
start to form a more complete picture of the process of BBB metastasis. Chapter 4 





monolayers as they interact with an HA-gelatin matrix that more accurately mimics 
the extracellular matrix structure and composition at the BBB, just outside the blood 
vessels, than does collagen or fibronectin. The HA-gelatin films are differently 
crosslinked, since during different physiological conditions the density of 
extracellular matrix molecules and their crosslinking can change significantly. Here, 
we established that while tumor cells are extremely sensitive to HA-gelatin 
crosslinking on bare films (tumor cell speed and area decrease significantly with 
increased crosslinking), this effect is diminished once HBMECs are introduced. This 
suggests that the underlying extracellular matrix might not be as significant during 
incorporation as the direct interaction of tumor cells and endothelial cells, and the 
extracellular matrix only begins to play a large role once tumor cells have crossed the 
endothelium. Alternatively, HBMECs could be depositing their own extracellular 
matrix that has a greater influence than the original HA/gelatin films. Fascinatingly, 
we have also shown that tumor cells might be crossing the BBB transcellularly, not 
only paracellularly as previously shown. These findings suggest that the underlying 
extracellular matrix is unlikely to be responsible for motivating tumor cells to cross 
the BBB, suggesting that other forces – biochemical or biophysical – are likely at 
play.   
7.3 Tumor cell morphology varies based on the preferred metastatic site. 
 Another potential driving force for selective brain metastasis could be the 
tumor cell phenotype itself. In order to examine that, in Chapter 5, we utilized brain- 
and bone-seeking tumor cell clones from the same cell line in order to determine if 





the proteomics of the clones and certain other parameters, here we were particularly 
interested in morphological differences. We found that parental and brain- and bone-
seeking tumor cells all varied in their morphology on all substrates, with the bone-
seeking tumor cells showing the greatest differences from the other two clones. 
However, the differences in morphology did not suggest that substrate stiffness alone 
can be used to distinguish between the cell types, especially given the heterogeneity 
of the cell population. The differences in morphology within each substrate stiffness, 
however, could indicate that with the addition of other biophysical and phenotypic 
parameters a system could be developed to distinguish between the different cell 
clones. Furthermore, it is possible that there is some functional significance to the 
differences in morphology.  
7.4 CAP selectivity is highly dependent on culture conditions. 
 This dissertation addresses several physico-chemical factors that influence 
tumor cell’s in a BBB microenvironment. However, the ultimate goal of 
understanding how tumor cells cross the BBB is to inform therapeutic design. In 
Chapter 6 we chose to further study CAP, which has been proposed as a novel cancer 
therapeutic. While CAP is not currently applied as treatments of brain metastasis or 
brain cancer, effective new cancer treatments are still gravely needed and could in the 
future be adapted for brain applications.  Here, we focused on understanding which 
cell culture and treatment parameters would render CAP most and least effective in 
selectively destroying tumor cells without harming normal cells. In fact, we found 
that cell culture medium makes a dramatic difference in the selectivity of CAP, while 





that certain treatments can be too long or too strong to be effective, while a reduction 
in dose or a change in CAP source actually renders it successful. Chapter 6 
establishes a baseline understanding on what needs to be considered as CAP is further 
developed into a therapeutic and underscores the fact that any molecules in the body 
or bodily fluid that CAP is expected to interact with has to be thoroughly vetted since 
even small changes can greatly affect the outcome of a treatment.  
7.5 Concluding remarks 
 The results presented in this dissertation suggest that the physico-chemical 
interactions of tumor cells with the BBB microenvironment could be responsible for 
phenotypical changes in tumor cells, making them potentially more migratory and 
invasive. This dissertation evaluates multiple steps in the metastatic cascade, from the 
phenotype of the tumor cells themselves, to the biochemical cues potentially outside 
the BBB, to the physical interactions of tumor cells with a BBB model. Together, 
these findings present a clearer picture of the tumor cell-BBB microenvironment than 
what was previously available and understood. This dissertation shows that metastasis 
across the BBB is a delicate balance of biochemical and physical cues from the 
endothelium, the extracellular matrix, cells inside the brain, and the tumor cells 
themselves, as predicted by the “seed and soil” hypothesis. While some of the 
pathways discussed in this dissertation have previously been studied in models of 
peripheral vasculature, the unique structure of brain vasculature and the BBB results 
in different outcomes and thus has to be studied independently. Thus, this dissertation 
addresses some key biological and medical gaps in the understanding of brain 





7.7 Contributions to the field 
7.7.1 Scientific contributions 
This dissertation makes the following contributions to the understanding of tumor cell 
metastasis across the BBB and novel therapeutics:  
• Establishes that astrocyte secreted factors enhance migration potential and alter 
morphology of tumor cells (Chapter 3);  
• Establishes that astrocyte secreted factors are able to alter the tumor cells’ 
extracellular matrix, leading to further alterations in tumor cell migration and 
morphology (Chapter 3); 
• Effect of ACM can be affected by the type of extracellular matrix and tumor cell 
line (Chapter 3); 
• Establishes that tumor cell migration is significantly affected by the crosslinking 
of a brain-liked, HA-based, extracellular matrix (Chapter 4); 
• Establishes that underlying extracellular matrix plays little role in the ability of 
tumor cells to incorporate into a brain-like endothelium (Chapter 4); 
• Establishes that tumor cells might be using a transcellular mechanism to cross a 
brain-like endothelium (Chapter 4);  
• Establishes that brain- and bone-seeking tumor cells do not show distinct 
morphological differences in response to substrate stiffness, however they do vary 
in morphology within each substrate stiffness (Chapter 5). 
• CAP treatment selectivity is highly dependent on favorable cell culture conditions 





7.7.2 Contributions to laboratory and field 
My work contributed the following additional tools to Dr. Stroka’s laboratory and my 
field: 
• As one of two first graduate students in Dr. Stroka’s laboratory, helped set-up 
most of the initial equipment and standard operating procedures. Adapted all 
protocols for use in the new lab and established sterile cell culture protocols.  
• Established protocol for work with conditioned media. 
• Optimized live-cell and timelapse imaging protocols specifically for studying cell 
morphology, migration, and transmigration with various staining and 
magnifications. (Appendix C) 
• Established experimental protocol for studying tumor cell incorporation into 
endothelial monolayers at both high and low resolution with both tumor cell 
staining and live VE-cadherin staining. 
• Developed systematic protocol for analysis of tumor cell incorporation into 
endothelial monolayers. 
• Developed HA/gelatin film extracellular matrix system with varying degrees of 
crosslinking specifically for timelapse imaging applications. 
• Created microfluidic device for HA gel incorporation and cell culture (see Section 
8.1, Figure 8.2).  
• Started a collaborative effort between materials’ science and engineering and 
bioengineering labs to pursue plasma-based cancer therapeutics.  
• Determined procedural flaws in plasma-based cancer therapeutics research and 





• Established collaboration with Dr. Geller’s lab at the National Institutes of Health.  
• Trained 6 undergraduates, 1 Research Experience for Undergraduates student, and 
3 rotation PhD students.  
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8 Future Work and Outlook  
8.1 Further examination of biochemical cues and pathways 
 This dissertation examines the effect of biochemical cues from astrocytes on 
migration and morphology of metastatic breast tumor cells (Chapter 3). It also 
discusses the role of reactive versus non-reactive astrocytes, the potential role of 
MMPs, and the Rho/ROCK pathway in the cross talk of tumor cells and astrocytes 
(Chapter 3). However, this dissertation only addresses the one-way cross talk where 
biochemical cues from astrocytes are applied to tumor cells. In the future, it is 
important to look at the effect of tumor cell secreted cues on astrocytes and determine 
whether they change phenotype (eg. from non-reactive to reactive) upon exposure to 
cues from tumor cells. Another important consideration is the fact that here we did 
not consider a co-culture system where the tumor cells and astrocytes interact 
directly. This is another area that should be addressed in the future. If these studies 
are performed systematically, they can lead to a more physiologically relevant 
interaction model of tumor cells and astrocytes and could shed light on the 
phenotypes of both cell types.  
 Additionally, while astrocytes are highly important during tumor cell 
metastasis to the brain, in part due to their location in the direct proximity to the BBB, 
there are other cells in the neurovascular unit, such as pericytes and neurons, that 
could also play a biochemical role in tumor cells being able to cross the BBB. 
However, while there is some information available about the role of pericytes in 





information available on the mechanisms by which pericytes or neurons interact with 
metastasizing tumor cells at the BBB. Thus, in the future similar studies can be 
carried out with pericytes and neurons as have been with astrocytes.  
8.2 Understanding incorporation in different disease states of the BBB 
 This dissertation examined the interaction of tumor cells and HBMEC 
monolayers on HA-gelatin films in order to shed light on the incorporation 
mechanisms involved in metastasis across the BBB (Chapter 4). However, in addition 
to understanding the tumor cell and HBMEC dynamics, the overall integrity of the 
monolayer during transmigration is also of interest. We have also shown from the 
data collected in Chapter 4, that the initial number of tumor cells does not 
consistently alter the monolayer quality at the end of analysis, suggesting that the 
tumor cell number does not necessarily control any tumor cell induced monolayer 
damage (Figure 8.1 A).  We have also shown that when the data from Chapter 4 is 
qualitatively sorted by apparent monolayer quality, except for in one case (0.2% 
Extralink), poorer monolayer quality does not correspond to higher percent 
incorporation (Figure 8.1 B) (which could in part be due to the fact that cells that 
simply spread into monolayer gaps were excluded from analysis), however, overall 
monolayer integrity did decrease over time for all Extralink concentrations (Figure 
8.1 C). Our data, combined with the fact that in a diseased state (such as during 
cancer), the BBB becomes disrupted and frequently exhibits weaker tight junctions, 
change in transport, and increased leukocyte infiltration and various biochemical cues 
have been implicated in damage of the BBB, such as VEGF, ROS, inflammatory 






Figure 8.1: HBMEC monolayer quality during tumor cell incorporation. A) 
Monolayer quality at 9.75 hours as a function of number of tumor cells at the start. B) 
Percent incorporation separated by tumor cells of good, medium, and poor quality of 
HBMEC monolayers. C) Change in HBMEC monolayer quality during the course of 
incorporation as assessed at time = 0 hours, 4 hours, and 9.75 hours. The monolayer 
quality is assigned the following values: 3 = good, 2 = medium, 1 = poor, and for each 
percent Extralink, the monolayer quality for all frames is averaged. Error bars represent 
standard error of the mean. Statistics carried out using a non-parametric Kruskal-Wallis 
test with a Dunn’s post-hoc analysis with p<0.05. (* p<0.05). Data is pooled from 3 








questions regarding the HBMEC barrier dynamics during tumor cell incorporation. 
While this dissertation studied the behavior of individual HMBECs, a next step is to 
dynamically study the tight junction and adherens junction formation and disruption 
during incorporation.  
8.3 More physiologically relevant 3D models of tumor cell-BBB 
interactions 
 This dissertation sheds light on crucial components of the metastatic cascade 
during tumor cell interaction with the BBB both during tumor cell incorporation into 
HBMEC monolayers and in the tumor cell response to astrocyte secreted factors. 
Additionally, in Chapter 4, a physiologically relevant extracellular matrix component, 
HA, is introduced in order to help understand the interaction of tumor cells not only 
with HBMEC monolayers but also with a more physiologically relevant extracellular 
matrix. The next will be to scale the system presented in Chapter 4 to a full 3D 
system that allows for better modeling. In fact, we have already shown that 
HA/gelatin gels have a physiologically relevant stiffness for the brain 
microenvironment (Figure 4.1). Furthermore, we have also shown that this gel can be 
incorporated into a microfluidic device that can be used to model the BBB in a co-
culture system and even physiological shear stress can be incorporated (Figure 8.2). 





8.4 Further examination of the different interactions of the BBB and 
brain- versus bone-seeking tumor cells 
 In Chapter 5, this dissertation begins to show some distinct physiological 
differences between brain and bone-seeking metastatic breast tumor cells. The next 
important step will be to begin to characterize not only the morphology, but also the 
traction forces and migration speed of the different tumor cell clones and their 
migration in confinement. These parameters could shed further light on biophysical 
differences among the tumor cells as well as well the functional significance of  
observed morphological changes. Furthermore, morphology combined with other 
biophysical parameters could allow us to determine the organotropic destination of a 
tumor cell prior to colonization of a secondary organ. Thus, factors such as migration, 
response to confinement, and traction force generation should be examined.  
Furthermore, ass more differences between the clones are established, one of 
the factors to consider will be whether the brain- and bone-seeking tumor cells will 
Figure 8.2: 3D microfluidic systems for BBB modeling. A) Diagram of a microfluidic 
device providing a starting point for a potential system where multiple cells from the BBB 
microenvironment can be co-cultured along with tumor cells and their dynamic interaction 
can be observed in a physiologically relevant HA-based 3D microenvironment. B) Proof 
of concept image showing an HBMEC monolayer on a vertical HA gel in microfluidic 






have the same response to ACM and other biochemical factors from the BBB and 
whether their transmigration mechanisms vary. Thus, a potential next step will be to 
repeat the studies from Chapters 3 and 4 with the metastasis specific tumor cell 
clones.  
Additionally, a novel concept in the field of detached tumor cells has recently 
been introduced, known as microtentacles (McTNs). McTNs are tubulin-based 
cytoskeletal projections in suspended tumor cells have been shown to help tumor cells 
attach to epithelium and thus play a large role in metastasis [248], [249]. McTNs have 
been introduced relatively recently, and thus a lot remains to be studied in this field. 
In Chapter 5, we showed that tumor cell clones in suspension vary in area, however it 
would be fascinating to explore the formation of McTNs in the different tumor cell 
clones that preferentially metastasize to the brain or bone, in order to determine 
whether McTNs could play a role in the preferential metastasis. 
8.5 Induced pluripotent stem cell (iPSC) derived cells of the 
neurovascular unit for BBB modeling 
 Chapter 4 examines a BBB model composed of HBMECs on HA/gelatin films 
and Chapter 3 looks at biochemical cues from mouse astrocytes. These model 
systems allowed us to conduct studies on tumor cell response to astrocyte secreted 
cues and incorporation into monolayers successfully and allowed others to examine 
HMBEC junction formation. However, a novel method for establishing the cell lines 
for modeling the BBB have recently been established by Lippmann et al [250], [251]. 





are from a common, human source [250], [251]. These models have been highly 
successful in attaching physiologically relevant barrier properties as measured by 
transendothelial electrical resistance, permeability, and tight junction staining [250], 
[251]. Thus, future work would include introducing novel BBB models using iPSCs.  
8.6 Further investigation of the feasibility of CAP 
 This dissertation demonstrated that while CAP treated media has the potential 
to be a selective cancer therapeutic, it is highly sensitive to experimental conditions 
and thus further work should examine its feasibility in vivo. Some in vivo studies on 
subcutaneous murine tumors have shown selective CAP treatment success [252]. 
However, that involved using direct CAP treatments of tumors close to a mouse’s 
skin surface, without the need for penetrating deep tissue. In order to achieve 
treatment of cancer beyond the surface of the skin, it is important to understand how 
CAP will behave in bodily fluids (both directly and through mixing with CAP treated 
media). In fact, it has been shown that CAP can coagulate blood for would healing 
purposes [253]. In addition, it has been shown that CAP can destroy some blood cells, 
such as leukocytes more readily than monocytes, and respective cell lines are more 
viable post CAP treatment than the same cell types from a human donor [254], in fact 
in general lymphocytes showed lower CAP tolerability than monocytes [254], [255]. 
This suggests that before CAP can be in used to treat tumor cells deep in the body, 
further optimization has to be carried out not only on the CAP treatments themselves, 
but also on the tolerability of CAP by different cell types along the way within the 





this has to be done with optimized conditions such that the composition of the fluids 
involved in the treatment are considered.  
8.7 Outlook 
 The work presented in this dissertation sheds light on crucial processes 
involved in tumor cell interaction with physico-chemical cues at the BBB. Here, we 
showed important pathways of interaction between tumor cells and astrocytes as well 
as elucidated the process of tumor cell incorporation specifically into a BBB-like 
endothelium on a physiologically relevant extracellular matrix. Additionally, we 
showed some morphological differences between metastatic tumor cells from the 
same original cell line, but selected to preferentially metastasize to the brain and 
bone. These findings show novel biophysical and biochemical factors that could 
influence brain metastasis, and that in the future could be utilized for the development 
of appropriate therapeutics. Furthermore, this dissertation touches on the subject of 
therapeutics by examining the effect of treatment conditions of the effectiveness of 
CAP as potential therapeutics. To the best of our knowledge, this is the first 
systematic study examining multiple culture parameters and treatment conditions and 
will allow for further investigation of the successful utilization of CAP in vivo. 
Together, this dissertation makes advances in the understanding of tumor cell 
metastasis to the brain as well as a novel therapeutic approach. It opens up doors for 
further investigation of these pathways, potentially in more physiologically relevant 






9 Appendices  
Appendix A: Shape parameter equations  




Increase: Larger cell 
Decreases: Smaller cell 
  




𝐿𝑎 = major axis length;  𝐿𝑏 = minor axis length 
Greater than 1: More elongated 
Closer to 1: Less elongated 








Closer to 1: Less elongated 














Acell = cell area;  Aconvex = convect hull area 
Closer to 1: Fewer protrusions 






A: area;   P: perimeter 
Closer to 1: More circular 




Aspect Ratio ~ 5 
Inverse Aspect Ratio ~ 0.2 
Aspect Ratio ~ 1 
Inverse Aspect Ratio ~ 1 
Lb 
Figure A.2: Aspect ratio. Aspect ratio calculation in Image J. 
La 
Solidity ~ 1 
Solidity ~ 0.5 






Circularity ~ 0.4 
Circularity ~ 1 





Appendix B: Migration equations 
All calculations were performed in a custom-written Matlab code written by 
Kimberly M. Stroka and edited by Marina A. Pranda.  




 where λ = time step, 〈d〉 = 
1
N
 ∑  |dn⃑⃑  ⃑ | 
N
n=1   [173] 
Mean squared displacement calculations (sliding time average): [173] 
• Square of x displacement plus square of y displacement 
• Averaged over time for each time step λ and for every time step n* λ 
• n: ≤ number of total time steps 
 
Non-linear random walk Langevin-like equation (fitted to linear region of mean 
squared displacement curve): [115], [173], [256] 
r2 = 4 D (t- τ (1 - e
- 
t
τ) [115], [173], [256] 
r2 : two-dimensional mean squared displacement 
D : random motility coefficient  
t : time 
Figure B.1: Migration parameters. (x,y) position of a single cell over 4 time points (3 time 
steps). Velocity is calculated based on d and λ, mean squared displacement is calculated for 
every n* λ where n is the number of time steps (n = 1 (green path, positions 1-4), n = 2 (red 





τ : persistence time 
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Figure B.2: Chemotactic Index. Chemotactic index calculation illustration for a cell 





Appendix C: Effects of confounding variables on the statistical analysis 
of the migration and morphology of metastatic tumor cells† 
Appendix C.1 Introduction 
Cell migration [72], [257], [258] and morphology [259], [260] are crucial and 
commonly quantified parameters in studies focusing on cellular physiology and 
various disease states. For example, in cancer, cell migration speed and their ability to 
invade tissue, as well as their mesenchymal morphology are key factors in 
understanding the tumor phenotype, as discussed in Chapter 3 [72]. In vitro, there are 
a variety of different assays that have been developed to study cell migration and 
morphology, including would healing assays [261], transwell assays [262], 
microfabricated devices [72], [263], [264], 3D invasion assays in hydrogels [265], as 
well as 2D chemokinesis assays, as discussed in Chapter 3. These assays provide 
different types of quantitative and qualitative information; however, it is most 
common to obtain the information in the form of microscopy images which then have 
to be further analyzed to quantify cell migration and morphology (Table C.1). 
Different laboratories and different studies utilize varying methods of cell migration 
and morphology quantification from image-based data (Table C.1). While some 
laboratories utilize automated software such as MetaMorph (Table C.1), many labs 
rely on manual tracking and tracing or tracking plugins in ImageJ (Table C.1). 
Furthermore, the parameters quantified, data presentation, cell number, and time steps 
† This chapter is modified from manuscript in preparation for publication as M.A 
Pranda*, G.M. Dawson*, T.S. Ornstein, B.J. Murugesan, K.M. Stroka, “Effects of 
confounding variables on the statistical analysis of the migration and morphology of 





for migration tracking vary from study to study and there are no clear guidelines on 
the appropriateness of various parameters for a given analysis (Table C.1). However, 
some aspects also remain consistent, such as the prevalence of speed, velocity, and 
area quantification, the presentation of data in bar graphs, and the prevalence of 
pooled data (Table C.1). Here, we explore whether some of the unaddressed 
variables, or confounding variables, in cell migration and morphology quantification 
can play a role in the outcome of a study. 
Confounding variables, in general, are factors within a study that could be 
affecting a seemingly cause and effect relationship [266], [267]. Confounding is 
sometimes referred to as the “mixing effect,” referring to the fact that it leads to 
experimental parameters mixing with additional factors, thereby potentially changing 
the relationship [267]. For cell migration and morphology analysis, some 
confounding variables are experimental and can be accounted for by setting up highly 
controlled studies with well-defined and characterized cell lines, and keeping cell 
health and passage consistent as well as accounting for any experimental conditions 
in cell culture and imaging (Figure C.1 A). These parameters are typically reported in 
the “methods” section of most scholarly papers and it is generally accepted that they 
have to be controlled for. However, that leaves confounding variables that could be 
present during image analysis not addressed (Figure C.1 A). One prior study has 
addressed some confounding in the quantification of cell persistence and presented a 
computational model for cell persistence quantification that minimizes the effect of 
confounding [268]. Here, we focus on the effect that the zoom level of an image, the 





results of migration and morphology analysis of single cells (Figure C.1 B). 
Furthermore, we investigated how the time interval and type of tracking of cell 
migration affected the results (Figure C.1 B).  
We hypothesize that the consistency of analysis parameters can play an 
important role in the outcomes of an experimental study, and that inconsistent usage 
of various parameters can skew the results of a data set. We have found that the zoom 
level of an image can have a significant effect on the outcome of morphology analysis  
 
Figure C.1 Schematic of typical data collection and processing. A) Typical workflow in 
analysis of cell migration and morphology, starting with selection of cells and ending with 
data analysis and generation of figures. B) Flow charts of manipulations to cell migration 
and morphology image post-processing methods for data quantification analyzed within this 






Table C.1: Literature review of papers with cell migration and morphology 
quantification. Thea Ornstein assisted with literature review. 
Ref. Method Parameters  Format 
# Cells 
(N: # trials, 
n: # cells) 
Pool 
∆ Time 
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while the time interval used can significantly affect the outcome of a migration study. 
Additionally, we have found differences in experimental conclusions based on the 
type of migration tracking used and variation in migration and morphology when the 
analysis is conducted by researchers with different experience levels. Overall, we 
conclude that seemingly minor confounding variables can play a significant role in 
the conclusions drawn from a study and thus need to be carefully controlled.  
Appendix C.2 Materials and Methods 
Appendix C.2.1 Cell Culture 
MDA-MB-231 (metastatic human breast adenocarcinoma) cells (American 
Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing high glucose and L-glutamine (ThermoFisher 
Scientific, Waltham, MA, USA) as previously described in Chapters 3, 4, and 5. The 
DMEM was supplemented with 1% 10,000 U/ml Penicillin/Streptomycin (Pen/Strep) 





Scientific). To passage, Phosphate-Buffered Saline (PBS) (VWR, Radnor, PA, USA) 
was used to wash cells and 0.25% Trypsin-EDTA (ThermoFisher Scientific) was used 
to detach cells. A climate-controlled incubator at 37°C, with 5% CO2:95% air and 
50% humidity was used to grow up the cells, as previously described in Chapters 3, 4, 
and 5.  
Appendix C.2.2 Preparation of Collagen Substrates 
24-well glass bottom plates with 13 mm diameter glass (MatTek, Ashland, 
MA, USA) were coated with 300 μL of 0.1, 1, 10, 20, and 100 μg/ml type I collagen 
from rat tail (Sigma Aldrich, St. Louis, MO, USA) dissolved in PBS, for 1 hour at 
37°C. 4 wells of each condition were plated. The wells were then washed three times 
with 1 mL of PBS at 37°C. 1 x 104 MDA-MB-231 cells were seeded in each well and 
left to incubate overnight. On the next day, the media was changed and timelapse 
imaging was set-up. The procedure was similar to that in Chapter 3, expect with 
varying concentrations.  
Appendix C.2.3 Microscopy   
Cells were imaged live, using a 10x phase-contrast objective, overnight with a 
5 minute time step using an IX83 microscope (Olympus, Center Valley, PA, USA). 
Multiple positions were imaged at the same time with a resulting four wells with two 
positions per each experimental condition. At the end of the time-lapse imaging, the 
objective was switched to 20x and corresponding stationary images were taking for 
morphology analysis. The Olympus cellSens Software (Olympus) was used to capture 
the images. An enclosed chamber surrounding the microscope was maintained at 





out in Chapter 3. For image presentation, intensities were adjusted arbitrarily for best 
visualization, since they were not quantified. 
Appendix C.2.4 Data Analysis 
Initial data analysis was carried out using ImageJ (https://imagej.nih.gov/ij/). 
For morphology analysis, cells were manually traced in ImageJ and their area, aspect 
ratio, circularity, and solidity were calculated as previously described, as previously 
described in Chapter 3. To calculate cell speed, centroid tracking was carried out 
using the ImageJ Manual Tracking plug-in, where the centroid of each cell was 
manually selected across all frames. When outline tracking was used, each cell was 
manually traced in ImageJ across all frames. The x and y positions of the cell were 
analyzed by a custom Matlab (MathWorks, Natick, MA, USA), cell speed was 
calculated, and trajectory plots were generated. Migration tracking was done by 
tracking cells every 5 minutes for 100 frames. In order to vary the time interval, the 
Matlab code was simply adjusted to read in only the position values corresponding to 
the desired time interval: 5, 10, 20, and 50 minutes. Zoom levels were adjusted to 50, 
100, and 200% directly in ImageJ during analysis. In order to generate random cell 
subsets for speed comparison, the Excel (Microsoft, Redmont, WA, USA) "rand" 
function was used and then sorting of the data with the adjacent data column in 
ascending order was carried out. Finally, simply the top 10 cells (for speed) and 10, 
25, or 50 cells for morphology from the randomly ordered list were selected. In order 
to obtain the mean square displacement and the diffusion coefficient for a random 
sample, the "randbetween" function was used to randomly select 10 cells between 1 





group). The selected data was analyzed by the same Matlab code as the full dataset. 
This difference in random selection is necessary because the diffusion coefficient and 
mean square displacement are values calculated for an entire data set, not a single 
cell. The process was repeated three times to obtain three separate data sets. When 
comparing different experience levels, three students in the lab were selected who 
either had never performed cell migration and morphology analysis (beginner), have 
done it a few times but not frequently (moderate), and a student with vast experience 
in migration and morphology analysis (advanced). 
Appendix C.2.5 Data Analysis 
GraphPad Prism 8 (GraphPad, La Jolla, CA, USA) was used to prepare graphs 
and perform statistical analysis. The non-parametric Kruskal-Wallis ANOVA test 
with a Dunn’s multiple comparison post-hoc test was used for statistical analysis 
where significance is indicated with stars. Statistical significance was calculated as 
follows: NS P > 0.05, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. All 
errors bars represent standard error of the mean.  
Appendix C.3 Results 
Appendix C.3.1 Zoom level affects morphological parameters acquired through 
manual cell tracing 
When analyzing visual data using ImageJ or other analysis software, one 
parameter that is often not controlled for is the zoom level of the images. The default 
zoom level of an open image can depend on the computer and screen type used, the 
software version, or even the operating system. Furthermore, different people have 





frequently adjust the zoom based on what is most individually comfortable at any 
given time. Thus, we examined whether equivalent analysis can yield different results 
based on zoom levels of the images, with 50%, 100%, and 200% zoom (Figure C.2  
A). In fact, we found that morphology parameters such as area, inverse aspect ratio 
(IAR), circularity, and solidity were different in some of the measurements with 
changes in zoom level (Figure C.2 B, C, D, E). However, the question remained 
whether our conclusions about data from several categories would vary depending on 
the zoom level at which it was analyzed. To test that, we compared the areas of cells 
grown on 0.1, 1, 10, 20, and 100 μg/ml collagen-1 (Figure C.2 C, D). We found that 
at 50% zoom, areas of cells grown on 0.1 and 1 μg/ml collagen-1 were significantly 
different from those grown on 100 μg/ml collagen-1. However, at 100% zoom, only 
0.1 and 100 μg/ml collagen-1 conditions were different, and finally at 200% zoom, 
there were no significant differences (Figure C.2 C, D). Thus, depending on which 
zoom level was used to for analysis, the conclusions about the data could be quite 
different. If the zoom levels were mixed and matched during analysis, it would have 
likely further skewed the data. Interestingly, within each collagen-1 concentration, 
there were no significant differences among any of the zoom levels (Figure C.2 D). 
When we compared IAR, circularity, and solidity at different zoom levels, we 
determined that in while there are no differences between IAR at different zoom 
levels, circularity and solidity were in fact different between each zoom level (Figure 
C.2 E). In general, circularity and solidity both decreased with increasing zoom 
(Figure C.2 E). The differences observed in morphology are potentially caused by the 



























Figure C.2: Analysis of the effect of zoom level on migration and morphology. 
 (A) Representative images of a typical cell in wells coated with 20 µg/mL collagen-I at 
50%, 100% and 200% zoom in ImageJ. Scale bars = 50 μm. (B) Table of individual cell 
characteristics at different zoom levels from part A. IAR = Inverse Aspect Ratio. (C) Areas 
of cells on different concentrations of collagen at different zoom levels. Significances are 
only indicated within each zoom level group, additional statistical significance presented in 
part D. (D) Charts of significance for experimentally relevant cell area categories at different 
zoom levels. (E) Morphological characteristics, inverse aspect ratio (AR), circularity, and 
solidity of cells on 20 µg/mL collagen-I at different zoom levels. (F) Speed of cells on five 
different concentrations of collagen-I at different zoom levels. Statistical significance was 
determined by a Kruskal-Wallis nonparametric test with a post-hoc Dunn’s multiple 
comparison test (n.s., P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001). 
All error bars indicate standard error indicate standard error of the mean and each dot 






smaller and more elongated cell measurements. A similar study was repeated by 
observing cells speeds on 0.1, 1, 10, 20, and 100 μg/ml collagen-1 and there were no 
significant differences between speeds on any zoom level or between any zoom levels 
at any given collagen-1 concentration (Figure C.2 F). This could be explained by the 
fact that speed was measured via centroid tracking and thus it appears that the 
centroid can be similarly estimated at all zoom levels. 
Appendix C.3.2 Random subsets of morphological data can produce altered statistical 
relationships in data 
There are several philosophies on how to select data sets for publication. One 
philosophy is to pool all the available analyzed cells from all trials together (Table 
C.1), and report the data for the pooled set. Another philosophy is to conduct multiple 
trials, test them for consistency, and then report the data for one representative trial. 
There is also a frequent debate over how many cells need to be analyzed to allow for 
both a realistic experiment and robust data. Here, we seek to show how the size of a 
data set randomly selected from a set of pooled data affects the conclusions one 
would make based on the data set. For this, cell morphology and migration on 0.1, 1, 
10, 20, and 100 μg/ml collagen-1 was assessed. For morphology, the full data set 
contained >152 cells, and the randomly selected subsets contained 50, 25, and 10 
cells. Within each set, there were no differences in inverse aspect ratio (Figure C.3 
A), circularity (Figure C.3 B), and solidity (Figure C.3 C) between the collagen 
concentrations or sample sizes, thus showing a consistent trend between all data sets. 
However, when it came to area, there was a significant difference between the 0.1 and 





(Figure C.3 D). Furthermore, we generated three different randomly selected data sets 
with 25 cells each and evaluated the inverse aspect ratio across the different collagen-
1 concentrations (Figure C.3 E). We found that there were no significant differences 
between any collagen concentrations or zoom levels among any of the subsets (Figure 
C.3 E). This suggests that a large enough randomly selected sample could lead to the 
same conclusions as a different, equally sized data set. When cell speed was 
observed, the full data set contained >27 cells and a 10 cell random subset was 
generated. There were no significant differences among the different collagen-1 
concentrations or sample sizes in either group (Figure C.3 F). However, when we 
visually observed the cell trajectories with three different subsets with 10 cells each 
as well as a full set of 38 cells, one can see that the trajectories are very different, 
suggesting that the cells chosen do affect the trends observed for a given experiment 
(Figure C.3 G). 
Appendix C.3.3 Time interval affects magnitude of cell migration speed  
Time interval during migration tracking is another parameter that is typically 
chosen arbitrarily. Here, we compared the outcome of migration studies where the 
same data was analyzed with a 5, 10, 20, and 50 minute time interval. We observed  
Figure C.3: The effect of sample size on measured migration and morphology.  
Comparison of (A) inverse aspect ratio (B) circularity, (C) solidity, and (D) area of cells 
under five different experimental conditions (collagen-I concentrations: 0.1, 1, 10, 20 and 
100 µg/) and four different sample sizes (>152, 50, 25, 10 cells). (E) Comparison of inverse 
aspect ratio of three different randomly generated subsets of data. Sample size of n = 25. (F) 
Comparison of cell speed with different sample sizes (n > 27, n = 10). A Kruskal-Wallis test 
with a Dunn’s post-hoc multiple comparison test was used to determine statistical 
significance (n.s., P > 0.05; *, P ≤ 0.05). (G) Trajectory plots of cells on 20 µg/mL collagen-
I, showing three different randomly selected subsets of cells along with the original full 
sample (n = 10 for each data set). All error bars indicate standard error indicate standard 
error of the mean and each dot represents an individual cell. Only experimentally relevant 













that the cell tracks changed slightly with a change in time step (Figure C.4 A). While 
the general trends remained the same with each time interval, the larger time steps 
lost some detail and definition in the migration trajectories (Figure C.4 B). The time 
interval change did not alter the trend between cells speeds on different collagen-1 
concentrations, however overall all speed values decreased with increasing time 
interval (Figure C.4 C). We found that altering the time interval, especially from 5 to 
50 minutes and 10 to 50 minutes actually resulted in significant differences in cell 
speed at the same collagen-1 concentrations (Figure C.4 D). However, we found that 
changing the time interval did not change the conclusions made about cell speeds on 
varying collagen-1 concentrations (Figure C.4 D). Together, these results suggest that 
the time step has a minor effect on the outcome of a migration study.  
Appendix C.3.4 Tracking method (point vs. outline) does not affect migration speed 
There are several different methods for tracking cell migration. Here, we will 
examine two common ways, namely the point tracking, where the x and y positions of 
the centroid of the cell over time are manually selected and recorded, and outline 
tracking, where each cell is traced manually at each time point and the centroid’s x   
and y positions are calculated in ImageJ, we compared the two analysis techniques to 
see if they provide different results. Intuitively it seems that outline tracking should 
provide more accurate data given that it calculates a more precise centroid (Figure 
C.5 A), and in fact there is a significant difference in the speeds on 20 μg/ml 
collagen-I between point and outline tracking (Figure C.5 B). However, such a trend 





























Figure C.4: The effect of changing time interval on cell migration. (A) Representative 
tracking path of cells at different time intervals, △t indicates amount of time between each 
point analyzed. (B) Trajectory plots of cells on 20 µg/mL collagen-I using different time 
intervals (△t = 5, 10, 20, 50 minutes). (C) Change in apparent cell speeds as a result of 
changing time interval during speed analysis. Error bars indicate standard error of the mean. 
(D) Charts of significance for experimentally relevant cell speed categories at different time 
intervals. A Kruskal-Wallis test with a Dunn’s post-hoc multiple comparison test was used 
to determine statistical significance (n.s., P > 0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; 






insignificant increase (Figure C.5 B). However, there was no difference in speeds 
between the two collagen-1 concentrations analyzed with the two different tracking  
methods (Figure C.5 B). When compared to each other directly for each cell, outline 
and point tracking speeds on 20 µg/mL collagen-I deviated slightly from each other,  
with a line of best fit with a slope of 0.7322 (Figure C.5 C). This is consistent with 
the differences in speed seen prior (Figure C.5 B). The different tracking methods  
also yielded different trends in mean squared displacement, where for point tracking 
there was a different between mean squared displacement of cells on 20 vs 100 μg/ml 
collagen-1, yet that difference was mostly absent with outline tracking (Figure C.5 
D). Furthermore, while during point tracking the diffusion coefficient decreased with 
increased collagen-1 concentration, during outline tracking it increased, showing an 
opposite trend (Figure C.5 D). Thus, point versus outline tracking can affect the 
outcome of a migration study and potentially change the conclusions made for some 
of the parameters.  
Appendix C.3.5 Experience level of data analyst affects migration results  
We were also interested in determining whether the experience level of the 
person conducting cell migration and morphology analysis can skew the results of the 
data. When we compared cell speed on 0.1 and 1 μg/ml collagen-1, we found a 
significant difference between the beginner and moderate experience analysis on 0.1 
μg/ml collagen-1 and a significant difference between the beginner and moderate and 
advanced level analysis on 1 μg/ml collagen-1 (Figure C.6 A). However, there were 
minimal differences in mean squared displacement, other than a deviation of the 



























Figure C.5: Centroid vs. Outline tracking of cell speed. (A) Representative image of a cell 
showing the discrepancy in cell centroid as determined by point tracking (crosshair labeled 
“1”) and centroid as determined by outline tracing (crosshair labeled “2”). Scale bar = 10 µm. 
(B) Cell speed based on point vs. outline tracking on 20 and 100 µg/mL collagen-I. A Kruskal-
Wallis test with a Dunn’s post-hoc multiple comparison test was used to determine statistical 
significance (n.s., P > 0.05; *, P ≤ 0.05). All error bars indicate standard error of the mean and 
each dot represents an individual cell. (C) Comparison of point tracked speed versus outline 
tracked speed of cells on 20 µg/mL collagen-I (n = 19). (D) Mean squared displacement of 
cells on 20 and 100 µg/mL collagen-I based on point vs. outline tracking. “D” represents 
diffusion coefficient. Only experimentally relevant statistical differences are discussed in-text. 






When the trajectories of cell migration at each experience level were observed, it was 
evident that there were some differences between all three groups, but especially 
between beginner and advanced levels, for both 0.1 and 1 μg/ml collagen-1 (Figure 
C.6 C).  Furthermore, when cell speed was observed at different time intervals of  
tracking for beginner and expert analysis, it was seen that the larger the interval, the 
more similar the results are between the two levels of analysis (Figure C.6 D), 
suggesting that increasing the time step could potentially reduce some error of a 
beginner tracker. The number of cells traced between beginner, moderate, and expert 
analysis also varied, with beginner tracking resulting in the smallest number of cells 
tracked (Figure C.6 E). However, there are actually no significant differences in area 
with different experience levels on 20 μg/ml collagen-1 and only a difference 
between the beginner and moderate analysis on 100 μg/ml collagen-1 (Figure C.6 F). 
On 20 μg/ml collagen-1, the inverse aspect ratio did not change at all with experience 
level, however, circularity significantly increased between the beginner and moderate 
levels, and solidity changed significantly between beginner and moderate and 
advanced levels (Figure C.6 G). These results suggest that differences in experience 
level can affect both migration and morphology outcomes of a study.  
Appendix C.4 Discussion 
Cell morphology and migration are frequently used as quantitative research 
metrics and many different assays and techniques exist to quantify them [281]. 
Among those assays one of the assays that is able to provide the greatest amount of 
information and is most flexible for different assays is timelapse-based migration 



























Figure C.6: The effect of experience level on cell migration and morphology. (A) 
Comparison of speeds as tracked by analysts of different experience levels. (B) Comparison 
of mean squared displacements as tracked by analysts of different experience levels. (C) 
Trajectory plots of cell migration as tracked by analysts of different experience levels on 0.1 
and 1 µg/mL collagen-1 concentrations. (D) Comparison of cell speed on 1 µg/mL as 
tracked by beginner and expert level analysts. (E) Comparison of number of cells tracked by 
analysts of different experience levels. (F) Cell areas as traced by analysts of different 
experience levels. (G) Morphological characteristics (inverse aspect ratio, circularity, 
solidity) of cells on 20 µg/mL collagen-1 as tracked by analysts of different experience 
levels. For panels, A, F, and G, Kruskal-Wallis test with a Dunn’s post-hoc multiple 
comparison test was used to determine statistical significance (n.s, P > 0.05; *, P ≤ 0.05; **, 
P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001) and each dot represents an individual cell. For 
all panels, error bars represent standard error of the mean. Only experimentally relevant 






order to obtain quantitative values for migration and morphology parameters.     
Multiple studies have reviewed the different available options for cell tracking for 
primarily migration but in some cases also morphology [282]–[284]. In general, while 
there is a significant push for the automation of cell tracking due to its time and labor  
intensiveness, it remains a challenge to carry out automatic cell tracking for phase-
contrast images and non-fluorescently stained cells. Thus, manual tracking in open 
source software such as ImageJ remains the most practical option for many labs. 
However, both automatic and manual tracking and tracing of cells leaves various 
confounding variables not controlled for, leaving studies open to potential 
inconsistencies.  
Here, we explored the variation that is introduced into analysis of migration 
and morphology images tracked manually when zoom levels, cell numbers, time 
steps, the type of tracking, and the experience level of the person analyzing the data 
are not held consistent. We have found that changing the zoom level of images being 
analyzed can lead to different conclusions about morphology data, however the 
migration results remain minimally affected (Figure C.2). This is potentially because 
zooming in closer to a cell allows for a more accurate morphology analysis with the 
inclusion of more protrusions. We have also learned that the number of cells being 
analyzed (≥ 10 cells) and the subset of a given larger data set, have a minimal impact 
on morphology and migration of results and conclusions, however they do change the 
appearance of cell trajectories (Figure C.3). This suggests that above a certain cell 
number threshold, if the cell population is not highly skewed, the sample size does 





migration analysis does not change the conclusions made about the data, however 
there are significant differences in absolute speeds between different step sizes 
(Figure C.4). This could be a result of the fact that increasing the time between 
recorded positions does skew the general path of the cells, but as long as the same 
time step is being compared, the changes become normalized for all cells. 
Additionally, when the same cells are tracked for migration using point and outline 
tracking, there was a significant difference for one of the collagen concentrations, but 
not the other suggesting while the conclusions about the data might not change 
between the analysis types, the exact values do change (Figure C.5). Outline and 
point tracking do lead to different outcomes for mean squared displacement and 
diffusion coefficients (Figure C.5). Outline tracking generally estimates the centroid 
more accurately and thus cell morphology can actually play a role in how the two 
tracking methods compare (depending on how easy it is to estimate a centroid). It is 
possible that the mean squared displacement and diffusion coefficient is more 
sensitive to small changes in centroid position than the speed, which is an average 
value, leading to more differences in conclusions. Finally, we found that both 
migration and morphology are sensitive to the experience level of the person doing 
the analysis (Figure 6). In particular, the beginner level stands apart the most from the 
other two. Interestingly, the difference in speed between beginner and advanced 
analysis disappears with increasing time step (Figure C.6). This suggests that 
potentially beginners are more likely to make mistakes in estimating the centroid, 
however as the time step increases, small mistakes become less significant among 





Confounding variables in analysis can have a significant impact on both the 
absolute quantification of migration and morphology as well as the relative outcome 
between different conditions, changing the outcome of a study. These differences 
could become more pronounced with more heterogeneous cell populations or with 
more complex studies. This suggest that researchers should be mindful of these types 
of confounding variables in their analysis and not limit controls to experiments.  
Appendix C.5 Conclusion 
 In conclusion, we have examined the importance of normalization of cell 
migration and morphology analysis, which is a frequently overlooked aspect of 
experimental control. Specifically, we examined the presence of confounding 
variables in the analysis step of cell migration and morphology analysis such as zoom 
level, sample size, time interval, different types of tracking, and experience level. We 
found that it is crucial to examine and normalize these variable parameters in 
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